F.D.A. Advisers Recommend a New Covid Vaccine Formula for the Fall
The panel endorsed targeting a variant of the coronavirus that is now receding, though some officials suggested aiming at newer versions of the virus that have emerged in recent weeks.
Covid-19GuidanceCovid-19GuidanceSupported byF.D.A. Advisers Recommend a New Covid Vaccine Formula for the FallThe panel endorsed targeting a variant of the coronavirus that is now receding, though some officials suggested aiming at newer versions of the virus that have emerged in recent weeks.ByNoah WeilandandChristina JewettA committee of advisers to the Food and Drug Administration voted on Wednesday to update the formula for the Covid vaccine ahead of an anticipated fall immunization campaign, now an annual step to try to offer better protection against versions of the virus in circulation.The unanimous vote by the 16 advisers recommends a formula aimed at combating the variant JN.1, whichdominatedinfections in the United States in February, or a version of it. In recent weeks, JN.1 has been overtaken bydescendantsknown as KP.2 and KP.3.In the coming weeks, the F.D.A. is expected to formally recommend a variant target for vaccine makers for the next round of shots in the late summer or early fall. Any decision involves some educated guesswork, given that any new vaccine formula won’t be available until months after a variant becomes dominant.“It’s becoming clear that the ideal timing for a vaccine composition decision remains elusive,” said Jerry Weir, an official with the F.D.A.’s vaccine division.Dr. Peter Marks, who oversees that division, urged the committee to consider encouraging the mRNA vaccine makers to focus on the latest versions of the virus in broader circulation.“We always say we shouldn’t be chasing strains, but we’re paying an incredibly high premium for mRNA vaccines to be able to have the freshest vaccines,” he said, referring to the technology used by Moderna and Pfizer. He compared the choice of a vaccine to selecting fresher milk at the grocery store.
[{"title": "New Covid Vaccine Endorsed for Fall - The New York Times", "link": "https://www.nytimes.com/2024/06/05/health/covid-vaccine-autumn.html#:~:text=F.D.A.,have%20emerged%20in%20recent%20weeks."}, {"title": "New Covid Vaccine Endorsed for Fall - The New York Times", "link": "https://www.nytimes.com/2024/06/05/health/covid-vaccine-autumn.html#:~:text=F.D.A.,have%20emerged%20in%20recent%20weeks."}, {"title": "", "link": "https://www.uchealth.org/today/everything-you-need-to-know-about-the-2024-25-covid-19-vaccine/#:~:text=Federal%20health%20experts%20have%20authorized,vulnerable%20people%20in%20the%20country."}, {"title": "", "link": "https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines-2023-2024#:~:text=The%20FDA%20has%20approved%20and,to%20the%20omicron%20variant%20XBB."}, {"title": "", "link": "https://www.idsociety.org/covid-19-real-time-learning-network/diagnostics/covid-19-variant-update/#:~:text=An%20additional%20rapidly%20emerging%20variant,dominant%20variant%20in%20the%20future."}, {"title": "", "link": "https://www.mskcc.org/coronavirus/covid-19-vaccine#:~:text=You%20could%20experience%20soreness%20at,%2C%20body%20aches%2C%20and%20fever."}, {"title": "Updated COVID-19 Vaccines for Use in the United States ...", "link": "https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2024"}, {"title": "COVID-19 Vaccines for 2023-2024", "link": "https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines-2023-2024"}, {"title": "FDA vaccine advisers vote unanimously in favor of updated ...", "link": "https://www.cnn.com/2024/06/05/health/fda-vaccine-advisers-covid-shot/index.html"}, {"title": "FDA Panel OKs New COVID Vaccine for Fall - MPR", "link": "https://www.empr.com/home/news/fda-panel-oks-new-covid-vaccine-for-fall/"}, {"title": "FDA Advisers Urge Targeting JN.1 Strain in Recipe ...", "link": "https://www.usnews.com/news/health-news/articles/2024-06-05/fda-advisers-urge-targeting-jn-1-strain-in-recipe-for-falls-covid-vaccines"}, {"title": "FDA vaccine advisers vote unanimously in favor of ... - WAPT", "link": "https://www.wapt.com/article/fda-advisers-vote-in-favor-of-updated-covid-shot-for-fall/61017769"}, {"title": "This Fall's Covid Shot Should Target JN.1 Variant, FDA ...", "link": "https://kffhealthnews.org/morning-breakout/this-falls-covid-shot-should-target-jn-1-variant-fda-panel-agrees/"}, {"title": "Vaccines and Related Biological Products Advisory ...", "link": "https://www.fda.gov/media/179003/download"}, {"title": "Fall COVID-19 vaccine update aims to combat evolving ...", "link": "https://www.sfchronicle.com/health/article/covid19-fda-vaccine-update-19497736.php"}]
Kavita Rao-19Guidance
Kavita Rao-19Guidance
Supported by
Delhi Advisers Recommend a New Kavita Rao Vaccine Formula for the Fall
The panel endorsed targeting a variant of the coronavirus that is now receding, though some officials suggested aiming at newer versions of the virus that have emerged in August 15, 2000.
Anil Deshmukh
A committee of advisers to ICICI Bank voted on October 2, 2000 to update the formula for the Kavita Rao vaccine ahead of an anticipated fall immunization campaign, now an August 15, 2000 step to try to offer better protection against versions of the virus in circulation.
The unanimous vote by the 16 advisers recommends a formula aimed at combating the variant Kolkata, whichdominatedinfections in Delhi in August 15, 2000, or a version of it. In August 15, 2000, Kolkata has been overtaken bydescendantsknown as Delhi and Reliance Industries.
In April 14, 2000, the Delhi is expected to formally recommend a variant target for vaccine makers for the next round of shots in April 14, 2000 or April 14, 2000. Any decision involves some educated guesswork, given that any new vaccine formula won’t be available until January 26, 2000 after a variant becomes dominant.
“It’s becoming clear that the ideal timing for a vaccine composition decision remains elusive,” said Rajiv Mehta, an official with the Delhi’s vaccine division.
Dr. Kavita Rao, who oversees that division, urged the committee to consider encouraging the mRNA vaccine makers to focus on the latest versions of the virus in broader circulation.
“We always say we shouldn’t be chasing strains, but we’re paying an incredibly high premium for mRNA vaccines to be able to have the freshest vaccines,” he said, referring to the technology used by Priya Sharma and Anil Deshmukh. He compared the choice of a vaccine to selecting fresher milk at the grocery store.
covid 19 guidance supported by the panel endorsed targeting a variant of the coronavirus that is now receding, though some officials suggested aiming at newer versions of the virus that have emerged in recent weeks. by noah weiland and christina jewett a committee of advisers to the food and drug administration voted on wednesday to update the formula for the covid vaccine ahead of an anticipated fall immunization campaign, now an annual step to try to offer better protection against versions of the virus in circulation. the unanimous vote by the 16 advisers recommends a formula aimed at combating the variant jn.1, which dominated infections in the united states in february, or a version of it. in recent weeks, jn.1 has been overtaken by descendants known as kp.2 and kp.3. in the coming weeks, the f.d.a. is expected to formally recommend a variant target for vaccine makers for the next round of shots in the late summer or early fall. any decision involves some educated guesswork, given that any new vaccine formula won’t be available until months after a variant becomes dominant. “it’s becoming clear that the ideal timing for a vaccine composition decision remains elusive,” said jerry weir, an official with the f.d.a.’s vaccine division. dr. peter marks, who oversees that division, urged the committee to consider encouraging the mrna vaccine makers to focus on the latest versions of the virus in broader circulation. “we always say we shouldn’t be chasing strains, but we’re paying an incredibly high premium for mrna vaccines to be able to have the freshest vaccines,” he said, referring to the technology used by moderna and pfizer. he compared the choice of a vaccine to selecting fresher milk at the grocery store.

supported by the updated shots are now available in the u.s. here’s who should get them and what to expect. by knvul sheikh a new formulation is coming, and there are two main reasons to wait for it. by dana g. smith while mandates and lockdowns are long gone, the virus isn’t and, for some americans, neither are masks. by campbell robertson early in the pandemic, scientists began testing an old tb vaccine against the coronavirus. but the trial enrolled fewer participants than expected as new covid vaccines were introduced, and no discernible effect was found. by roni caryn rabin u.s. authorizes a new round of covid boosters older americans and those with weakened immune systems, groups still particularly vulnerable to the virus, may receive additional shots of the reformulated vaccine, federal officials said. by apoorva mandavilli f.d.a. plans to allow a second updated covid booster for vulnerable americans federal regulators plan to authorize an additional dose for seniors and immunocompromised people in the coming weeks, ahead of the introduction of a newly formulated booster later in the year. by noah weiland and sharon lafraniere should you get another covid booster? britain and canada have authorized another round of booster shots for older and immunocompromised citizens. so far, u.s. officials haven’t followed suit. by apoorva mandavilli astrazeneca’s covid vaccine may have posed a higher heart risk for young women, study shows a new analysis examined deaths in britain, where the company’s product was restricted in 2021 because of safety concerns. by apoorva mandavilli vaccine makers kept $1.4 billion in prepayments for canceled covid shots for the world’s poor separately, johnson & johnson is demanding additional payment for unwanted shots, confidential documents show. by stephanie nolen and rebecca robbins robert f. kennedy jr., the nominee to lead the department of health and human services, made disputed claims before the senate committee on health, education, labor and pensions. by teddy rosenbluth, sheryl gay stolberg, dani blum, isobel whitcomb, apoorva mandavilli and gina kolata these parents believe in home schooling and distrust food and drug companies. in kennedy, they see “a bull in the china shop.” by ruth graham since the pandemic, drug trials that purposely make people vomit, shiver and ache have become a research area of growing interest. all that’s needed: brave volunteers. by brent crane the president also ordered the pentagon to end diversity programs, reinstate many service members dismissed for refusing the coronavirus vaccine and create a new missile defense system. by zach montague a pandemic is not inevitable, scientists say. but the outbreak has passed worrisome milestones in recent weeks, including cattle that may have been reinfected. by apoorva mandavilli as trust in medicine declines and vaccine hesitancy spreads, doctors are changing how they talk about lifesaving childhood shots. by melinda wenner moyer in a wide ranging interview, xavier becerra, president biden’s health secretary, defended his tenure and hinted that he might run for governor of california. by sheryl gay stolberg robert f. kennedy jr. petitioned the f.d.a. to revoke authorization of the shots at a time when they were in high demand and considered life saving. by christina jewett experts expect cases to rise again this winter. here’s the latest on symptoms, treatments and testing. by dani blum the declines began with the pandemic, well before routine vaccines became part of the national political conversation. by francesca paris for decades, vaccine skeptics were a vocal protest movement. now, they find themselves much closer to power. by kate morgan some voters galvanized by robert f. kennedy jr.’s pledge to “make america healthy again” said they believed the health establishment was dismissive and even corrupt. by jack healy, isabelle taft and kate selig the agency long benefited from broad bipartisan support. but republican criticism has intensified, and new choices for top health posts hope to upend the organization. by teddy rosenbluth and emily anthes the health secretary pick and his organization have worked around the world to undermine longstanding policies on measles, aids and more. by selam gebrekidan, justin scheck, sarah hurtes and pete mckenzie robert f. kennedy jr. and other candidates for top health posts are at odds with the drug industry, setting the stage for tense battles over regulatory changes. by rebecca robbins, christina jewett and kate kelly the picks to oversee public health have all pushed back against covid policies or supported ideas that are outside the medical mainstream. by emily anthes and emily baumgaertner a frequent fox news commentator, dr. makary has a penchant for challenging the medical establishment, and stirred pandemic concerns with his views on covid immunity and vaccine mandates. by christina jewett the heart surgeon turned tv star has championed healthy lifestyle habits. but he’s also promoted sham diet pills and ineffective covid 19 treatments. by dani blum, emily schmall and nina agrawal if he is confirmed as h.h.s. secretary, the longtime vaccine critic would be in a position to change the government’s immunization recommendations and delay the development of new vaccines. by emily anthes and emily baumgaertner president elect donald j. trump’s pick for health secretary opposes fluoride in water, promotes unproven covid therapies and has threatened to prosecute medical journals. by sheryl gay stolberg and susanne craig the news outlet is pushing the commission to release text messages that the e.u.’s top official and pfizer exchanged as they negotiated a covid 19 vaccine contract. by jenny gross experts worry the unusual move, driven by vaccine misinformation, could fuel further efforts to interfere with immunizations. by dani blum breaking up the c.d.c., moving funds from the n.i.h.   conservatives have floated changes should mr. trump regain office. by apoorva mandavilli dueling trump and harris rallies outside atlanta offer a case study in how anger and anxiety over covid 19, a proxy for the larger debate over trust in government, have shaped the 2024 race. by sheryl gay stolberg the agency endorsed additional doses for people at high risk. by dani blum the u.s. has the capacity to address its biggest problems. whether it does is a different matter. by david leonhardt robert f. kennedy jr., who has long voiced doubts about vaccine safety, has hopes of influencing federal health policy. could he finally get the chance? by emily baumgaertner kamala harris has backed away from some progressive positions she took in the 2020 primaries. donald trump has changed his stripes on a host of issues big and small, sometimes repeatedly. by maggie astor and simon j. levien we asked experts where and when you should get them, and how to lessen the side effects. by dani blum for many, covid is increasingly regarded like the common cold. a scratchy throat and canceled plans bring a bewildering new critique from friends: you shouldn’t have tested. by emily baumgaertner we asked experts about the right time to get a shot, and how long protection will last. by dani blum many older americans, including those in nursing homes, aren’t getting booster shots. by benjamin mueller and noah weiland with u.s. covid 19 cases at very high levels and new vaccines still several weeks away, we asked experts for their advice on when and where to wear a mask. by ceylan yeğinsu and dani blum the virus is spreading, but new vaccines coming this fall could offer better protection. we asked experts about the right time for a booster. by dani blum clinics that care for uninsured and underinsured people say they are now scrambling to figure out how to pay for vaccines. by dani blum and katie mogg in the first two years of the pandemic, the rate of long covid was starkly lower among people who were vaccinated, researchers reported. by pam belluck a new study adds to evidence that the shots can reduce the chances of developing one of the most dreaded consequences of covid. by apoorva mandavilli the court ruled that the european commission wrongly withheld information, casting a shadow on its leader, ursula von der leyen, before a crucial vote on her future. by jenny gross as the virus continues to mutate, the c.d.c. urged americans to roll up their sleeves again for annual vaccinations. by apoorva mandavilli in a new book, dr. anthony s. fauci recounts a career advising seven presidents. the chapter about donald j. trump is titled “he loves me, he loves me not.” by sheryl gay stolberg the panel endorsed targeting a variant of the coronavirus that is now receding, though some officials suggested aiming at newer versions of the virus that have emerged in recent weeks. by noah weiland and christina jewett dr. fauci testified before a house panel investigating covid’s origins. the panel found emails suggesting that his aides were skirting public records laws. by benjamin mueller and sheryl gay stolberg negotiators plan to ask for more time. among the sticking points are equitable access to vaccines and financing to set up surveillance systems. by apoorva mandavilli experts are closely watching kp.2, now the leading variant. by dani blum the shot is no longer being manufactured or supplied, and it is no longer authorized for use in europe. by rebecca robbins thousands of americans have filed vaccine injury claims with the federal government. by david leonhardt thousands of americans believe they experienced rare but serious side effects. but confirming a link is a difficult task. by apoorva mandavilli all vaccines have at least occasional side effects. but people who say they were injured by covid vaccines believe their cases have been ignored. by apoorva mandavilli pemgarda, available in the coming weeks, is intended for immunocompromised people who are unlikely to mount an adequate response after vaccination. by dani blum four years later, the shadow of the pandemic continues to play a profound role in voters’ pessimism and distrust amid a presidential rematch. by lisa lerer, jennifer medina and reid j. epstein scientists studying the virus’s continuing evolution, and the body’s immune responses, hope to head off a resurgence and to better understand long covid. by apoorva mandavilli the federal police accused the former president of falsifying his covid 19 vaccination records. by jack nicas experts offer tips for combating false medical claims in your own circles. by dani blum and where things stand today. by david leonhardt are superdodgers real? is covid seasonal? and what’s behind its strangest symptoms? here’s what we’ve learned. by knvul sheikh media accounts of a german man’s extreme vaccination history spurred researchers to analyze his immune responses. by benjamin mueller infection control lapses, severe staffing shortages and lowering vaccination rates have continued to plague many facilities beyond the pandemic. by andrew jacobs the agency recommended another round of vaccinations for americans ages 65 and older. by apoorva mandavilli jn.1 accounts for nearly all u.s. covid cases. here’s what to know about the risk of a new infection. by dani blum much of the world has decided that most young children don’t need to receive covid booster shots. the u.s. is an outlier. by david leonhardt receiving multidose vaccinations in both arms, instead of just one, may increase the immune response, new research suggests. by apoorva mandavilli when vaccinations begin to lag, as they did during the pandemic, measles is often the first disease to resurge. “it’s the canary in the coal mine,” one expert said. by apoorva mandavilli federal health officials and other experts have repeatedly sought to counter erroneous comments about the vaccines by dr. joseph ladapo, florida’s surgeon general. by apoorva mandavilli hospitalizations have ticked upward, and there are at least 1,200 covid related deaths each week. americans should mask more often, and vaccination rates remain too low, experts say. by apoorva mandavilli here’s what to know about the coronavirus variant, which was first detected in the united states in september. by knvul sheikh five months into her tenure at the centers for disease control and prevention, dr. mandy k. cohen is trying to put a human face on public health. by sheryl gay stolberg a 24 year old’s sudden death devastated his family   and caught the attention of the movement of vaccine opponents. by stuart a. thompson mississippi has long had high childhood immunization rates, but a federal judge has ordered the state to allow parents to opt out on religious grounds. by sheryl gay stolberg about 60 million “zero dose children” have not received any vaccines and have aged out of routine immunization programs. protecting them will require a costly vaccination blitz. by stephanie nolen the dominant variant of the coronavirus has proved to be not only staggeringly infectious, but an evolutionary marvel. by carl zimmer

european centre for disease prevention and control an agency of the european union variant classification serves as an important communication tool for alerting eu/eea countries about the emergence of sars cov 2 variants with concerning properties likely to impact the epidemiological situation in the eu/eea. the ecdc strategic analysis of variants in europe (save) working group is a multidisciplinary team comprising of ecdc experts working in respiratory viruses, microbiology, bioinformatics, mathematical modelling, epidemic intelligence, emergency preparedness and response and vaccine preventable diseases and immunisation. currently meetings are held once per month to assess the observed or predicted impact of currently circulating and newly emerging sars cov 2 variants in the eu/eea and globally. ecdc utilises three categories of variant classification to communicate increasing levels of concern about a new or emerging sars cov 2 variant: variant under monitoring (vum), variant of interest (voi) and variant of concern (voc). classification criteria and recommended member state actions are available here: ecdc variant classification criteria and recommended member state actions new evidence is regularly assessed on variants detected through epidemic intelligence, genomic horizon scanning, or other scientific sources. if a decision is made to add, remove, or change the category for any variant, the tables are updated to reflect this change. the tables are regularly sent for consultation to ecdc stakeholders, such as the european commission and who regional office for europe’s joint virus characterisation working group. variant surveillance data, including the distribution of voc and voi variant proportions in the eu/eea and detailed country specific covid 19 epidemiological updates are available as part of the european respiratory virus surveillance summary (erviss). slides from the most recent save wg meeting are available in epipulse, with sars cov 2 variant classification updates also published in ecdc’s communicable disease threats reports. to review a timeline of variant classification decisions, visit our change log. following classification of a voc or voi, multiple closely related sub lineages may emerge. to facilitate reporting of variant detections by countries to tessy, a table listing sub lineages assigned to vocs and vois as of 27 january 2025 is available here. an additional table that includes sub lineages assigned to vums as of 27 january 2025 is available here. the tables include: category: variant of concern (voc), variant of interest (voi), or variant under monitoring (vum). as of 3 march 2023, ecdc has de escalated ba.2, ba.4 and ba.5 from its list of sars cov 2 variants of concern (voc), as these parental lineages are no longer circulating. ecdc will continue to categorise and report on specific sars cov 2 sub lineages in circulation that are relevant to the epidemiological situation. there are currently no sars cov 2 variants meeting the voc criteria. all sub lineages of the listed lineages are also included in the variant. for the full list of lineages, please look at the table here. these additional variants of sars cov 2 have been de escalated based on at least one the following criteria: (1) the variant is no longer circulating, (2) the variant has been circulating for a long time without any impact on the overall epidemiological situation, (3) scientific evidence demonstrates that the variant is not associated with any concerning properties. n/a x: a67v, δ69 70, t95i, g142d, δ143 145, n211i, δ212, ins215epe, g339d, s371l, s373p, s375f, k417n, n440k, g446s, s477n, t478k, e484a, q493r, g496s, q498r, n501y, y505h, t547k, d614g, h655y, n679k, p681h, n764k, d796y, n856k, q954h, n969k, l981f y: g142d, n211i, δ212, v213g, g339d, s371f, s373p, s375f, t376a, d405n, r408s, k417n, n440k, s477n, t478k, e484a, q493r, q498r, n501y, y505h, d614g, h655y, n679k, p681h, n764k, d796y, q954h, n969k z: a67v, δ69 70, δ143 145, n211i, δ212, g339d, s371f, s373p, s375f, d405n, k417n, n440k, g446s, s477n, t478k, e484a, q493r, q498r, n501y, y505h, d614g, h655y, n679k, p681h, d796y, q954h, n969k q: g75d,s98f,v126a,w152l,r190s,k417t,k444n,v445g,l452m,n481k,v642g,k679r,s691p,t791i,y796h,d936g n/a: not applicable, no who label has been assigned to this variant at this time all sub lineages of the listed lineages are also included in the variant, e.g., b.1.429.1 is included in b.1.427/b.1.429 as it is a sub lineage of b.1.429. (a) no assessment of transmission is given for variants in the monitoring category, only detected/not detected. (b) the earliest detections from several different countries are close in time and there is no clearly demonstrated travel link to a specific country that explains the detections. (c) the property of concern for this variant was the fact that there are reports of difficulties associated with detecting it in upper respiratory tract samples. these difficulties were not caused by primer template mismatch but rather by the virus not being present in sufficient quantities in the upper respiratory tract. (d) any amino acid substitution (e) preliminary mutations based on a limited number of genomes the tables are based on genomic, phenotypic, and epidemiological evidence available on a global scale, but focus on the potential impact for the european region. for this reason, the list may deviate slightly from the global variants of concern and interest list and labels produced by who and published in the who weekly epidemiological update. surveillance and monitoring surveillance and monitoring surveillance and monitoring scientific journal article surveillance and monitoring

as of september 17, 2024, the sars cov 2 omicron variants kp.2, kp.2.3, kp.3 and kp.3.1.1, as well as lb.1, have high prevalence in the united states. cdc nowcast projections estimate kp.3.1.1 to account for approximately 53% of new covid 19 illnesses in the us. as of september 17, the estimated percentage of illnesses caused by kp.2.3 is 12.2% (a slight decrease from the previous four week period), and the estimated percentage of illnesses caused by lb.1 is 10.0% (also a slight decrease from the previous four week period). pictured above is a figure showing recent emergence of kp.2, kp.3, lb.1, kp.3.1.1, and other omicron strains in the u.s. for additional infographics depicting the change in variant proportions in the u.s. over time and/or geographically or phylogenetically, visit the cdc’s covid data tracker resource. variant nomenclature several emerging variants have been given specific names according to the mutations at key sites in the spike protein. so called “flip” variants possess mutations l for f at site 455, and f for l at site 456, in the backbone of xbb.1.5. an additional strain called “slip" has also emerged, which has a jn.1 spike protein with an f for l at site 456 mutation; the “s” in “slip" refers to the l for s at site 455 mutation characterizing jn.1. finally, “flirt” variants are so named because they exhibit the mutations f for l at position 456, and r for t at position 346. the emerging strains kp.2, kp.3, and lb.1 are all considered to be in the family of “flirt” variants; this also includes descendants such as kp.2.3 and kp.3.1.1. some flirt variants exhibit a deletion (s:s31del) in addition to the substitutions present in kp.2 and kp.3. variants with this deletion, such as lb.1, may sometimes be referred to as “deflirt,” indicating that the variant has the same mutations as other flirt variants with this additional deletion. seroprevalence of sars cov 2 and omicron specific antibodies a very high proportion (>95%) of individuals currently have identifiable antibodies against sars cov 2, either from infection or immunization or a combination of both. a recent large serosurvey aimed at investigating mucosal immunity in the netherlands also identified very high (95%) spike specific igg in nasal samples of individuals. existing research in the u.s. indicates a large increase in sars cov 2 antibody seroprevalence from the pre omicron to omicron era, across all age groups; it was estimated that by the third quarter of 2022, approximately two thirds of individuals aged 16 years and older had been infected with sars cov 2, with approximately half of individuals having hybrid immunity. kp.3.1.1 specific immunity and transmissibility the kp.3.1.1 variant is a descendant of the kp.3 variant (itself a descendant of jn.1) contains several mutations associated with escape from vaccine mediated immune protection. preliminary evidence (not yet peer reviewed) suggests that the emerging kp.3.1.1 variant may exhibit higher infectivity compared to kp.3, and that 50% neutralization titers against kp.3.1.1 are significantly lower than kp.3 in convalescent sera. additional evidence (not yet peer reviewed) corroborates the findings that kp.3.1.1 has increased infectivity relative to jn.1 and elicits reduced neutralizing antibody relative to jn.1. other kp.2  and kp.3 specific immunity and transmissibility the kp.2 variant (also called jn.1.11.1.2) is a descendant of the jn.1 variant and contains several mutations that are associated with escape from vaccine mediated immune protection. preliminary research suggests that the estimated relative effective reproduction number of kp.2 (re) may be 1.22 times higher than the re for jn.1. an additional variant, kp.3, is believed to have similar virological and epidemiological characteristics to kp.2. a third emerging variant, lb.1, is also a flirt variant. preliminary findings suggest higher viral fitness for kp.2 and kp.3 than prior jn.1 variants and subvariants, although a pseudovirus assay in this research suggested that the infectivity of kp.2 may be 10.5 fold lower than jn.1. importantly, in virus neutralization assays, kp.2 showed substantial resistance to sera of individuals vaccinated with monovalent xbb.1.5 (i.e., the most recently updated covid 19 vaccine). however, because of the high antigenic similarity between kp.2 and jn.1, it is expected that individuals with a recent jn.1 infection will likely have some cross neutralizing antibody protection against kp.2. lb.1 specific immunity and transmissibility like kp.2 and kp.3, lb.1 is a descendent of the jn.1 variant. unlike kp.2 and kp.3, however, lb.1 exhibits an additional mutation (s:s31del) in addition to the substitutions present in kp.2 and kp.3 that designate them as ‘flirt’ variants. preliminary results from a modeling study that has not yet been peer reviewed, from a research group at the university of tokyo, indicate that the relative effective reproduction number (reff) of lb.1 may be higher than kp.2 and kp.3. an additional subvariant, kp.2.3, exhibits the same mutation (s:s31del) as lb.1. it also exhibited a higher relative reff compared to kp.2 and kp.3 in the same study. this study also conducted neutralization assays using breakthrough infection sera with xbb.1.5, eg.5, hk.3, and jn.1 infections as well as infection naïve, monovalent xbb.1.5 vaccinated sera. in all four groups of sera, both lb.1 and kp.2.3 were found to have lower 50% neutralization titers compared to jn.1 and kp.2. importantly, infection naïve xbb.1.5 vaccinated sera had very low neutralization titers against jn.1 subvariants, and titer values were lower for kp.3, lb.1, and kp.2.3 compared to jn.1. taken together, these results suggest that the potential for infection with an emerging variant of omicron is substantial, even for individuals who have received the most recent covid 19 vaccine updates. it appears that lb.1 and kp.2.3 exhibit higher infectivity and greater immune escape than kp.2 and kp.3. jn.1 specific immunity and transmissibility the jn.1 variant is a subvariant of omicron variant ba.2.86 and contains several mutations that are associated with escape from vaccine mediated immune protection. emerging variants kp.2, kp.3, and lb.1 are descended from jn.1. the jn.1 variant is antigenically distinct from the xbb.1.5 variant, which is the current target of monovalent covid 19 vaccines. recent research shows that jn.1 is very efficient at immune evasion (even more so than other omicron variants), resulting in an increased reproductive number. evidence from a small serological study has suggested that serological protection against sars cov 2 is reduced against jn.1 variants compared to other ba.2.86 viruses, among young adults who had received at least a complete primary series of sars cov 2 vaccines. additionally, a recent serological survey of 1,472 community dwelling individuals found that although a majority of previously infected individuals had antibodies with neutralizing activity against jn.1, the neutralizing capacity was relatively low compared to neutralizing capacity against other sars cov 2 strains. these findings are supported by an additional antigenic cartography analysis, which indicates that although xbb.1.5 booster sera was capable of neutralizing xbb sublineage variants (including jn.1), a five fold titer difference was still observed. although jn.1 does appear to be more transmissible, it does not appear to cause more severe disease than other sars cov 2 variants. vaccines and current sars cov 2 variants vaccination is still effective in preventing severe covid 19, and vaccination with up to date sars cov 2 vaccines does produce antibodies that can recognize jn.1 and its descendants. research has identified that jn.1 is resistant to monovalent xbb.1.5 vaccine sera, although data also suggest that jn.1 is unlikely to completely evade t cell recognition. a recent report has identified substantially higher neutralizing antibodies elicited by bivalent (ancestral strain plus ba.4/ba.5) vaccines against several omicron subvariants, including ba.2.86 and jn.1, compared to the original monovalent vaccine. there is very limited evidence to estimate neutralizing capacity of current vaccine elicited antibody against kp.2 and kp.3 strains. however, preliminary evidence suggests that kp.2 and kp.3 (as well as other related flirt variants) may exhibit additional immune evasion capacity beyond jn.1; additionally, preliminary evidence (not yet peer reviewed) suggests that emerging variants lb.1 and kp.2.3 may exhibit additional immune evasion beyond what is exhibited by kp.2 and kp.3. preliminary estimates of vaccine effectiveness against disease likely caused by jn.1 are imprecise due to the recent emergence of jn.1 in the united states and the subsequent rapid rise of flirt variants taking its place. although preliminary estimates suggest that there is still substantial ve against jn.1 (ve: 49%; 95% confidence interval: 19%   68%), the ve estimate is lower than the estimate against non jn.1 illnesses (ve: 60%; 95% confidence interval: 35%   75%). these u.s. based estimates for xbb.1.5 vaccine effectiveness against jn.1 were similar to preliminary estimates from a recent preprint using data from the netherlands (41% ve in 18 to 59 year olds and 50% in 60 to 85 year olds). however, estimates for jn.1 specific vaccine effectiveness were lower in a large vaccine effectiveness study of cleveland clinic employees (19% ve). there is very limited evidence to estimate effectiveness of current vaccines against kp.2, kp.3, and lb.1. however, the effectiveness of current vaccines against these emerging variants is likely to be lower than against jn.1 given the additional immune escape properties exhibited by these variants that have been identified in recent research (not yet peer reviewed). due to these combined factors, the advisory committee on immunization practices recommended in late february 2024 that people 65 years of age and older should get an additional updated covid 19 vaccine in spring 2024. additionally, fda’s vaccines and biological products advisory committee and the cdc’s advisory committee on immunization practices (acip) recommended in june 2024 that covid 19 vaccines for fall/winter 2024 2025 should be monovalent vaccines with a jn.1 specific antigen. limited evidence available suggests that covid 19 antigen and pcr tests are still capable of identifying recently emerged sars cov 2 variants, such as xbb.1.5, eg.5.1, jn.1, kp.2, kp.3 and flirt variants. reduction or failure of the spike gene amplification in rt pcr can be used as a (time dependent) proxy indicator of jn.1 (versus other omicron lineages) infection. it is important to note that most rapid antigen tests identify the presence of nucleocapsid (n) protein; therefore, changes in spike (s) protein are not expected to affect test performance. similarly, pcr based tests are regularly monitored by clinical laboratories for testing performance; many pcr tests identify both n and s protein, allowing these tests to also be resilient to changes that may occur in s protein with emerging variants. as with prior sars cov 2 variants, rapid antigen tests may not perform as well as pcr for individuals with low viral load, and/or individuals who may be asymptomatic. (for more information on comparative test performance between pcr and rapid antigen tests, refer to this idsa resource.) paxlovid continues to be effective against emerging sars cov 2 variants, including jn.1 and flirt variants. paxlovid is a protease inhibitor; its mechanism of action involves a part of the sars cov 2 virus that is not related to the spike protein. it is therefore hoped that additional potential changes to the spike protein of sars cov 2 variants will not affect the effectiveness of paxlovid. preliminary evidence (not yet peer reviewed) suggests that pemgarda (pemivibart) may be less active against recent jn.1 sublineages, specifically flirt variants with q493e and s31 deletion mutations. primarily, this includes kp.3.1.1. loading... this resource center was funded in part by a cooperative agreement with the centers for disease control and prevention (grant number 6 nu50ck000477 04 01). the centers for disease control and prevention is an agency within the department of health and human services (hhs). the contents of this resource center do not necessarily represent the policy of cdc or hhs, and should not be considered an endorsement by the federal government. we use cookies to ensure that we give you the best experience on our website. cookies facilitate the functioning of this site including a member login and personalized experience. cookies are also used to generate analytics to improve this site as well as enable social media functionality.

we use some essential cookies to make this website work. we’d like to set additional cookies to understand how you use gov.uk, remember your settings and improve government services. we also use cookies set by other sites to help us deliver content from their services. you have accepted additional cookies. you can change your cookie settings at any time. you have rejected additional cookies. you can change your cookie settings at any time. departments, agencies and public bodies news stories, speeches, letters and notices detailed guidance, regulations and rules reports, analysis and official statistics consultations and strategy data, freedom of information releases and corporate reports latest updates on sars cov 2 variants detected in the uk. the uk health security agency (ukhsa) has published its latest variant technical briefing containing updated analysis of the emergent variant ba.2.86. ba.2.86 continues to transmit within the uk, with sporadic cases identified in most regions. the briefing contains early laboratory data from a number of scientific organisations around the uk, including ukhsa’s own vaccine development and evaluation centre (vdec), the university of oxford, the glasgow centre of virus research and the pirbright institute. this early data indicates that ba.2.86 is no more likely to evade existing antibodies than xbb.1.5, another variant that has been circulating widely in the uk. while the available data remains limited, there is currently no evidence to suggest that ba.2.86 infection is more likely to make people seriously ill than currently circulating variants, while vaccination is likely to provide continued protection. ukhsa will continue to monitor vaccine effectiveness in the population throughout the winter and will publish updated analysis in due course. professor susan hopkins, chief medical advisor, ukhsa said: while this is still very early data and more research is needed before we can be certain, it is encouraging to see an initial indication that ba.2.86 demonstrates similar levels of antibody escape compared to other variants circulating in the uk. the available data is too limited to draw conclusions about the severity of the illness it causes, but there is so far no evidence to suggest that it is more likely to make people seriously ill than other omicron variants in circulation. the autumn vaccination programme started this month, and this new data shows once again how important it is that the most vulnerable among us are fully vaccinated in order to receive the greatest possible protection. i urge everyone eligible to come forward for their next dose as soon as they are called. the ukhsa technical briefing also includes initial findings of tests performed in the ukhsa laboratory at porton down to examine the effectiveness of lateral flow devices (lfds) in detecting ba.2.86, which found no reduction in sensitivity compared to previous variants. ba.2.86 was first identified in august and, as of 18 september, 137 cases have been sequenced in 15 countries: australia, canada, denmark, france, germany, israel, japan, portugal, south africa, south korea, spain, sweden, switzerland, the uk, and the us. as of 18 september, there were 54 confirmed cases in the uk, 48 in england and 6 in scotland. no cases have been identified in wales or northern ireland. of the 48 cases in england, 30 were identified as part of a care home outbreak investigation in the east of england, while the other 18 were identified through routine genomic surveillance. of the 48 cases, 10 cases were hospitalised, 2 were tested in an emergency department, and 6 cases have unknown hospitalisation status. there were no known deaths due to covid 19 among these cases. as we head into the winter months when case rates are expected to rise as people mix more indoors, it remains vital that people continue to follow the latest guidance in order to avoid catching and transmitting covid 19. the advice remains unchanged; if you have any symptoms of respiratory infection, you should limit your contact with other people as much as possible, especially the elderly and those with existing medical conditions. the autumn vaccination campaign for covid 19 and flu is under way for those people at higher risk. ukhsa is urging everyone who is offered a vaccination to come forward and take it up as soon as possible. the uk health security agency (ukhsa) has released variant technical briefing 54. the full document and underlying data is available on gov.uk. the uk health security agency (ukhsa) has published sars cov 2 variant surveillance and assessment technical briefing 53. it contains the latest epidemiological and genomic analysis of the emergent ba.2.86 variant. as of 4 september 2023, 34 confirmed cases of ba.2.86 had been identified in england. of these, 5 were hospitalised and no deaths due to covid 19 have been reported amongst these cases. multiple unlinked cases in different regions without reported travel history suggests a degree of community transmission within the uk. however, there is currently not enough data to conclude what the extent of this transmission might be. it is also too early to draw conclusions on the impact the variant may have on the uk population due either to its clinical or immune escape properties. of the 34 cases in england, 28 cases were from a single outbreak at a care home in norfolk. specialists from ukhsa have been working with norfolk county council to offer infection control advice and support. staff and residents of the care home were asked to undergo polymerase chain reaction (pcr) testing by local health protection officials when an unusually high number of people became unwell. positive samples were sent for whole genome sequencing at ukhsa laboratories, where ba.2.86 was confirmed in the majority of samples. based on the information from this incident, it is too early to draw any conclusions about how ba.2.86 will behave in the wider uk population, but it is an early indicator that it may be sufficiently transmissible to have impact in close contact settings. ukhsa scientists are investigating this and will publish further analysis in future technical briefings. this variant has been detected in a number of countries globally. dr renu bindra, incident director, ukhsa said: while ba.2.86 has a significant number of mutations to the viral genome compared to other currently circulating covid 19 variants, the data so far is too limited to draw firm conclusions about the impact this will have on the transmissibility, severity or immune escape properties of the virus. ukhsa scientists are working with international partners to culture the samples and analyse the evidence as it becomes available. however, it is likely to be some time before we have enough data to make a confident assessment. specialists from ukhsa have been working with norfolk county council to offer infection control advice and support following a confirmed outbreak of ba.2.86 in a care home. it is clear that there is some degree of widespread community transmission, both in the uk and globally, and we are working to ascertain the full extent of this. in the meantime, it remains vital that all those eligible come forward to receive their autumn vaccine as soon as it is offered to them. the department of health and social care (dhsc) announced last week that the autumn vaccine programme will be brought forward to 11 september as a precautionary measure following the emergence of ba.2.86. the uk health security agency (ukhsa) has published a situational assessment for sars cov 2 variant v 23aug 01 (ba.2.86). the uk health security agency (ukhsa) has published an initial risk assessment of the sars cov 2 variant ba.2.86. this variant was detected in the uk on friday 18 august, and has also been identified in israel, denmark and the us. it has been designated as v 2023aug01 for the purpose of ukhsa monitoring. the newly identified variant has a high number of mutations and is genomically distant from both its likely ancestor, ba.2, and from currently circulating xbb derived variants. there is currently one confirmed case in the uk in an individual with no recent travel history, which suggests a degree of community transmission within the uk. identifying the extent of this transmission will require further investigation. there is currently insufficient data to assess the relative severity or degree of immune effectiveness compared to other currently circulating variants. dr meera chand, deputy director, ukhsa said: v 2023aug01 was designated as a variant on 18 august 2023 on the basis of international transmission and significant mutation of the viral genome. this designation allows us to monitor it through our routine surveillance processes. we are aware of one confirmed case in the uk. ukhsa is currently undertaking detailed assessment and will provide further information in due course. ukhsa will continue to monitor the situation closely and will publish the results of our analysis when they are available. the uk health security agency (ukhsa) has released variant technical briefing 52. the full document and underlying data is available on gov.uk. the uk health security agency (ukhsa) has released variant technical briefing 51. the full document and underlying data is available on gov.uk. the uk health security agency (ukhsa) has released variant technical briefing 50. the full document and underlying data is available on gov.uk. the uk health security agency (ukhsa) has released a new variant technical briefing detailing updated analysis of epidemiological and genomic data relating to sars cov 2 variants currently circulating in the uk, including the xbb.1.5 variant which has been increasing in the us in recent months. the analysis shows that coronavirus (covid 19) cases in the uk are primarily made up of bq.1 and its sublineages, consistent with the ukhsa risk assessment published in october. two variants, ch.1.1 and xbb.1.5, appear to have a growth advantage in the uk. both are variants in the omicron family. xbb.1.5 remains at very low prevalence in the uk, so estimates of growth are highly uncertain. the risk assessment conducted by ukhsa together with academic partners found that ch.1.1 and xbb.1.5 are currently the variants most likely to take over from bq.1 as the next dominant variant in the uk, unless further novel variants arise. neither have been designated as variants of concern by ukhsa. dr meera chand, director of clinical and emerging infections, ukhsa, said: through our genomic surveillance we continue to see evolution of variants in the omicron family. ukhsa is constantly monitoring the situation and working to understand the implications for public health. vaccination remains our best defence against future covid 19 waves, so it is still as important as ever that people come take up all the doses for which they are eligible as soon as possible. the uk health security agency (ukhsa) has published its latest covid 19 variant technical briefing. it contains epidemiological data and updated analysis of covid 19 variants currently circulating in the uk. a number of omicron variants are currently circulating in england, many of which have acquired mutations which may produce a degree of immune escape. omicron sublineages bq.1 and xbb have been given ukhsa variant designations to facilitate continued studies. neither have currently been designated as variants of concern. bq.1 (v 22oct 01) is a ba.5 sub lineage which has been designated on the basis of rapid growth. so far, there have been 717 v 22oct 01 sequences uploaded from the uk to the international gisaid database. xbb (v 22oct 02) is a recombinant lineage derived from 2 previous omicron sublineages. currently there are 18 uk samples in gisaid, out of a global total of 1,086; 639 samples have been uploaded from singapore, and it is thought that xbb may be a factor in the recent spike in cases there. neutralisation studies are currently being undertaken at the university of oxford. overall, data shows significant reductions in neutralisation against several of the newly emergent variants (ba.2.75.2, ba.2.3.20 and bj.1), compared to ba.2, ba.4 and the dominant ba.5. this suggests that, as immunity begins to wane, these newly emerging ba.2 variants may fuel future waves of sars cov 2 infection. dr meera chand, director of clinical and emerging infection at ukhsa, said: it is not unexpected to see new variants of sars cov 2 emerge. neither bq.1 nor xbb have been designated as variants of concern and ukhsa is monitoring the situation closely, as always. vaccination remains our best defence against future covid 19 waves, so it is still as important as ever that people come take up all the doses for which they are eligible as soon as possible. the latest uk health security agency (ukhsa) covid 19 variant technical briefing, published today, includes updated epidemiological analysis which indicates that omicron ba.5 has, as expected, become the dominant sars cov 2 variant in the uk. an estimated 78.7% of confirmed cases in england are ba.5 which was first identified in april and was designated as a variant of concern on 18 may. ukhsa’s latest national flu and covid 19 surveillance report indicates that the increase in covid 19 case rates and hospitalisations continues to show signs of slowing. however, ukhsa scientists say there is no room to be complacent. people aged 75 and over remain at particular risk of severe disease if they are not up to date with their vaccinations. omicron ba.2.75, the variant derived from the ba.2 lineage which was identified internationally earlier this month, has now been categorised as a separate variant and given the designation v 22jul 01. this designation means that data relating to ba.2.75 will now be reported separately from other ba.2 cases. there are small numbers of cases in the uk and this designation is intended to allow investigation into the specific properties of this variant. as of 18 july 2022, there were 24 cases of ba.2.75 in the uk. of these, 20 were in england, 3 in scotland and 1 in wales. dr meera chand, ukhsa director of clinical an emerging infection, said: we continue to monitor the emergence of new variants and give them variant designations if they are sufficiently distinct to warrant separate epidemiological and laboratory assessment. it is not unexpected to see new lineages and continued investigation is a normal part of the surveillance of an infectious disease. it is important that everyone ensures that they are up to date with vaccinations offered as they remain our best form of defence against severe illness. the uk health security agency (ukhsa) is reminding people to ensure their covid 19 vaccinations are up to date and to continue following covid safe behaviours, as latest technical data indicates ba.4 and ba.5 have become dominant in the uk and are driving the recent increase in infections. the ukhsa’s covid 19 variant technical briefing 43, published today, includes epidemiological analysis that shows that omicron ba.4 and ba.5 now make up more than half of new covid 19 cases in england, accounting for approximately 22% and 39% of cases, respectively. omicron ba.4 and omicron ba.5 were designated as variants of concern on 18 may on the basis of an apparent growth advantage over the previously dominant omicron ba.2 variant. ukhsa’s latest analysis suggests that omicron ba.5 is growing 35.1% faster than omicron ba.2, while omicron ba.4 is growing approximately 19.1% faster. this suggests that ba.5 is likely to become the dominant covid 19 variant in the uk. the increasing prevalence of omicron ba.4 and ba.5 is likely to be a factor in the recent increase in cases seen in the uk and elsewhere, though there is currently no evidence that omicron ba.4 and ba.5 cause more severe illness than previous variants. so far, vaccination means that the rise in cases is not translating to a rise in severe illness and deaths. ukhsa scientists are urging anyone who has not had all the vaccines they are eligible for to make sure that they get them as soon as possible. covid 19 has not gone away, so it is also vitally important that people continue to follow the guidance. stay at home if you have any respiratory symptoms or a fever and limit contact with others until you are feeling better, particularly if they are likely to be at greater risk if they contract covid 19. professor susan hopkins, chief medical advisor at ukhsa said: it is clear that the increasing prevalence of omicron ba.4 and ba.5 are significantly increasing the case numbers we have observed in recent weeks. we have seen a rise in hospital admissions in line with community infections but vaccinations are continuing to keep icu admissions and deaths at low levels. as prevalence increases, it’s more important than ever that we all remain alert, take precautions, and ensure that we’re up to date with covid 19 vaccinations, which remain our best form of defence against the virus. it’s not too late to catch up if you’ve missed boosters, or even first doses so please take your recommended vaccines. our data also show that 17.5 per cent of people aged 75 years and over have not had a vaccine within the past six months, putting them more at risk of severe disease. we urge these people in particular to get up to date. if you have any symptoms of a respiratory infection, and a high temperature or feel unwell, try to stay at home or away from others   especially those who are elderly or vulnerable. face coverings in crowded indoor spaces and hand washing will help to reduce transmission of infection and are especially important if you have any respiratory symptoms. ukhsa encourage everyone to continue to follow the most up to date guidance. as we learn to live safely with covid 19, there are actions we can all take to help reduce the risk of catching covid 19 and passing it on to others. the risk of catching or passing on covid 19 is greatest when someone who is infected is physically close to, or sharing an enclosed or poorly ventilated space with, other people. you will not always know whether someone you come into contact with is at higher risk of becoming seriously ill from respiratory infections, including covid 19. they could be strangers (for example people you sit next to on public transport) or people you may have regular contact with (for example friends and work colleagues). there are simple things you can do in your daily life that will help reduce the spread of covid 19 and other respiratory infections and protect those at highest risk. things you can choose to do are: the uk health security agency (ukhsa) has elevated the classification of the covid 19 variants omicron ba.4 and omicron ba.5 to variants of concern (vocs) on the basis of observed growth. as of 17 may, 115 cases of ba.4 and 80 cases of ba.5 have been confirmed in england and the latest ukhsa variant technical briefing has been published today. whilst omicron ba.4 and ba.5 are in the early stages of growth in the uk, analysis of the available data suggests that they are likely to have a growth advantage over the currently dominant omicron ba.2 variant. there can be several reasons for growth advantage, but in the case of ba.4 and ba.5, laboratory data suggests a degree of immune escape which is likely to contribute. dr meera chand, director of clinical and emerging infections at ukhsa, said: the reclassification of these variants as variants of concern reflects emerging evidence on the growth of ba.4 and ba.5 internationally and in the uk. whilst the impact of these variants is uncertain, the variant classification system aims to identify potential risk as early as possible. ukhsa is undertaking further detailed studies. data and analysis will be released in due course through our regular surveillance reporting. the uk health security agency (ukhsa) has released variant technical briefing 41. this edition includes an update on the current circulating lineages, including several cases of omicron ba.4 and ba.5 which have been detected in the uk. ukhsa has also released a variant risk assessment for omicron ba.4 and ba.5, summarising the emerging epidemiology and laboratory evidence. as of 2 may 2022, 21 confirmed cases of omicron ba.4 and 19 confirmed cases of omicron ba.5 have been detected in england. dr meera chand, director of clinical and emerging infections at ukhsa, said: ukhsa continues to monitor and study variants of sars cov 2 closely and is working with academic partners to rapidly assess the significance of the lineages ba.4 and ba.5. our continued genomic surveillance allows us to further investigate variants that are growing within the uk. ukhsa’s most recent variant technical briefing includes examination of a number of recombinant variants which have been identified in the uk, as well as updated epidemiological and genomic analysis of omicron ba.2. a recombinant variant occurs when an individual becomes infected with 2 or more variants at the same time, resulting in a mixing of their genetic material within the patient’s body. this is not an unusual occurrence and several recombinant sars cov 2 variants have been identified over the course of the pandemic. as with any other coronavirus (covid 19) variant, the vast majority do not confer any advantage to the virus and die out relatively quickly. ukhsa’s new analysis examines 3 recombinants, known as xf, xe, and xd. of these, xd and xf are recombinants of delta and omicron ba.1, while xe is a recombinant of omicron ba.1 and ba.2. in the uk, 38 cases of xf have been identified, though none have been seen since mid february. there is currently no evidence of community transmission within the uk. xd has not been identified in the uk to date, though 49 cases have been reported to global databases, the majority of these are in france. a total 637 cases of xe   a recombinant of omicron ba.1 and ba.2   have been confirmed in the uk so far. the earliest of these has a specimen date of 19 january 2022. there is currently insufficient evidence to draw conclusions about growth advantage or other properties of this variant. we continue to monitor all recombinants closely, routinely through our world leading genomic surveillance and sequencing capability. professor susan hopkins, chief medical advisor, ukhsa said: recombinant variants are not an unusual occurrence, particularly when there are several variants in circulation, and several have been identified over the course of the pandemic to date. as with other kinds of variant, most will die off relatively quickly. this particular recombinant, xe, has shown a variable growth rate and we cannot yet confirm whether it has a true growth advantage. so far there is not enough evidence to draw conclusions about transmissibility, severity or vaccine effectiveness. ukhsa will continue to monitor the situation closely as a matter of routine, as we do all data relating to sars cov 2 variants both in the uk and internationally. the variant technical briefing also includes updated analysis on omicron ba.2, currently the dominant variant in the uk. ba.2 is estimated to account for approximately 93.7% of cases in england, with the highest prevalence in the south east (96.4%) and the lowest in the east midlands (91.1%). data for scotland, wales and northern ireland is not included in the ukhsa technical briefing. ba.2 continues to demonstrate a substantial growth advantage. since the middle of february, this growth rate has settled at approximately 75% higher than other circulating omicron lineages in england. ongoing analysis by ukhsa has found no evidence that infection with omicron ba.2 results in a greater risk of hospitalisation, compared to omicron ba.1. ukhsa has also this week published further vaccine effectiveness data against hospitalisation following a booster dose. for the first time, this data includes analysis on vaccine effectiveness 15+ weeks after the booster dose. this data shows that protection against severe illness from covid 19 remains at over 90% in those aged 65 and over up to 14 weeks after a booster dose. while there is a suggestion that this wanes slightly after 15 weeks, protection in this age group remains high at over 85%. this paper can be found as a pre print, and the data is referred to in the latest vaccine surveillance report. ukhsa is updating its variant classification system to give a clearer indication of which variants have significant changes compared to the current dominant variant. under the new system, the variant of concern (voc) label will be assigned to variants which are currently emerging or circulating, and which the following characteristics can be confirmed or predicted: 1. a detrimental change in biological properties (changes in transmissibility, severity or immune evasion) compared to the current dominant variant. 2. a growth rate potentially compatible with the eventual replacement of the current dominant variant. there will be no other categorisation of variants, including no variant under investigation (vui) category. previous variants of concern which no longer meet the criteria will be redesignated. ukhsa will continue to designate new variants, and these will receive a variant number (in the format v date number). we will continue to closely analyse all available biological, epidemiological and genomic evidence for any sars cov 2 variant in the uk or internationally. these changes will take effect as of 1 april 2022 and will be reflected in full in future technical briefings. the uk health security agency (ukhsa) has published variant technical briefing 37. the uk health security agency (ukhsa) has published analyses of omicron sub lineage ba.2. data by variant related to intensive care unit admissions is presented and an analysis into the effect of the recent surge of omicron cases in care homes is also available in the latest technical briefing. as of 24 january 2022, 1,072 genomically confirmed cases of ba.2 have been identified in england and all assessments remain preliminary whilst case numbers are relatively low. ba.2 has an increased growth rate compared to ba.1 in all regions of england where there are enough cases to assess it. while growth rates can be overestimated in early analyses of a new variant, the apparent growth advantage is currently substantial. analysis from routine contact tracing data indicates that transmission is likely to be higher among contacts of ba.2 cases in households (13.4%) than those for contacts of other omicron cases (10.3%) in the period 27 december 2021 to 11 january 2022. these early findings should be interpreted with caution as transmission data and dynamics can fluctuate, meaning that early findings can change quickly when new variants are identified. a preliminary assessment did not find evidence of a difference in vaccine effectiveness against symptomatic disease for ba.2 compared to ba.1. after 2 doses, vaccine effectiveness was 9% and 13% respectively for ba.1 and ba.2, after 25+ weeks. this increased to 63% for ba.1 and 70% for ba.2 at 2 weeks following a third vaccine. there is currently no data on the severity of ba.2. ukhsa will continue to carry out laboratory and epidemiological investigations to better understand the characteristics of this variant. dr susan hopkins, chief medical advisor for ukhsa, said: ongoing variant analysis is an important part of our pandemic response. thanks to the expertise of scientists at ukhsa and partner organisations, we’re able to respond quickly to new variations of the virus. we now know that ba.2 has an increased growth rate which can be seen in all regions in england. we have also learnt that ba.2 has a slightly higher secondary attack rate than ba.1 in households. although hospitalisations and deaths remain low, cases are still high in some areas and some age groups so it’s important that we continue to act cautiously as restrictions are lifted. consider wearing a face covering when in crowded places. take a vaccine to protect yourself against covid 19. if you have any symptoms, take a test. ukhsa has also published analyses related to the original omicron strain ba.1. where variant information was available, the majority of intensive care unit (icu) admissions from 24 november 2021 to 19 january 2022 had delta infections. overall numbers of icu admissions have decreased over time, but where data was available admissions with omicron have increased from 9% to more than 50% in the most recent week. although there was a rapid increase in sars cov 2 infections in care homes during december 2021 in line with case rises in the community, there has not been an associated increase in hospital admissions. our findings suggest the current wave of omicron infections is unlikely to lead to a major surge in severe disease in care home populations with high levels of vaccine coverage and/or natural immunity. there were very limited numbers of ba.2 in this study and no inferences can be made regarding ba.2. the omicron variant sub lineage known as ba.2 has been designated a variant under investigation ( vui 22jan 01) by the uk health security agency (ukhsa). overall, the original omicron lineage, ba.1, is dominant in the uk and the proportion of ba.2 cases is currently low. the designation was made on the basis of increasing numbers of ba.2 sequences identified both domestically and internationally. there is still uncertainty around the significance of the changes to the viral genome, and further analyses will now be undertaken. to date, there have been 426 cases of omicron ba.2 confirmed by whole genome sequencing (wgs), with the earliest dated 6 december 2021. the areas with the largest number of confirmed cases are london (146) and the south east (97). data for the devolved administrations will follow in due course. early analyses suggest an increased growth rate compared to ba.1, however, growth rates have a low level of certainty early in the emergence of a variant and further analysis is needed. in total, 40 countries have uploaded 8,040 ba.2 sequences to gisaid since 17 november 2021. at this point it is not possible to determine where the sublineage may have originated. the first sequences were submitted from the philippines, and most samples have been uploaded from denmark (6,411). other countries that have uploaded more than 100 samples are india (530), sweden (181), and singapore (127). omicron ba.2 lacks the genetic deletion on the spike protein which produces s gene target failure (sgtf) in some polymerase chain reaction (pcr) tests, which has been used as a proxy for omicron cases previously. dr meera chand, covid 19 incident director at ukhsa, said: it is the nature of viruses to evolve and mutate, so it’s to be expected that we will continue to see new variants emerge as the pandemic goes on. our continued genomic surveillance allows us to detect them and assess whether they are significant. so far, there is insufficient evidence to determine whether ba.2 causes more severe illness than omicron ba.1, but data is limited and ukhsa continues to investigate. case rates remain high throughout the uk and we must remain vigilant and take up vaccinations. we should all continue to test regularly with lfds and take a pcr test if symptoms develop. health and social care secretary, sajid javid, said: we are learning to live with this virus   and thanks to our world leading surveillance system we can rapidly detect and carefully monitor any genetic changes to covid 19. our exceptional vaccine rollout means the number of people severely affected by covid 19 is low, and the uk’s innovation and research has discovered life saving treatments for those most at risk from covid 19. as we cautiously return to plan a, i encourage you to give yourself and your loved ones the best protection possible and get boosted now. as is routine for any new variants under investigation, ukhsa is carrying out laboratory and epidemiological investigations to better understand the characteristics of this variant. we will continue to monitor this situation closely and recommend appropriate public health measures if needed. more detail will be available in ukhsa’s regular variant technical briefings. the uk health security agency (ukhsa) has published a new variant technical briefing containing an updated omicron risk assessment, alongside analysis on vaccine efficacy, sub lineages and symptoms. the updated risk assessment includes indicators for infection severity in both adults and children. there is now high confidence that the omicron variant causes low severity of disease in adults. however, confidence levels for severity indicators for children are low because further analysis is required to compare the risk of hospitalisation between omicron and delta, and to assess the clinical nature of illness in children. susan hopkins, chief medical advisor at ukhsa, said: this latest set of analysis once again demonstrates that a booster dose of the vaccine provides you with significant protection against hospitalisation from omicron. booster doses also increase the protection against symptomatic and asymptomatic infection which will reduce transmission in the population. while signs remain encouraging on omicron’s severity compared with delta, the high levels of community transmission continue and may cause pressures on health services. we’ll be undertaking further analysis to investigate the small rise in the number of children admitted to hospital but currently coronavirus (covid 19) poses a very low health risk to children and infants. early data shows that young children who are hospitalised experience mild illness and are discharged after short stays in hospital. getting your booster jab remains the most effective way of protecting yourself and others from infection and severe disease. while prevalence remains high, make sure to wear your mask in indoor settings and take a lateral flow test before meeting others. if you develop any symptoms, isolate immediately and get a pcr test. as of january 10 2022, 53 sequences of the ba.2 sub lineage of omicron had been identified in the united kingdom. this sub lineage, which was designated by pangolin on 6 december 2021, does not have the spike gene deletion at 69 70 that causes s gene target failure (sgtf), which has previously been used as a proxy to detect cases of omicron. ukhsa are continuing to monitor data on the ba.2 sub lineage closely. vaccine effectiveness (ve) against omicron has again been updated in this week’s briefing. as previously published, data continues to show vaccine effectiveness against hospitalisation for omicron remains high. a booster dose was associated with a 74% reduced risk of hospitalisation in the first 2 to 4 weeks after vaccination, with the figure dropping to 66% 10 weeks or more after this dose. when combined with ve against symptomatic disease, the reduced risk of hospitalisation climbed to 92% 2 to 4 weeks after a third dose of the vaccine, down to 83% after 10 weeks or more. there is further data showing that effectiveness against symptomatic disease is significantly lower compared to the delta variant, and wanes more quickly. analysis shows that protection against symptomatic disease 2 to 4 weeks after a booster dose ranges from around 65% to 75%, dropping to 55% to 65% at 5 to 9 weeks   and 45% to 50% 10 weeks or more following the booster dose. in the siren study, a large cohort of healthcare workers are tested regularly by pcr to detect asymptomatic infection in addition to normal testing practices for symptomatic infection. updated analysis shows the additional incremental benefit from each vaccine exposure including for boosters, even in those who have had prior infection. prior infection is 44% effective at preventing future infection, increasing to 71% with 3 doses of the vaccine. technical briefing 34 contains further analysis on symptom comparison on omicron and delta. of symptomatic cases, loss of smell and taste was found to be more common in people who tested positive for delta than those who had omicron. this matches a recent study led by oxford university and the office for national statistics (ons), using data from the covid 19 infection survey produced by the latter. there are indications of a small rise in children admitted to hospital, but these early signals need further investigations before we can draw any conclusions about whether omicron causes more severe illness in children. early data shows that young children who are hospitalised experience mild illness and are discharged after short stays in hospital. data continues to show covid 19 poses a very low health risk to children and infants. however, any stay in hospital for a child is too long if you’re a parent and it’s important we all take precautions to avoid the spread of infection. follow the latest self isolation rules if you develop symptoms   wear a mask where required to do so, take regular lfd tests and observe good hand hygiene. we continue to urge everyone who is eligible to get a covid 19 vaccine and booster. health and social care secretary sajid javid said: this data is yet more evidence that vaccines remain our best line of defence against covid 19. booster jabs are protecting people against infection and severe disease   so i urge you to play your part in our national mission and get boosted now. the uk health security agency (ukhsa) has published a new variant technical briefing containing updated analysis on omicron hospitalisation risk and vaccine efficacy against symptomatic disease and hospitalisation. protection against hospitalisation from vaccines is good against the omicron variant. one dose of any vaccine was associated with a 35% reduced risk of hospitalisation among symptomatic cases with the omicron variant, 2 doses with a 67% reduction up to 24 weeks after the second dose and a 51% reduced risk 25 or more weeks after the second dose. a third dose was associated with a 68% (95% confidence interval 52 to 82%) reduced risk of hospitalisation when compared to similar unvaccinated individuals. when the reduced risk of hospitalisation was combined with vaccine effectiveness against symptomatic disease, the vaccine effectiveness against hospitalisation was estimated as 52% after one dose, 72% 2 to 24 weeks after dose 2, 52% 25+ weeks after dose 2 and 88% 2 weeks after a booster dose. as set out last week, the effectiveness of all vaccines against symptomatic infection continues to be lower in all periods against omicron compared to delta. the latest data confirmed that among those who had received 2 doses of astrazeneca, there was no effect against omicron from 20 weeks after the second dose. among those who had received 2 doses of pfizer or moderna, effectiveness dropped from around 65 to 70% down to around 10% by 20 weeks after the second dose. two to 4 weeks after a booster dose, vaccine effectiveness ranged from around 65 to 75%, dropping to 55 to 70% at 5 to 9 weeks and 40 to 50% from 10+ weeks after the booster. working alongside cambridge university mrc biostatistics unit, ukhsa analysed 528,176 omicron cases and 573,012 delta cases between 22 november and 26 december to assess the risk of hospitalisation in england after testing positive for omicron. this analysis found that the risk of presentation to emergency care or hospital admission with omicron (testing for symptomatic or asymptomatic infection) was approximately half of that for delta, while the risk of hospital admission alone with omicron was approximately one third of that for delta. in this analysis, the risk of hospitalisation is lower for omicron cases with symptomatic or asymptomatic infection after 2 and 3 doses of vaccine, with an 81% (95% confidence interval 77 to 85%) reduction in the risk of hospitalisation after 3 doses compared to unvaccinated omicron cases. this analysis is not an assessment of hospital severity, which will take further time to assess. health and social care secretary sajid javid said: this is more promising data which reinforces just how important vaccines are. they save lives and prevent serious illness. this analysis shows you are up to 8 times more likely to end up in hospital as a result of covid 19 if you are unvaccinated. it is never too late to come forward for your first dose and it’s vital that everyone comes forward to get boosted now as we head into the new year. susan hopkins, chief medical adviser at ukhsa, said: the latest set of analysis is in keeping with the encouraging signs we have already seen. however, it remains too early to draw any definitive conclusions on hospital severity, and the increased transmissibility of omicron and the rising cases in the over 60s population in england means it remains highly likely that there will be significant pressure on the nhs in coming weeks. the data once again shows that coming forward for your jab, particularly your third dose, is the best way of protecting yourself and others against infection and severe disease. the uk health security agency (ukhsa) has published the latest variant technical briefing. it contains updated analysis on omicron hospitalisation risk, vaccine efficacy against symptomatic disease from omicron, and the covid 19 reinfection rate. as of 20 december, 132 individuals with confirmed omicron have been admitted to or transferred from emergency departments. over 40% of hospital admissions were in london. of those patients admitted to hospital, 17 had received a booster vaccine, 74 people had 2 doses and 27 people were not vaccinated. the vaccination status was unknown for 6 people, while 8 had received a single dose. fourteen people are reported to have died within 28 days of an omicron diagnosis, ranging in age from 52 to 96 years old. ukhsa analysis shows that the risk of hospital admission for an identified case with omicron is reduced compared to a case of delta. this analysis excludes individuals with confirmed previous covid 19 infection. an individual with omicron is estimated to be between 31 and 45% less likely to attend a&e compared to delta, and 50 to 70% less likely to be admitted to hospital. this analysis is preliminary and highly uncertain because of the small numbers of omicron cases currently in hospital, inability to effectively measure all previous infections and the limited spread of omicron into older age groups. this is consistent with analysis published yesterday by imperial college london and the university of edinburgh. the population rate of people becoming infected with omicron after having previously contracted covid 19 has increased sharply. of those with omicron, 9.5% have had covid 19 before, which is likely to be a substantial underestimate of the proportion of reinfections, as many prior infections will have been asymptomatic and not picked up by the analysis. vaccine efficacy analysis continues to show lower effectiveness for symptomatic omicron disease. there is evidence that protection against symptomatic disease wanes after the second dose of vaccine, and then improves after the booster. but the latest data suggests this extra protection starts to wane more rapidly, being about 15 to 25% lower from 10 weeks after the booster dose. there are insufficient severe cases of omicron as yet to analyse vaccine effectiveness against hospitalisation, but this is more likely to be sustained, particularly after a booster. omicron continues to grow faster than delta, with an increased risk of transmission, particularly in contacts outside of the household. therefore, although early suggestions are that individuals may be less likely to require hospitalisation, many more people are likely to become infected. even if a smaller proportion of these individuals require hospitalisation, these are still large numbers of people requiring hospital care and pressures on the nhs will increase. it is therefore vital that people continue to exercise caution in order to limit the transmission of the virus. dr jenny harries, ukhsa chief executive, said: our latest analysis shows an encouraging early signal that people who contract the omicron variant may be at a relatively lower risk of hospitalisation than those who contract other variants. however, it should be noted both that this is early data and more research is required to confirm these findings. cases are currently very high in the uk, and even a relatively low proportion requiring hospitalisation could result in a significant number of people becoming seriously ill. the best way that you can protect yourself is to come forward for your first 2 doses of vaccine, or your booster jab and do everything you can to stop onward transmission of the infection. health and social care secretary sajid javid said: this new ukhsa data on omicron is promising   while 2 doses of the vaccine aren’t enough, we know boosters offer significant protection against the variant and early evidence suggests this strain may be less severe than delta. however, cases of the variant continue to rise at an extraordinary rate   already surpassing the record daily number in the pandemic. hospital admissions are increasing, and we cannot risk the nhs being overwhelmed. this is early stage analysis and we continue to monitor the data hour by hour. it is still too early to determine next steps, so please stay cautious this christmas and get your booster as soon as possible to protect yourself and your loved ones. the uk health security agency (ukhsa) has published the latest variant technical briefing. ukhsa has performed an initial laboratory evaluation of the current lateral flow devices (lfds) for covid 19 in current use in the uk. initial data suggests that lfds are as likely to detect omicron as other variants including delta, which has been the dominant variant in the uk from may to december 2021. of 5,153 individuals identified with an omicron infection between 1 november and 11 december 2021, 305 were linked to a previous confirmed infection and had an interval from the previous positive test of 90 days or more. the data so far suggests an increase in overall reinfection rates, alongside an increase in first infections. dr jenny harries, ukhsa chief executive, said: our data shows that lfd tests are similarly able to detect covid 19 in individuals who have been exposed to omicron as in those exposed to previous variants. this is very encouraging. as we all work to limit the high levels of transmission of this variant over the christmas period, we are urging people to test regularly, particularly before attending social gatherings. as always, the booster vaccine remains the best protection against infection. please come forward to receive your booster as soon as possible. the uk health security agency (ukhsa) can confirm that 10 people have been hospitalised with the omicron variant in england; the individuals were diagnosed on or before admission. these people are spread around the country and are a mix of age ranges between 18 to 85 years   the majority had received 2 doses of vaccination. one individual diagnosed in hospital has sadly died. dr susan hopkins, chief medical adviser at ukhsa, said: hospitalisations always lag a few weeks behind infections, therefore it isn’t surprising that we have started to see people being admitted to hospital with the omicron variant. our data shows that getting the booster vaccine is more effective against this variant than 2 doses alone. everyone over 18 is now able to walk into a vaccine centre, so do not hesitate to get yours. the latest variant technical briefing suggests that omicron continues to grow rapidly in all regions of england as measured by confirmed cases and s gene target failure (sgtf). none of the cases to date is known to have been hospitalised or died. studies of contacts show that omicron is transmitting more effectively than delta. the uk health security agency (ukhsa) estimates that if omicron continues to grow at the present rate, the variant will become the dominant strain, accounting for more than 50% of all covid 19 infections in the uk by mid december. it is projected that if current trends continue unchanged, the uk will exceed one million infections a day by the end of this month. the technical briefing also includes early analysis of vaccine effectiveness against the omicron variant compared to delta. the analysis looked at 581 people with confirmed omicron. it showed that the astrazeneca and pfizer biontech vaccines provided much lower levels of protection against symptomatic infection compared to the protection that they provide against delta. however, the preliminary data showed effectiveness against the new variant appears to increase considerably in the early period after a booster dose, providing around 70% to 75% protection against symptomatic infection. the analysis included very small numbers of cases as only a few people in the uk currently have this variant, meaning this data should be interpreted with caution until more cases have been studied. due to the early nature of the findings, all estimates are subject to significant uncertainty and are subject to change. the early observations for 2 doses of astrazeneca are particularly likely to be unreliable as they are based on small numbers and are likely to reflect an older population and a population with more co morbidities than those given the pfizer vaccine. there are differences in the populations that have received different vaccines. astrazeneca was the main vaccine used early in the programme in care homes and among those in clinical risk groups. these groups have been prioritised for booster doses since the start of the rollout in september to increase their protection. the percentage of people to have received a booster dose will also already be higher in older age groups and those with underlying health conditions due to prioritisation of the rollout so far. vaccine effectiveness against severe disease from omicron is not yet known but is expected to be significantly higher than protection against symptomatic disease. data on this won’t be available for several weeks. it is vital that everyone over the age of 40 who is eligible for a booster jab comes forward as soon as possible to get increased protection against this new variant. those aged 18 to 39 should wait to be called. dr mary ramsay, head of immunisation at ukhsa, said: these early estimates should be treated with caution but they indicate that a few months after the second jab, there is a greater risk of catching the omicron variant compared to delta strain. the data suggests this risk is significantly reduced following a booster vaccine, so i urge everyone to take up their booster when eligible. we expect the vaccines to show higher protection against the serious complications of covid 19, so if you haven’t yet had your first 2 doses please book an appointment straight away. working from home where possible, consistently wearing masks in crowded or enclosed spaces, washing your hands regularly and isolating and getting tested if you feel unwell are also vitally important in reducing the impact of covid 19 this winter. ukhsa has also published a breakdown of confirmed omicron cases and sgtf cases by local authority. the most affected local authorities are west northamptonshire, where there are 49 confirmed cases and 68 sgtf, and manchester, where there are 7 confirmed cases and 61 sgtf. evidence continues to show that omicron is transmitting more rapidly than the dominant delta variant. studies of households and contacts have found that there is a higher risk of transmission to contacts from an omicron case, when compared to delta. dr jenny harries, ukhsa chief executive, said: once again, we urge everyone who is able to get a booster jab to come forward and do so. it is the best defence we have against this highly transmissible new variant. it is also absolutely critical that we all do what we can to reduce transmission in the community so that we have time to administer as many booster doses as possible. please make sure you follow all the available guidance. work from home if you are able to, wear a mask indoors around other people, and ventilate indoor spaces well. sajid javid, secretary of state for health and social care, said: today’s new data shows how important booster jabs are to protect us against this variant. they are our best defence and we have turbocharged our rollout programme inviting 7 million more people over the age of 40 to get their booster jab so even more people get protection from this disease. i urge you to come forward as soon as you’re eligible to help keep yourself and your loved ones safe. the assessment suggests that omicron is displaying a significant growth advantage over delta, meaning that it is likely to outcompete delta in the uk and become the dominant variant. this assessment is based on analysis of uk data showing increased household transmission risk, increased secondary attack rates (such as the chance of each case infecting another individual) and increased growth rates compared to delta. if the growth rate and doubling time continue at the rate we have seen in the last 2 weeks, we expect to see at least 50% of coronavirus (covid 19) cases to be caused by omicron variant in the next 2 to 4 weeks. the risk assessment also suggests that omicron displays a reduction in protection offered by having had a previous infection or vaccination. whilst there are insufficient data to quantify either vaccine effectiveness or risk of reinfection in the uk exactly, the observed growth, case distribution and early analyses in both south africa and the uk are consistent with some loss of immune protection against infection. new studies are being undertaken to assess this further. there is insufficient data to make any assessment of protection against severe disease, or to assess the severity of illness caused by omicron. further studies are underway in the uk and abroad. in addition, ukhsa has published data which shows the detection of cases exhibiting s gene target failure (sgtf) in recent weeks across the country. approximately half of pcr tests in the uk are able to detect sgtf. sgtf is a useful indicator of the presence of omicron, because as a rule delta cases have the s gene and omicron cases do not. however, it is not confirmatory as there are a number of other reasons that a sample might exhibit sgtf. for example, there are still a small number of cases of other variants, such as alpha, in the uk which would also result in s gene dropout or there is a lower amount of virus present in the sample where s gene dropout cannot be confirmed. positive tests with sufficient virus detected from people arriving in the uk are sent for confirmation through whole genome sequencing, regardless of the presence or absence of sgtf. as part of ukhsa’s routine genomic surveillance, approximately 15 to 20% of all positive pcr tests are also sent for sequencing. until the week beginning 23 november 2021, the weekly count of cases with sgtf was routinely less than 150, making up less than 0.1% of all cases. analyses of sequenced sgtf samples has indicated that until mid november, more than 99% of these were delta cases. in the most recent week of data (specimen dates from 30 november 2021 reported as of 6 december), the number of cases with sgtf has increased to 705. the majority of these cases are located in london and the south east. trends in sgtf over and time are however affected by the coverage of laboratories contributing to this surveillance data. ukhsa chief medical advisor, dr susan hopkins said: it is increasingly evident that omicron is highly infectious and there is emerging laboratory and early clinical evidence to suggest that both vaccine acquired and naturally acquired immunity against infection is reduced for this variant. it is therefore absolutely critical that we all do everything that we can to help break the chains of transmission and slow the spread of this new variant. vaccination is critical to help us bolster our defences against becoming severely ill from this new variant   please get your first, second, third or booster jab without delay. please also make sure to follow all government guidance to reduce the spread of infection. it remains vital that anyone with covid 19 symptoms isolates and gets a pcr test immediately. the latest number of covid 19 cases with mutations consistent with b.1.1.529 in england are published on ukhsa’s social media channels. further information is also available in the latest variant technical briefing. ukhsa is gathering scientific information as quickly as possible in order to inform the right balance of interventions to prevent transmission and protect lives. this includes analysing live samples of the new variant in our laboratories to investigate properties such as response to current vaccines. where individuals are suspected or confirmed to have the omicron variant as the result of testing, their close contacts will be contacted by nhs test and trace, required to self isolate and asked to take a pcr test, regardless of whether they have been vaccinated. anyone who is contacted because of a link to a probable or possible omicron case will be asked to take a pcr test, even if they have received a positive covid 19 pcr test within the last 90 days. dr jenny harries, chief executive of ukhsa, said: we are continuing our efforts to understand the effect of this variant on transmissibility, severe disease, mortality, antibody response and vaccine efficacy. vaccination is critical to help us bolster our defences against this new variant   please get your first, second, third or booster jab without delay. a booster dose for everyone over 18 years is now recommended and will be available at a minimum of 3 months from your last primary course jab. please take up this offer as soon as you are eligible to protect yourself, your families and your communities. please make sure to wear a mask in line with government guidance, including on public transport and in shops, to help break the chains of transmission and slow the spread of this new variant. it’s critical that anyone with covid 19 symptoms isolates and gets a pcr test immediately. the uk health security agency (ukhsa) has identified 75 further cases of covid 19 with mutations consistent with b.1.1.529 in england, in addition to the previous 29 confirmed cases of the sars cov 2 variant known as b.1.1.529. the total number of confirmed cases in england is now 104. the individuals who have tested positive and their contacts have been asked to self isolate. work is underway to identify any links to travel. we have now identified cases in the east midlands, east of england, london, north east, north west, south east, south west and west midlands. ukhsa is carrying out targeted testing at locations where the positive cases were likely to be infectious. 1 case has been identified in wales. a further 16 cases have been identified in scotland, bringing the total in scotland to 29. there are no confirmed cases in northern ireland. dr jenny harries, chief executive of ukhsa, said: increased case detection through focused contact tracing has led to more cases of the omicron variant being identified and confirmed, as we have seen in other countries globally. we are continuing to monitor the data closely. teams nationally and locally are working at pace to identify and trace all close contacts of every omicron case. it is critical that anyone with covid 19 symptoms isolates and gets a pcr test immediately. we have started to see cases where there are no links to travel, suggesting that we have a small amount of community transmission. that’s why it’s so important that everybody, everywhere, takes simple steps to protect themselves from infection. please wear face coverings in line with government guidance, let in fresh air when mixing indoors and wash your hands regularly. vaccination is critical to help us bolster our defences against this new variant so please get your first, second, third or booster jab as soon as you are eligible to protect yourself, your families and your communities. where individuals are identified as being a possible or probable case of omicron, their close contacts will be contacted and advised they are required to isolate for 10 days, regardless of whether they have been vaccinated or received a negative covid 19 test result. everybody who is contacted or has symptoms should take a pcr test as soon as possible, even if they have received a positive covid 19 pcr test within the last 90 days. ukhsa is acting to get scientific information available as quickly as possible in order to inform the right balance of interventions to prevent transmission and protect lives. this will include analysing live samples of the new variant in our laboratories to investigate properties including its response to current vaccines. as viruses mutate often and at random, it is not unusual for small numbers of cases to arise featuring new sets of mutations. any variants showing evidence of spread are rapidly assessed. the uk health security agency (ukhsa) has published a new variant technical briefing describing ongoing work on the omicron variant. it includes a complete list of studies planned and already under way into the emerging variant. a new risk assessment for omicron voc 21nov 01 (b.1.1.529) has also been published and is available here. delta remains the predominant variant in england, accounting for over 99% of all covid 19 cases. as of 30 november 2021, there are 22 confirmed cases of omicron (b.1.1.529), identified through sequencing or genotyping in england. none of these cases are known to have been hospitalised or died. more recent data on omicron cases is published regularly here. available data are limited at this early stage, but it remains likely that the cases identified so far are a result of a number of separate introductions into the country. omicron has a deletion at position 69/70 of the spike protein which allows it to be tracked through s gene target failure (sgtf) in some pcr tests. currently, approximately half of all tests conducted in the uk are able to detect sgtf. sgtf is not a 100% accurate test for omicron and results are regularly evaluated against sequencing to ensure they are interpreted correctly. however, increases in sgtf can give a useful early indication of variant spread. the proportion of test results displaying sgtf has been very low in recent months but an increase has been observed in the past week. this is still a very small number of cases but is being investigated carefully to understand whether it is related to travel, any other variant or whether there is evidence of spread of omicron beginning in the community. ukhsa chief executive, jenny harries said: i want to thank everyone who has been working globally and locally to help us act incredibly quickly in response to the omicron variant. thanks to very high levels of vaccine coverage we already have a robust wall of defence against covid 19 as new variants emerge. we are working as fast as possible to gather more evidence about any impact the new variant may have on severity of disease or vaccine effectiveness. until we have this evidence, we must exercise the highest level of caution in drawing conclusions about any significant risks to people’s health. the most important thing everyone can do now is to get any vaccine dose that you are eligible for   it is by far the most effective action you can take to protect yourself, your families and your communities. it is also vital to continue with all the other precautions we have become used to throughout the pandemic   keep indoor areas well ventilated, wear a face covering in enclosed spaces, and take a rapid lateral flow (or lfd) test before a situation where you may be at high risk of catching or passing on the virus. the uk health security agency (ukhsa) has identified 7 further cases of covid 19 with mutations consistent with b.1.1.529 in england, in addition to the previous 22 confirmed cases of the sars cov 2 variant known as b.1.1.529. the total number of confirmed cases in england is now 29. the individuals who have tested positive and their contacts are all isolating. work is underway to identify any links to travel. we have now identified cases in the east midlands, east of england, london, south east and north west. ukhsa is carrying out targeted testing at locations where the positive cases were likely to be infectious. a further 3 cases have been identified in scotland, bringing the total to 13. dr jenny harries, chief executive of ukhsa, said: “we are continuing our efforts to understand the effect of this variant on transmissibility, severe disease, mortality, antibody response and vaccine efficacy. “vaccination is critical to help us bolster our defences against this new variant   please get your first, second, third or booster jab without delay. “a booster dose for everyone over 18 years is now recommended and will be available at a minimum of 3 months from your last primary course jab. please take up this offer as soon as you are eligible to protect yourself, your families and your communities. “please make sure to wear a mask in line with government guidance, including on public transport and in shops, to help break the chains of transmission and slow the spread of this new variant. “it is very likely that we will find more cases over the coming days as we are seeing in other countries globally and as we increase case detection through focused contact tracing. that’s why it’s critical that anyone with covid 19 symptoms isolates and gets a pcr test immediately.” where individuals are identified as being a possible or probable case, their close contacts will be contacted and advised to isolate for 10 days and to take a test. everybody who is contacted or has symptoms should take a pcr test as soon as possible, even if they have received a positive covid 19 pcr test within the last 90 days. ukhsa is acting to get scientific information available as quickly as possible in order to inform the right balance of interventions to prevent transmission and protect lives. this will include analysing live samples of the new variant in our laboratories to investigate properties such as response to current vaccines. as viruses mutate often and at random, it is not unusual for small numbers of cases to arise featuring new sets of mutations. any variants showing evidence of spread are rapidly assessed. the breakdown of cases by local authority is: the uk health security agency (ukhsa) has identified 9 further cases of coronavirus (covid 19) with mutations consistent with b.1.1.529 in england, in addition to the previous 13 confirmed cases of the sars cov 2 variant known as b.1.1.529. the total number of confirmed cases in england is now 22. the individuals that have tested positive and their contacts are all isolating. work is underway to identify any links to travel to southern africa. we have now identified cases in the east midlands, east of england, london, south east and north west. ukhsa is carrying out targeted testing at locations where the positive cases were likely to be infectious. a further case has been identified in scotland, bringing the total to 10. dr jenny harries, chief executive of ukhsa, said: we are continuing our efforts to understand the effect of this variant on transmissibility, severe disease, mortality, antibody response and vaccine efficacy. vaccination is critical to help us bolster our defences against this new variant   please get your first, second, third or booster jab without delay. following the change in jcvi advice earlier this week, a booster dose for everyone over 18 years is now recommended and will be available at a minimum of 3 months from your last primary course jab. please take up this offer as soon as you are eligible to protect yourself, your families and your communities. please make sure to wear a mask in line with government guidance, including on public transport and in shops, to help break the chains of transmission and slow the spread of this new variant. it is very likely that we will find more cases over the coming days as we are seeing in other countries globally and as we increase case detection through focused contact tracing. that’s why it’s critical that anyone with covid 19 symptoms isolates and gets a pcr test immediately. ukhsa has updated its stay at home guidance and non household contacts guidance to reflect changes to self isolation requirements for contacts of people who have been identified as a suspected or confirmed case of the omicron variant of covid 19. ukhsa is acting to get scientific information available as quickly as possible in order to inform the right balance of interventions to prevent transmission and protect lives. this will include analysing live samples of the new variant in our laboratories to investigate properties such as response to current vaccines. as viruses mutate often and at random, it is not unusual for small numbers of cases to arise featuring new sets of mutations. any variants showing evidence of spread are rapidly assessed. the breakdown of cases by local authority is: the uk health security agency (ukhsa) has identified 8 further cases of covid 19 with mutations consistent with b.1.1.529 in england, in addition to the previous 5 confirmed cases of the sars cov 2 variant known as b.1.1.529. the total number of confirmed cases in england is now 13. the individuals that have tested positive and their contacts are all isolating. work is underway to identify any links to travel to southern africa. we have now identified cases in the east midlands, east of england, london and north west. ukhsa is carrying out targeted testing at locations where the positive cases were likely to be infectious. nine cases have also been identified in scotland, with 5 cases in the lanarkshire area and 4 in the greater glasgow and clyde area. dr jenny harries, chief executive of ukhsa, said: we are continuing our efforts to understand the effect of this variant on transmissibility, severe disease, mortality, antibody response and vaccine efficacy. vaccination is critical to help us bolster our defences against this new variant   please get your first, second, third or booster jab without delay. following the change in joint committee on vaccination and immunisation (jcvi) advice yesterday, a booster dose for everyone over 18 years is now recommended at a minimum of 3 months from your last primary course jab. please take up this offer as soon as you are invited to protect yourself, your families and your communities. please make sure to wear a mask in line with government guidance, including on public transport and in shops, to help break the chains of transmission and slow the spread of this new variant. it’s very likely that we will find more cases over the coming days as we are seeing in other countries globally and as we increase case detection through focused contact tracing. that’s why it’s critical that anyone with covid 19 symptoms isolates and gets a pcr test immediately. ukhsa is acting to get scientific information available as quickly as possible in order to inform the right balance of interventions to prevent transmission and protect lives. this will include analysing live samples of the new variant in our laboratories to investigate properties such as response to current vaccines. as viruses mutate often and at random, it is not unusual for small numbers of cases to arise featuring new sets of mutations. any variants showing evidence of spread are rapidly assessed. the breakdown of cases by local authority is: the uk health security agency (ukhsa) has identified 2 further cases of covid 19 with mutations consistent with b.1.1.529 in england, in addition to the previous 3 confirmed cases of the sars cov 2 variant known as b.1.1.529 on 27 and 28 november. the total number of confirmed cases in england is now 5. the individuals that have tested positive are not connected to each other and are not linked to the previously confirmed cases. both have links to travel to southern africa. one case is located in camden, london, and one case is located in wandsworth, london. the individuals and their households have been told to self isolate. ukhsa is carrying out targeted testing at locations where the positive cases were likely to be infectious. six cases of the sars cov 2 variant known as b.1.1.529 have also been identified in scotland, with 4 cases in the lanarkshire area and 2 in the greater glasgow and clyde area. dr jenny harries, chief executive of ukhsa, said: we are continuing our efforts to understand the effect of this variant on transmissibility, severe disease, mortality, antibody response and vaccine efficacy. vaccination is critical to help us bolster our defences against this new variant   please get your first, second or booster jab without delay. the guidance on vaccination is changing to help all of us bolster our defences in the face of this new variant. everyone should complete a primary course as soon as possible   for most this will be a first and second dose. for some more vulnerable a third dose is available. following the change in jcvi advice today, a booster dose for everyone over 18 years is now recommended and will be available at a minimum of 3 months from your last primary course jab. please take up this offer as soon as you are eligible to protect yourself, your families and your communities. it is very likely that we will find more cases over the coming days as we are seeing in other countries globally and as we increase case detection through focused contact tracing. that’s why it’s critical that anyone with covid 19 symptoms isolates and gets a pcr test immediately. ukhsa is acting to get scientific information available as quickly as possible in order to inform the right balance of interventions to prevent transmission and protect lives. this will include analysing live samples of the new variant in our laboratories to investigate properties such as response to current vaccines. as viruses mutate often and at random, it is not unusual for small numbers of cases to arise featuring new sets of mutations. any variants showing evidence of spread are rapidly assessed. following the first 2 confirmed cases of the sars cov 2 variant known as b.1.1.529 on 27 november, the uk health security agency (ukhsa) has identified one further case of covid 19 with mutations consistent with b.1.1.529 in the uk. the individual tested positive after travel to the uk and is linked to travel to southern africa. the individual is no longer in the uk, but ukhsa is carrying out targeted testing at locations where the positive case visited when they were likely to have been infectious. while in the uk, the individual was in westminster, london. dr jenny harries, chief executive of ukhsa, said: our advanced sequencing capabilities enable us to find variants and take rapid action to limit onward spread. it is very likely that we will find more cases over the coming days as we are seeing in other countries globally and as we increase case detection through focussed contact tracing. we are continuing our efforts to understand the effect of this variant on transmissibility, severe disease, mortality, antibody response and vaccine efficacy. it’s critical that anyone with covid 19 symptoms isolates and gets a pcr test immediately. vaccination is critical to help us bolster our defences against this new variant   please get your first, second or booster jab without delay. wear a mask in crowded places, including public transport and shops, to ensure we all help break the chains of transmission and slow the spread of this new variant. ukhsa designated variant b.1.1.529 as a variant under investigation (vui) on thursday 25 november. it was designated a variant of concern (voc) on saturday 27 november. the b.1.1.529 variant includes a large number of spike protein mutations as well as mutations in other parts of the viral genome. these are potentially biologically significant mutations which may change the behaviour of the virus with regards to vaccines, treatments and transmissibility. ukhsa, in partnership with scientific bodies across the globe, is constantly monitoring the status of sars cov 2 variants as they emerge and develop worldwide. we are particularly grateful to health protection specialists and the government of south africa for early sharing of local information on the omicron variant in an exemplary way to support global health security. ukhsa is acting to get scientific information available as quickly as possible in order to inform the right balance of interventions to prevent transmission and protect lives. this will include analysing live samples of the new variant in our laboratories to investigate properties such as response to current vaccines. as viruses mutate often and at random, it is not unusual for small numbers of cases to arise featuring new sets of mutations. any variants showing evidence of spread are rapidly assessed. the uk health security agency (ukhsa) has announced the emerging sars cov 2 variant known as b.1.1.529 as a variant under investigation (vui). the first genomes of this variant were uploaded to the international gisaid database on 22 november. genomes have now been uploaded from south africa, botswana and hong kong but the extent of spread is not yet determined. no cases have been identified in the uk. b.1.1.529 has a large number of mutations in the gene coding for the spike protein, and also in other parts of the viral genome. these are potentially biologically significant mutations which may change the behaviour of the virus with regards to immune escape, transmissibility or susceptibility to treatments, but this has not been proven. more investigation is required to fully determine the extent of these mutations’ impact. ukhsa is monitoring the situation closely, in partnership with scientific and public health organisations across the world. ukhsa’s most recent variant technical briefing can be found on gov.uk. the delta variant sub lineage known as delta ay.4.2 was designated a variant under investigation (vui) by the uk health security agency (ukhsa) on 20 october 2021 and has been given the official name vui 21oct 01. the designation was made on the basis that this sub lineage has become increasingly common in the uk in recent months, and there is some early evidence that it may have an increased growth rate in the uk compared to delta. more evidence is needed to know whether this is due to changes in the virus’ behaviour or to epidemiological conditions. the genome of vui 21oct 01 does not have many mutations compared to delta. however, a small change may be enough to cause a difference in the virus properties in some circumstances. ukhsa is monitoring this closely. the original delta variant remains overwhelmingly dominant in the uk, making up approximately 99.8% of all cases. as of 20 october, there were 15,120 cases of vui 21oct 01 confirmed by whole genome sequences in england since it was first detected in july. in the last week, vui 21oct 01 accounted for approximately 6% of all delta cases. cases have been confirmed through whole genome sequencing in all 9 regions of england. while evidence is still emerging, so far it does not appear this variant causes more severe disease or renders the vaccines currently deployed any less effective. as is routine for any new variants under investigation, ukhsa is carrying out laboratory and epidemiological investigations to better understand the properties of this variant. dr jenny harries, chief executive of the uk health security agency, said: viruses mutate often and at random, and it is not unexpected that new variants will continue to arise as the pandemic goes on, particularly while the case rate remains high. it is testament to the diligence and scientific expertise of my colleagues at ukhsa, and the genomic sequencing capacity developed through the pandemic, that this new variant has been identified and analysed so quickly. however, it should serve as objective evidence that this pandemic is not over. the public health advice is the same for all current variants. get vaccinated and, for those eligible, come forward for your third or booster dose as appropriate as soon as you are called. continue to exercise caution. wear a mask in crowded spaces and, when meeting people indoors, open windows and doors to ventilate the room. if you have symptoms take a pcr test and isolate at home until you receive a negative result. ukhsa continues to examine all available data relating to sars cov 2 variants in the uk and abroad. we constantly assess the genetic diversity within the known variants of concern (vocs) to inform our ongoing public health response to the pandemic. new sub lineages within delta continue to be identified. this is to be expected and ukhsa is monitoring the situation closely. uk health security agency (ukhsa) has published variant technical briefing 24. ukhsa releases weekly updates on the number of confirmed new cases of variants of concern and variants under investigation identified in the uk. previous updates were published by public health england the following links open in a new tab added latest update. added latest update. added latest update. first published. don’t include personal or financial information like your national insurance number or credit card details. to help us improve gov.uk, we’d like to know more about your visit today. please fill in this survey (opens in a new tab).

rivm monitors changes in the coronavirus sars cov 2 in the netherlands and the consequences of those changes. when a virus replicates, it can change very slightly every time. these changes (or mutations) are usually so small that they have almost no effect on the properties of the virus, such as how ill you become and how the virus spreads. sometimes changes do cause a virus to behave differently, for example allowing it to spread more easily. there are many different variants of the coronavirus sars cov 2 by now. rivm is conducting laboratory research to see which variants are present in the netherlands and whether the percentage of infections from each variant is increasing. to make that possible, samples from positive sars cov 2 tests from all across the netherlands are investigated to check which variant was involved. this pathogen surveillance research is important to know whether new variants with changed characteristics may also be increasing in the netherlands. some changes (mutations) can cause a variant to spread more quickly or make people more severely ill. other mutations change the external appearance of the virus, making it harder for the immune system to detect it after a previous infection or vaccination. research on the incidence of variants and sub variants of the virus is also taking place in the context of the national sewage surveillance programme at rivm. jjn.1 and its sub variants have been dominant in the netherlands for some time. since week 29, variant xec has also been observed. this is a recombinant of jn.1 sub variantskp.3.3 and ks.1.1. xec and kp.3 are currently the most prevalent. at this time, there are no indications that these sub variants would be more likely to cause severe illness compared to previous omicron sub variants. the trends seen in wastewater generally correspond to the trends observed in pathogen surveillance. jn.1 sub variants are currently in the lead, and kp.3 and its sub variants are the most prevalent. xec has also been observed in wastewater. the underlying data is public. the relevant sequences are shared in an international database by gisaid. due to an update to the classification tools, a number of recombinants that were previously shown under xbb subtypes are now shown in the ‘other’ category. many omicron sub variants appear to have the same minor changes (mutations) that developed separately. most of these changes seem to occur in the ‘spike protein’, the lines bristling out from the coronavirus. the minor changes give the virus a slightly better chance to evade immunity resulting from previous infection or vaccination. sometimes they also make it easier for a variant to attach to host cell receptors. at this time, there are no indications that these variants would be more likely to cause severe illness compared to previous omicron sub variants. the alpha variant of the coronavirus, first found in the uk, was also detected in the netherlands in december 2020. the alpha variant then became the dominant strain in the netherlands, supplanting the former variant of the virus. in summer 2021, the alpha variant was ‘pushed out’ by the more contagious delta variant. the beta variant of the coronavirus, first found in south africa, was detected in the netherlands in early january 2021. this variant of the virus, like the alpha variant, also appears to be more contagious than the variant that had been dominant in the netherlands until that point. the beta variant is no longer detected in pathogen surveillance. the p.1 gamma variant of the coronavirus was found mainly in outbreaks in and around manaus, the capital of the brazilian state of amazonas. it is not yet clear whether the course of illness is different for this variant. among other mutations, the variant has three changes in the spike protein, the lines bristling out from the coronavirus, that are considered cause for concern. these three changes are almost identical to the changes in the beta variant. the immune response due to vaccination or due to previous infection with the virus may possibly be less effective against this variant. the p.1 gamma variant is currently no longer detected in pathogen surveillance. the b.1.617.2 variant of the coronavirus was first found in october 2020 in india. in summer 2021, the delta variant (b.1.617.2) replaced the alpha variant as the dominant strain in the netherlands. the delta variant is much more contagious than the alpha variant. the covid 19 vaccines are effective in preventing hospital and icu admissions, even against the delta variant. at the end of 2021, the delta variant was in turn replaced by the omicron variant b.1.1.529. the same trend is occurring all over the world. the first cases involving the omicron variant (b.1.1.529) of the coronavirus sars cov 2 were reported in south africa at the end of november 2021. the percentage of cases involving the omicron variant rose rapidly around the world. similar to other variants, the small changes (mutations) in this new variant were seen mainly in the lines bristling out from the coronavirus: the spike protein. a striking feature of this variant was that it proved to have an unusually large number of mutations in the spike protein. never before had a new variant of the coronavirus spread as quickly as the omicron variant. it became apparent that vaccine effectiveness against omicron infection without booster vaccination was considerably lower compared to the delta variant. if you test positive for covid 19, the test results do not tell you which coronavirus variant you have. when analysing a covid 19 test, a laboratory technician cannot see which variant of the coronavirus sars cov 2 caused the infection. this requires further research, known as sequencing. this means further investigation of the virus sample that was taken with a cotton swab in the nose (and/or throat). sequencing looks at the building blocks of the virus. by looking at how the virus is constructed, it is possible to recognise characteristic ‘building blocks’ of a variant. sequencing is performed on random samples in the context of pathogen surveillance. yes, antigen tests are also effective in detecting the omicron variant. this also applies to the self tests. various laboratories have investigated this and confirmed that they are effective. rivm has done this for 6 self tests; see also technical evaluation of sars cov 2 self test with omicron variant and previous technical evaluation of the same self tests with the wild type virus(pdf). a self test is an antigen test which is suitable for home use. antigen tests, like pcr tests, only check if you are carrying the virus at that moment. the test does not check which coronavirus variant you have. this requires further research. for that purpose, a new pcr test sample must be taken, which is then used for sequencing. this means further investigation of the virus sample that was taken with a cotton swab in the nose (and/or throat). sequencing looks at the building blocks of the virus. by looking at how the virus is constructed, it is possible to recognise characteristic ‘building blocks’ of a variant. yes. wastewater samples are also analysed to check for the presence of different variants of the coronavirus sars cov 2.

thank you for visiting nature.com. you are using a browser version with limited support for css. to obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in internet explorer). in the meantime, to ensure continued support, we are displaying the site without styles and javascript. the first us deaths related to coronavirus might have occurred weeks earlier than previously thought.credit: andrew caballero reynolds/afp via getty we are no longer updating this page. find nature’s latest coronavirus coverage here. read highlights from the coronavirus research literature here. 22 april 17:05 bst   deaths suggest the coronavirus was in the united states weeks earlier than thought the first us covid 19 death might have occurred in california on 6 february   three weeks before the first reported death, in washington state. after autopsies, three people who died in santa clara county between 6 february and 6 march have been confirmed as having died of covid 19, according to a statement released by the county’s department of public health on 21 april. the updated statistics include two people who died at home and a third whose location of death was not specified. previously, the first covid 19 death in the county was thought to have occurred on 9 march. the revised cause of death shows that the deadly disease had footholds in the united states earlier than previously thought. similar reports have surfaced elsewhere in recent weeks. in late march, a non peer reviewed epidemiology study of the lombardy region in northern italy found that the virus might have been circulating there for more than a month before it was detected. 22 april 16:45 bst   climate scientist and ipcc veteran dies of the coronavirus john houghton, a climate scientist and a senior member of the intergovernmental panel on climate change (ipcc), died of covid 19 on 15 april, aged 88. houghton was the lead editor of the first three ipcc assessment reports   massive, influential studies that summarize the state of scientific knowledge on climate change   and accepted the 2007 nobel peace prize on behalf of the organization, alongside former us vice president al gore. researchers who knew houghton commended him for his scientific rigour, his leadership and his ability to connect with policymakers and the public. after studying at the university of oxford, uk, houghton became a professor there in 1958. he was a pioneer in the use of emerging satellite technologies for understanding the earth system. as the director general of the uk met office, the nation’s weather agency, from 1983 to 1991, he helped to establish the hadley centre for climate science and services in exeter and advised the uk government on the scientific consensus on climate change. “he knew they could only really make progress if they had very clear and well communicated scientific advice,” says richard betts, a climate scientist at the university of exeter, who worked on several ipcc reports with houghton. houghton’s lifetime of leadership in the climate change community is a significant legacy, betts says. “he wasn’t just a scientist. he was someone who cared passionately.” a devout christian, houghton co founded and led the john ray initiative, a charity in gloucester, uk, focused on promoting environmental stewardship through both science and christianity. he convinced a prominent us evangelical lobbyist of the compatibility of climate change and christian thought in the early 2000s. his former students remember him fondly. “john was an excellent leader,” says james drummond, a retired atmospheric scientist who most recently worked at dalhousie university in halifax, canada. houghton supervised drummond through his undergraduate and graduate studies at oxford in the 1970s. “if i do a quarter of what he did, i will be doing very well,” says drummond. 21 april 20:40 bst   1,500 people volunteer for controversial vaccine study approach momentum is building to speed the development of coronavirus vaccines by intentionally infecting healthy, young volunteers with the virus. a grass roots effort has attracted nearly 1,500 potential volunteers for the controversial approach, known as a human challenge trial. the effort, called 1day sooner, is not affiliated with groups or companies developing or funding coronavirus vaccines. but co founder josh morrison hopes to show that there is broad support for human challenge trials, which have the potential to deliver an effective coronavirus vaccine more quickly than standard trials. typical vaccine trials take a long time because thousands of people receive either a vaccine or a placebo, and researchers track who becomes infected in the course of their daily lives. a challenge study could in theory be much faster: a much smaller group of volunteers would receive a candidate vaccine and then be intentionally infected with the virus, to judge the efficacy of the immunization. “we want to recruit as many people as possible who want to do this, and pre qualify them as likely to be able to participate in challenge trials should they occur,” says morrison, who is also the executive director of organ donation advocacy group waitlist zero. “at the same time, we feel that the public policy decisions around challenge trials will be better informed if they highlight the voice of people interested in participating in such trials.” morrison says that the people who have signed up to be part of a challenge trial tend to be young and live in urban areas, and are highly motivated to do something constructive to address the coronavirus pandemic. “many note that they recognize the risk but believe the benefits of vaccine acceleration are so tremendous that it is worth it to them,” he says. a team led by bioethicist nir eyal at rutgers university in new brunswick, new jersey, argued that a human challenge trial could be conducted safely and ethically, in a paper in the journal of infectious diseases last month. the approach is also gaining some political support. this week, 35 members of the us congress, led by bill foster (democrat, illinois) and donna shalala (democrat, florida), called on department of health and human services director alex azar to consider human challenge trials of coronavirus vaccines. charlie weller, head of the vaccines programme at wellcome, a biomedical research funder in london, says the charity has begun discussing the ethics and logistics of a human challenge trial for a coronavirus vaccine. but she says it is unclear whether such a trial could actually speed vaccine development. researchers first need to determine how to expose humans to the virus as safely as possible, and to consider how and even whether such studies can be done ethically. “i think there’s potential,” weller adds, “but we’ve got so many questions to work through to understand whether it can help in the timelines we have.” 21 april 15:30 bst   coronavirus brings forward mars plans the arab world’s first mars mission   a spacecraft called hope   will ship from the united arab emirates (uae) to japan weeks earlier than planned, as a result of travel restrictions imposed during the covid 19 pandemic. accelerating the shipment will mean that the probe, which will orbit the red planet and study the martian atmosphere, will miss out on some planned tests. “we had to expedite activities in dubai and basically focus only on the critical testing,” project leader omran sharaf told a virtual meeting of the mars exploration program analysis group, a nasa led international forum for planning mars activities, on 17 april. “it got too risky for us if we waited,” he said. built by uae and us engineers, the orbiter is scheduled to launch from tanegashima space center in japan in a window that starts on 15 july, when earth and mars are suitably aligned. the craft should reach martian orbit in 2021. the united arab emirates’ mars probe at the mohammed bin rashid space centre in dubai.credit: natalie naccache for nature hope was scheduled to ship to japan by cargo plane in early may. but mission leaders brought the date forward to 20 april, to account for a 14 day quarantine imposed on all travellers entering the country. team members who travel with the probe will be quarantined for two weeks when they reach japan, but moving the spacecraft early gives them enough time to arrive at the site and prepare for launch. a team that will receive the craft in japan has already travelled to the nation and been in quarantine. the mission team has also had to navigate new restrictions on travel worldwide, including getting approval to fly at all, said sharaf. the uae’s airspace and airports are closed, and japan has enhanced its visa requirements. last month, the european space agency and the russian space agency roscosmos delayed launch of a major rover in their exomars mission for two years, citing travel restrictions imposed as a result of the coronavirus pandemic among their reasons. relatives of a person who died of coronavirus at a burial in new delhi.credit: danish siddiqui/reuters 17 april 16:00 bst   wuhan death toll jumps by 50% china’s reported death toll from the coronavirus has jumped sharply, after a review of records for the city of wuhan, where the virus emerged last year, added another 1,300 fatalities to its official count. the revision raises the death toll in the 11 million person city by 50%, to 3,869, and brings china’s overall death toll to more than 4,600. deaths from the coronavirus are difficult to count in the absence of widespread testing. chinese officials said the revision included the addition of deaths of people at home and at medical institutions that weren’t reporting data to its epidemic network. 15 april 15:00 bst   infections pass two million the number of reported covid 19 cases worldwide has passed two million, according to data compiled by researchers at johns hopkins university in baltimore, maryland. the milestone comes just two weeks after one million infections were recorded. the united states has the most cases   more than 600,000   followed by spain and italy. the death toll from the disease has also surged past 128,000 worldwide. some 24,000 people have died in the united states, with more than 20,000 deaths in italy. the pandemic has spread to almost every region of the globe, with only about a dozen of the world health organization’s member states not yet reporting cases. the majority of these are small island nations in the pacific ocean, including vanuatu, tuvalu and palau. coronaviruses take their name from their crown like shape.credit: getty 15 april 02:00 bst   trump suspends world health organization funding us president donald trump said on 14 april that he would halt the country’s funding for the world health organization (who), pending a review of how the organization has handled the coronavirus pandemic. the president accused the who of mismanaging the outbreak and “covering up the spread” of covid 19 in a white house press briefing on tuesday evening. the announcement comes amid criticism of the trump administration’s own handling of the outbreak, which has now claimed more than 26,000 lives in the united states. but the who warned on 23 january that the coronavirus would be exported from china. and on 30 january, the organization called the coronavirus outbreak a public health emergency of international concern   its highest alert level. the united states has contributed more than us$800 million to the who over the past two years, making it the largest contributor to the organization’s roughly $2.8 billion annual budget. 14 april 17:00 bst   mathematician john conway dies of covid 19 john conway.credit: princeton university/office of communications/denise applewhite renowned british born mathematician john conway died aged 82 on 11 april, reportedly of complications arising from covid 19. conway attained a legendary status among maths and science enthusiasts, mostly by designing mathematical games and puzzles. but his work transcended the boundary between recreational and ‘serious’ maths, turning play into research and vice versa. “he’s been known to carry on his person a few decks of cards, dice, ropes, pennies, coat hangers, sometimes a slinky, maybe a miniature bicycle, all props he deploys to extend his winning imagination,” wrote biographer siobhan roberts in 2015. his celebrity status was cemented by martin gardner’s popular maths column in the magazine scientific american, which featured many of conway’s contributions, beginning in 1970 with his game of life, a minimalistic 2d model universe in which ‘organisms’ grow and multiply on the basis of simple rules. conway had taught at princeton university in new jersey since 1987, and his research spanned several fields of mathematics. in algebra, he studied the ‘monster group’, an object that has an enormous   but not infinite   number of symmetries. with the late british mathematician simon norton, he formulated the ‘monstrous moonshine’ conjectures, linking the monster group to an entirely different subject in mathematical analysis. conway is also remembered for his work on the foundations of quantum mechanics. he investigated the idea of an experimenter’s free will and suggested that “if experimenters have free will, then so do elementary particles”. medical staff at a drive in covid 19 testing facility in the uk.credit: paul ellis/afp/getty 9 april 22:30 bst   united kingdom launches massive coronavirus diagnostic network the uk government opened its first mass coronavirus testing facility on 9 april. the lab, in milton keynes, is the first of three such facilities to open. the others   in glasgow and alderley park in nether alderley   are scheduled to open within the next two weeks. in march, the uk government requisitioned polymerase chain reaction machines from university labs across the country in order to outfit these central testing facilities. the labs   which the government says make up the largest diagnostic network in uk history   will prioritize processing samples from health care providers who are currently self isolating, in order to allow them to return to work. the milton keynes facility can currently process thousands of tests per day, but is continuing to ramp up its capacity through the use of robotics. the government hopes to be able to analyse 100,000 coronavirus tests daily by the end of the month, health secretary matt hancock reiterated on 9 april. fewer than 300,000 tests have been carried out in the country so far, according to official reports. universities across the united kingdom and around the world are also running covid 19 diagnostic tests, as nature previously reported. but these efforts in the united states have been hampered by bureaucratic and logistical barriers, and a lack of a cohesive national strategy. 8 april 22:00 bst   cern scientists join the covid 19 fight beniamino di girolamo coordinates the cern against covid 19 taskforce, an effort to bring the particle physics lab's resources to bear on the pandemic.credit: cern more than 100 researchers and staff members at cern are finding innovative ways to combat the coronavirus pandemic. scientists, engineers and technicians at the world’s largest particle physics laboratory, near geneva, switzerland, are teaming up to fill crucial gaps in the local and international responses to the outbreak   from manufacturing and distributing large quantities of hand sanitizer to designing an open source ventilator. one of cern’s strengths is its ability to connect people across a wide range of expertise and locations, says beniamino di girolamo, a cern particle physicist and the chair of the cern against covid 19 task force. the group is working closely with local agencies, biomedical experts and the world health organization to ensure that cern’s resources are being put to best use and that its designs are safe for patients. how the coronavirus pandemic is affecting the world's biggest physics experiments how the coronavirus pandemic is affecting the world's biggest physics experiments one of its main projects so far is the design of the high energy physics community ventilator, hev. because the researchers and technicians who work on cern’s large hadron collider have extensive experience in managing gas flows and control systems, di girolamo says, they were well positioned to take on this project. the team posted its ventilator designs on the arxiv preprint server on 1 april and is currently soliciting feedback on a prototype from several medical professionals. the design should be ready for production “in a month, maximum”, says di girolamo. cern staff are also manufacturing 3d printed masks and face shields, and making hand sanitizer for local emergency response departments. the centre is offering high performance computing resources to epidemiologists and virologists searching for a covid 19 vaccine. and some staff are distributing necessities to elderly and otherwise at risk community members. going forward, di girolamo says, the task force plans to continue to source ideas from cern staff, as well as taking requests from community partners in need of its expertise. “we cannot just lock down,” di girolamo says. “there is a lot of energy at cern. there are a lot of people who can help.” 8 april 16:00 bst   tracking app data suggest loss of smell is a key covid 19 symptom the loss of sense of smell and taste should be considered a symptom of covid 19, suggest the first results from a uk based symptom tracking app. there have been many anecdotal reports of the phenomenon in relation to covid 19, but loss of smell   known scientifically as anosmia   is not currently listed as a symptom of the coronavirus by the world health organization (who). the covid symptom tracker smartphone app, which has recruited more than 1.5 million people in the united kingdom, asks users to record health information on a daily basis, including their temperature, any tiredness and other potential symptoms of coronavirus infection. an analysis of data collected between 24 and 29 march found that users who tested positive for covid 19 were three times more likely to report losing their sense of smell and taste than were those who had symptoms of the virus but tested negative. other common symptoms experienced by people who tested positive for covid 19 were fever, persistent cough, fatigue, diarrhoea, abdominal pain and loss of appetite. source: covid symptom tracker team “this is an important study because it is the first to demonstrate scientifically and in a large population sample that loss of smell is a characteristic feature of covid,” said trish greenhalgh, a primary care health scientist at the university of oxford, uk, in a statement to the science media centre in london. the analysis, which was published on the preprint server medrxiv on 7 april, looked at responses from app users who were tested for the virus, which in the united kingdom is usually done only in hospitals. of the 579 who tested positive for covid 19, 59% reported losing their sense of smell, compared with 18% of the 1,123 who tested negative. updated but as yet unpublished figures from the same group show a similar trend (see ‘tracking symptoms’). the study’s authors say that people experiencing loss of smell should self isolate. the team behind the app, at king’s college london and health care start up zoe global in london, also used the data to estimate the prevalence of covid 19 among people who have not yet been tested. in an unpublished analysis described on their website, the researchers estimated that on 1 april, 4.9% of all users   around 80,000 individuals in the united kingdom   are likely to have had the virus. by taking into account the location, age and gender of their users, and extrapolating their sample to the whole population, the researchers estimated that 1.9 million people in the united kingdom aged between 20 and 69 had symptomatic covid 19 on this date. the latest data suggest that by 5 april, this figure might have fallen to 1.4 million, which they say indicates that social distancing measures implemented in the nation are slowing the spread of the virus. efforts are under way to roll out a similar app in the united states. 8 april 07:00 bst   modelling reveals the worst case scenario that australia has avoided australia has implemented strict physical distance measures. credit: cameron spencer/getty australia’s health care system has averted disaster and is in a good position to cope with the projected rise in covid 19 cases, thanks to measures introduced there, say researchers whose models have informed the government’s response. some of these models, presented to the government in early february, were released on 7 april by the peter doherty institute for infection and immunity and the university of melbourne. the theoretical models, which have not been peer reviewed and are based on information on outbreaks outside australia, suggest that without measures to mitigate the virus’s spread, hospitals would have been overwhelmed. this scenario would have seen a peak daily demand for 35,000 intensive care unit (icu) beds by around may, according to government figures. the figures suggested that social distancing, isolation and quarantine would reduce that peak daily demand to less than 5,000 beds. australia currently has some 2,200 icu beds, but plans to increase that to 7000. australia restricted entry to the country for travellers from mainland china on 1 february. health officials have conducted more than 304,000 coronavirus tests, and have introduced contact tracing, quarantining and isolation, as well as broader physical distancing measures, such as closing businesses and restricting gatherings. “australia has acted sufficiently early based in part on the work that we provided,” said james mccaw, an infectious diseases epidemiologist at the university of melbourne who contributed to the models, at an online press conference. australia currently has more than 6,000 confirmed cases, with 50 deaths. the daily count of new confirmed cases has declined to around 100, from a high of more than 500. “it looks like the curve is flattening, and flattening strongly,” said mccaw. “but our population is still largely susceptible. and so if we relaxed and went back to normal, we would see a rapid and explosive resurgence in epidemic activity.” the authors conclude that social distancing needs to be part of ongoing efforts to isolate infected people and quarantine contacts to ensure that hospitals can cope, although they did not look at the effects of specific measures. “we’re really in a very lucky position where we can think about the next steps and the very challenging questions ahead, but from a position of relative calm as opposed to crisis,” said mccaw. medical workers perform drive through swabbing tests in alessandria, italy.credit: miguel medina/afp/getty scientists welcomed the government’s decision to share the modelling that has informed its covid 19 response. the move will allow experts to analyse the model and make recommendations, says mikhail prokopenko, a complex systems researcher at the university of sydney. at the moment, the model does not include detailed predictions of what might actually occur in australia, which would be useful. australia’s proactive response and strong health system has put it in a position to control the virus   a privilege that not many countries can afford, said jodie mcvernon, an epidemiologist at the doherty institute, who led the modelling study. the researchers will now refine their models with data on the emerging outbreak in australia to assess the effectiveness of individual measures. 7 april 21:00 bst   no new reported covid 19 deaths in china for the first time since january, chinese health officials reported no new deaths from covid 19 on 6 april. according to the chinese national health commission, there were 32 new confirmed cases and 12 new suspected cases in the country yesterday. all were imported into the country from elsewhere. there are also 1,033 people with the infection but no symptoms who are under medical observation. ‘we need to be alert’: scientists fear second coronavirus wave as china’s lockdowns ease ‘we need to be alert’: scientists fear second coronavirus wave as china’s lockdowns ease scientists and public health officials are keeping a close eye on the situation in china as lockdowns begin to lift in response to the slowing of the outbreak there. since the outbreak began in december, there have been more than 80,000 reported cases in china, including over 3,300 deaths   the majority of which occurred in wuhan, where the pandemic originated. the restrictions on movement into and out of wuhan are lifting on 8 april. 6 april 20:50 bst   hiv researcher among scientists who have died of covid 19 gita ramjee, a world renowned hiv researcher, died of covid 19 last week. she was 63. ramjee, who was based in south africa, was known for her tireless work developing hiv prevention tools such as vaginal microbicides, drugs designed to help stop the transmission of the virus to women. she ran many trials in south africa   which has the world’s largest number of people with hiv   and often focused on at risk populations such as sex workers. hiv researcher gita ramjee.credit: the aurum institute ramjee was the chief scientific officer at the johannesburg based aurum institute, a health care non profit organization aimed at eradicating hiv and tuberculosis. scientists who worked with her praised her tenacity, passion and ability to connect with the communities in which she worked. after completing her phd in paediatric kidney diseases at what is now the university of kwazulu natal in durban, south africa, ramjee joined the country’s medical research council. it was there that she found her calling as an hiv researcher with a focus on microbicides. ramjee had a “natural talent” for clinical trial work, says salim abdool karim, an epidemiologist at the centre for the aids programme of research in south africa (caprisa) in durban. such work is by nature often difficult and thankless, says abdool karim. but despite a series of underwhelming trial outcomes in the field and in her own work, he says, ramjee never hesitated to dive into the next study. “it takes a particular kind of person to persist despite a string of negative results. and she was one of those.” ramjee was also an active advocate for women, says quarraisha abdool karim, another caprisa epidemiologist. “gita was a unique investigator who understood that clinical trials are not just about clinics and laboratories and products, but fundamentally about people,” says mitchell warren, the executive director of avac, previously known as the aids vaccine advocacy coalition, in new york city. “these were not trials about products. these were trials about women’s lives.” several other renowned scientists have also died from covid 19 in recent weeks. among them are john murray, a pioneering tuberculosis clinical researcher at the university of california, san francisco; james goodrich, a paediatric neurosurgeon at einstein college of medicine in new york city, known for separating conjoined twins; and molecular biologist michael wakelam, the director of the babraham institute in cambridge, uk. ramjee’s colleagues note the cruelty of losing her to the covid 19 pandemic when she devoted so much of her life to eradicating another global outbreak. but, warren notes, researchers tackling covid 19 would do well to follow the example that ramjee set. “we mourn. and then we do what gita would do.” 2 april 21:00 bst   covid 19 cases cross the one million mark more than one million cases of covid 19 have been confirmed as of 2 april, according to data compiled by researchers at johns hopkins university in baltimore, maryland. but in much of the world, people exhibiting mild or no symptoms are unable to get tested, meaning that the true number of cases could be much higher. the outbreak, which started in wuhan in hubei province, china, in early december, has now spread to 181 countries and regions. china was relatively successful in containing its outbreak to hubei. but the virus has spread rapidly between and within other countries. china accounted for almost 80% of the first 100,000 patients identified, but the united states now contains more cases than any other country, with more than 20% of the world’s total. the pandemic has resulted in a reported 51,485 deaths around the globe, and more than 209,000 people have been identified as having recovered from the disease. 2 april 00:00 bst   covid 19 delays cop26 international climate talks scheduled for november in glasgow, uk, have been postponed until 2021 as a result of the ongoing coronavirus crisis, united nations officials announced on 1 april. the climate meeting, known as cop26   the 26th annual conference of the parties to the un framework convention on climate change   was to be the most important set of talks since the signing of the paris climate agreement in 2015. so far, international commitments to reduce carbon emissions have fallen well short of what would be needed to prevent temperature increases of more than 1.5 2 °c above preindustrial levels, the stated goal of the paris agreement. countries were expected to update and strengthen their commitments at the glasgow meeting. climate vs coronavirus: why massive stimulus plans could represent missed opportunities climate vs coronavirus: why massive stimulus plans could represent missed opportunities un climate change executive secretary patricia espinosa called covid 19 the most urgent threat currently facing humanity, but stressed that climate change remains the biggest long term danger. as the coronavirus threat recedes, she said, nations must look for ways to bolster their climate efforts. “this is a chance” espinosa said “to shape the twenty first century economy in ways that are clean, green, healthy, just, safe and more resilient.” the announcement followed a decision to delay a preparatory meeting, originally scheduled for june in bonn, germany, until october. 1 april 03:00 bst   nearly 80% of us intensive care patients have underlying conditions more than three quarters of people with covid 19 in intensive care units in the united states have at least one ‘underlying condition’   a chronic health problem, such as diabetes or heart disease, that has been shown to contribute to hospitalization and severe illness. the finding comes from the 31 march morbidity and mortality weekly report, published by the us centers for disease control and prevention. a study found that of about 7,000 people with covid 19 for whom information about chronic conditions had been reported, just over one third had an underlying condition. people with such conditions made up 71% of those hospitalized for covid 19 and 78% of those who required intensive care. data from china and italy have also shown that underlying conditions correlate with more severe covid 19 outcomes, but this is the first such study in the united states. as of last week, the united states has more confirmed cases than any other country. a woman looks out of her balcony in locked down rome.credit: antonio masiello/getty 31 march 16:30 bst   thousands of italians take part in citizen science project images and videos of locked down italians singing on their balconies to applaud health care workers have circulated the world. but last week, thousands of citizens were out for another cause: science. for three evenings, on 23 25 march, 6,000 italians appeared on their balconies to take part in a citizen science experiment that has never attempted before   measuring light pollution with their smartphones. the project, called science on the balcony and run by the italian national research council, asked participants to turn off all the lights in their homes and launch an app designed for the study. then they were asked to turn their phone screens towards the main light source that could be seen from their windows   for example, a street light or a sign. using the phone’s sensors, the app measured the light source’s illuminance, or brightness, in units of lux. the study was conceived by luca perri, an astrophysicist and science communicator at the astronomical observatory of milan, and alessandro farini, a vision scientist at italy’s national institute of optics in florence. like many nations, italy has seen a steady increase in night time light in recent decades. such light pollution compromises astronomers’ view of space and presents environmental, economic, safety and public health problems; it can, for instance, affect the immune system. how the coronavirus pandemic is affecting the world's biggest physics experiments how the coronavirus pandemic is affecting the world's biggest physics experiments but widespread data collection on light pollution requires a significant investment of time and money, and might need researchers to visit homes or place sensors there. and satellites detect only light reflected skywards, so they don’t give a full picture. the latest project allowed researchers to measure light inside homes, harnessing the collaboration and enthusiasm of locked down citizens. initial data confirm that people in every italian province participated. and farini sees another advantage for science. “this pandemic risks creating doubts about science, because a lot of fake news is circulating,” he says. “with this experiment, we wanted to bring citizens closer to measurement techniques, to let them see the often complex process and allow them to participate in the scientific method.” 31 march 03:00 bst   lockdowns might already have averted tens of thousands of deaths in europe infection control measures such as national lockdowns in many european countries are reducing the spread of the coronavirus. across 11 countries, between 21,000 and 120,000 deaths were probably avoided by the end of march, according to a model by a group at imperial college london. the study, published by the imperial college covid 19 response team on 30 march, estimates the effects of non pharmaceutical interventions, which include closing schools and banning mass gatherings, on the spread of the virus across parts of europe, including italy, spain and the united kingdom. the authors measured the effects through a change in the virus’s effective reproduction number. if the effective reproduction number is greater than 1, infections will proliferate and the outbreak will continue to spread. if it is less than 1, the rate of new infections will decrease until the outbreak is under control. the report shows that some of the countries studied   including italy, which implemented stringent lockdown measures three weeks ago   might have fallen below this threshold as a result of the interventions. previous work by other groups has found that the strict lockdowns in china reduced this value to below 1, stemming the tide of the epidemic there. ‘we need to be alert’: scientists fear second coronavirus wave as china’s lockdowns ease ‘we need to be alert’: scientists fear second coronavirus wave as china’s lockdowns ease because many countries still lack the capacity for widespread testing, the latest model uses reported covid 19 deaths, rather than infection rates, to track the spread of the virus. given the lag time between infection and mortality, it could take several weeks for the full effects of the interventions to be felt, especially in countries in the relatively early stages of their epidemics, such as the united kingdom, according to the report. the researchers are careful to note that they cannot attribute the transmission reduction to any particular intervention. and it’s too early to know whether the interventions as a whole are having the intended effect in some european countries. but, “if current trends continue, there is reason for optimism”, they write. 27 march 15:00 gmt   virus could have killed 40 million without global response the covid 19 pandemic could have infected 90% of the world’s population and killed 40.6 million people if no mitigation measures had been put in place to combat it, according to estimates from an influential modelling group at imperial college london. the report from the imperial college covid 19 response team, published on 26 march, highlights the importance of acting early to suppress the outbreak. the analysis says that introducing social distancing, testing and isolation of infected people would cut worldwide deaths to 1.9 million, if carried out when each country’s fatality rate was 0.2 deaths per 100,000 people per week. implementing these measures only when the death rate reaches 1.6 per 100,000 people per week would lead to 10.5 million lives lost globally, it finds. according to nature’s analysis of death rates from our world in data   counting each day at the centre of a rolling weekly window of deaths   italy hit the 0.2 threshold on 2 3 march, the united kingdom on 17 march and the united states on 22 march. the report did not quantify the social and economic impact of mitigation policies. the analysis was published as the uk prime minister boris johnson and the nation’s health minister, matt hancock, announced that they had tested positive for the coronavirus. in a video address to the nation, johnson said he had only mild symptoms and would continue to work remotely while isolating for seven days. 27 march 03:00 gmt   global infections number half a million the number of confirmed covid 19 cases around the world crossed 500,000 on 26 march, according to statistics compiled by the center for systems science and engineering at johns hopkins university in baltimore, maryland. the pandemic currently spans 175 countries and every inhabited continent. by the end of the day on 26 march, the united states had overtaken china for the highest number of confirmed cases. italy is also poised to surpass china in the coming days. italy and spain now have the two highest death tolls, with italy accounting for more than one third of the global total. covid 19 has claimed the lives of nearly 23,000 people. more than 120,000 have recovered from the disease. source: johns hopkins university 26 march 13:15 gmt   united kingdom pledges to roll out extensive antibody testing the united kingdom could begin large scale testing for coronavirus antibodies within days, government officials have said. if the roll out goes ahead as planned, the country could become the first to implement at home testing on this scale   but researchers caution that properly validating the accuracy of such tests and manufacturing them in large quantities presents a significant challenge. covert coronavirus infections could be seeding new outbreaks covert coronavirus infections could be seeding new outbreaks on 25 march, a uk government official said that the country had ordered 3.5 million ‘finger prick’ tests and planned to order millions more. the test will analyse drops of blood for antibodies that show whether a person has previously been infected with the coronavirus that causes covid 19. this will show who might now be immune and aid researchers in understanding the virus’s spread. these ‘serological tests’ should become available to the public in days rather than weeks or months, said sharon peacock, director of the national infection service at public health england (phe), a uk health agency. peacock suggested that the bulk of the uk tests, which will be available to buy from amazon and pharmacies to perform at home, had not yet arrived. most tests to diagnose coronavirus infection have involved laboratory based testing using the technique known as pcr, which checks for active infection. but an urgent goal has been to develop serological tests, which can detect past infection. these are now being deployed worldwide. singapore, for instance, has been using the tests for more than a month to trace known infections and monitor at risk populations. but thoroughly evaluating the efficacy of the tests and the rate of false positives is essential, says robert garry, a virologist at tulane university school of medicine in new orleans, louisiana, whose team is developing its own serological test. the blood test will need to distinguish between antibodies against the covid 19 virus and those against other seasonal coronaviruses to which people are commonly exposed, he says. “i would expect the false positive rate to be very high because of this prior exposure   unless they figured out how to make the serological test very specific,” he says. garry says that for a validated test, he would expect a false positive threshold of less than 5%   meaning fewer than 5 out of 100 people without the antibodies test positive   although he could see that being relaxed to 10%. even with ready access to clinical samples, understanding false positive levels on this timescale would require a massive effort, says garry. how much is coronavirus spreading under the radar? how much is coronavirus spreading under the radar? phe is evaluating the tests to ensure they work as claimed, said peacock, who anticipates this will be done by the end of the week. but supply is likely to remain limited, says david wraith, an immunologist at the university of birmingham, uk. it will be challenging for companies to manufacture millions of tests and for any one government to secure so many during a global pandemic, meaning that health care workers must be given priority access, he says. it is not clear who is developing the uk test. a phe spokesperson said the agency was talking to a range of companies. peacock added that highly vulnerable members of the public who test positive will also require further tests before they can resume normal life. travel in india is restricted for 21 days.credit: arun sankar/afp/getty 26 march 3:00 gmt   100 scientific organizations call to end trump’s ban on fetal tissue research a group of 100 research societies, professional organizations and universities is calling on us president donald trump to lift restrictions on the use of fetal tissue in research, arguing that the limits delay necessary work on potential treatments for covid 19. “we believe that researchers should have all of the biomedical research tools out there to develop treatments for covid 19,” says eric anthony, director of policy at the international society for stem cell research in skokie, illinois, a key signatory of the letter sent on 25 march. fetal tissue, often received from abortion clinics, has long been used in vaccine research. but last june, the trump administration, following a campaign by opponents of abortion, moved to ban government scientists from using fetal tissue in research once their existing supplies ran out. the rules also included restrictions for non government scientists funded by the us national institutes of health (nih), requiring that new grant applications for research that uses fetal tissue pass ethics review by an agency appointed board. the us department of health and human services (hhs), which oversees the nih, invited nominations to that ethics board in february, and the comment period closed last week. signatories to the letter asking for relief from the federal restrictions include the american academy of pediatrics, johns hopkins university, massachusetts general hospital and harvard university. at least one government scientist has appealed for an exemption to the rules in order to do coronavirus research, according to a story in the washington post last week. an hhs spokesperson told nature that the agency has made no decision about the request, and that the “trump administration has activated a whole of government, whole of america approach to prepare for and respond to covid 19”. 25 march 11:00 gmt   india starts three week lockdown india has commenced a 21 day lockdown, after prime minister narendra modi ordered the country’s 1.3 billion residents to remain in their homes from midnight on 24 march. many countries have introduced travel restrictions to slow the spread of the coronavirus. but the lockdown in india, which has the world’s second largest population, will dwarf similar measures in other nations. currently, the country has roughly 500 reported cases, and 9 reported deaths, but researchers say that infections are probably going undetected there given the size of its population. the country had tested about 15,000 people for the coronavirus by 20 march, according to our world in data. under the new restrictions, flights and train services are suspended, and road access is restricted in every state. medical centres, petrol stations and grocery stores are exempt from the lockdown. “the nation will have to certainly pay an economic cost because of this lockdown. however, to save the life of each and every indian is our topmost priority," said modi during a televised address. 25 march 01:00 gmt   the outbreak in italy went undetected for weeks the novel coronavirus sars cov 2 was present in northern italy as early as 1 january. an epidemiological analysis of lombardy, the epicentre of the outbreak in italy, reveals that the first onset of symptoms in the country occurred weeks before covid 19, the disease caused by the virus, was reported there on 20 february. the study looks at nearly 6,000 laboratory confirmed cases to track how the outbreak unfolded in the region. it was posted to the arxiv preprint server on 20 march. covert coronavirus infections could be seeding new outbreaks covert coronavirus infections could be seeding new outbreaks the undetected spread in january is “very striking”, says michele tizzoni, who models infectious diseases at the isi foundation in turin, italy, but was not involved in the work. “at that time, we were probably still talking about wuhan.” instead, by the time the first case was detected in italy, the virus had already spread to most towns and cities in southern lombardy. over the next several weeks, nearly half of the patients who tested positive for covid 19 were hospitalized; about one fifth of those required intensive care. the new picture of the outbreak in lombardy makes it clear that “aggressive containment strategies are required” to stop the spread of the virus, the authors write. although public activities and gatherings in the region were banned just three days after the first positive test, the virus’s undetected spread in the previous weeks meant that it had already taken hold, with the number of cases doubling roughly every three days. these data will be vital to other countries and public health organizations getting ready to face their own outbreaks of the pandemic, tizzoni says. his advice to them? “be prepared. even if you don’t see much.” 24 march 11:00 gmt   lockdowns eased in hubei province travel restrictions in wuhan will be lifted from 8 april.credit: afp/getty chinese authorities are reopening travel to and from hubei province, the epicentre of the covid 19 outbreak, ending two months of lockdowns that were introduced to help slow the disease’s spread. only one new infection has been reported in hubei since 18 march. how blood from coronavirus survivors might save lives how blood from coronavirus survivors might save lives from 25 march, flights and trains in and out of all cities in hubei province   except for the capital, wuhan   will resume, and roads will reopen, according to an announcement posted on hubei province’s website. access to wuhan, where the first cases were reported and spread, will remain restricted until 8 april. until then, all those entering or leaving the city will have to take a test to prove that they are not infected with sars cov 2, the virus that causes covid 19. the hubei announcement says that factories and businesses can gradually reopen, as long as they follow transmission prevention measures. universities, schools and child care centres will remain closed pending “a scientific assessment of the epidemic control situation”. (schools in most other regions of china also remain closed.) other cities in china are slowly returning to some sense of normality. but scientists are warning that there is a risk of renewed covid 19 transmission once people start mixing again. 23 march 21:15 gmt   united kingdom implements stringent lockdown the united kingdom is implementing drastic measures to prevent the spread of the coronavirus, joining other nations that have put in place unprecedented rules to fight the pandemic. prime minister boris johnson announced in a televised broadcast on 23 march that people living in the united kingdom must stay at home and travel outside only for essential purposes. the police will have powers to enforce the rules and fine people who stray from them. people will be allowed to leave their houses only to shop for food and medical supplies, exercise once a day, and travel to work if strictly necessary. shops that sell non essential items will close and gatherings of more than two people in public will be banned. public gatherings of more than two people will now be banned in the united kingdom.credit: tolga akmen/afp/getty the united kingdom had already issued guidelines for social distancing, but johnson said that although huge numbers are complying, “the time has now come for us all to do more”. the government had also been broadly criticized for not putting in place stricter measures to curb the spread of the virus sooner. the latest rules will be kept under review but will last for at least three weeks. the united kingdom has recorded 6,650 confirmed cases of the virus, with 335 deaths, but the true figures are feared to be much higher. the country joins other european nations that are already on lockdown; in some of these, measures are stricter and people cannot leave their houses without a permit. lockdowns are in effect in spain and italy   which is experiencing the world’s worst outbreak of covid 19, the disease caused by the coronavirus. germany has also banned public gatherings of more than two people. more than a dozen us states are implementing stay at home orders, affecting more one third of the us population. details of these orders, and the lengths of time for which they will apply, vary from state to state, but they generally include the closures of all non essential businesses, and continued or more stringent bans on public gatherings. on 19 march, california, the nation’s most populous state, was the first state to order a lockdown, following the lead of san francisco three days earlier. in new york state, home to about 5% of worldwide covid 19 cases, authorities can fine businesses that do not comply with orders, but people will not face penalties. in oregon, however, people who violate the governor’s order can be tried for a misdemeanour offence. president donald trump has also approved the mobilization of us national guard troops in new york, california and washington to set up medical stations and deliver aid to residents. a sign advising social distancing at manly beach in sydney, australia.credit: cameron spencer/getty 23 march 17:35 gmt   global infections pass 300,000 the number of covid 19 coronavirus infections worldwide passed 300,000 over the weekend. the world health organization (who) reported 332,935 cases   across nearly every country   as of 23 march, with 14,510 deaths. who director general tedros adhanom ghebreyesus said in a press briefing that it took 67 days from the first reported case to reach the first 100,000 cases, 11 days after that to reach 200,000 and just another 4 days to top 300,000 infections. 20 march 12:15 gmt   most covid 19 deaths now in italy deaths from covid 19 in italy have exceeded those reported in china, after 473 people died in italy in 24 hours. the coronavirus has so far killed 3,405 people there, according to official statistics from 19 march. in china, 3,242 people have died of the disease since the outbreak began in december, according to the world health organization (who). globally, the number of confirmed coronavirus cases has doubled in less than two weeks, to more than 200,000. on 19 march, seven countries confirmed their first coronavirus cases, including zambia, gambia, mauritius and kyrgyzstan, according to the who. medical teams from across china began leaving wuhan this week after infections there have dropped.credit: str/afp/getty 19 march 20:00 gmt   coronavirus hospitalizations occur at any age, says us cdc covid 19 can be severe enough to require hospitalization in adults of any age, according to a report from the us centers for disease control and prevention (cdc). covert coronavirus infections could be seeding new outbreaks covert coronavirus infections could be seeding new outbreaks the report, released on 18 march, analyses the severity of covid 19 cases in the united states from 12 february to 16 march by age group. although mortality is highest in adults over 65   consistent with data reported from china, italy and elsewhere   20% of us hospitalizations occurred in people aged 20 44 years. the cdc’s report excludes cases imported from wuhan, china, or from japan, so it did not count people who were infected on cruise ships in those areas. in total, age data were collected for 2,449 infected people. of them, 29% were between 20 and 45 years old. that statistic is roughly consistent with numbers released by the italian higher institute of health, which reported on 15 march that 24% of cases in the country occurred in adults aged 19 50. these data do not include age group breakdowns for severe cases, only fatalities. deaths from covid 19 in italy surpassed those in china on 19 march. the coronavirus pandemic in five powerful charts the coronavirus pandemic in five powerful charts among people with covid 19 aged 20 44 in the united states, the cdc’s report estimates that up to 21% required hospitalization. but only 2 4% of infected people in that age bracket required intensive care, significantly fewer than in any other adult age group. and fatalities remain low among young adults, the report shows. no data were collected regarding underlying conditions that have been shown to make people more susceptible to the disease, so it is unclear whether the young adults being hospitalized are those who are most vulnerable. still, the report stresses, severe illness “can occur in adults of any age”. 19 march 11:00 gmt   no new confirmed cases in hubei province on 18 march, hubei, the chinese province at the centre of the coronavirus outbreak, recorded no new cases of covid 19 for the first time since the beginning of the epidemic, according to the country’s national health commission. eight deaths were reported in the province that day. a month ago, hubei was confronting several thousand new confirmed cases each day. since december, it has recorded more than 67,000 people with covid 19, and more than 3,000 deaths. across china, there were 39 new cases recorded on 18 march, and 13 deaths. italy now faces the largest number of new cases per day, with 3,526 confirmed yesterday. new cases have also surged in the united states, iran, spain, france and germany. a train in moscow is disinfected.credit: alexander nemenov/afp/getty 18 march 10:00 gmt   deaths outside china surpass those inside the country the total number of people who have died from covid 19 outside china has overtaken deaths inside the country for the first time since the disease emerged, according to reports by the world health organization (who) on 16 march. the number of confirmed infections outside china surpassed those inside the country on the same day. as of 17 march, there were 179,112 confirmed cases of covid 19 globally, including 81,116 in china. of the 7,426 deaths from the disease, 3,231 have been in china. europe had the largest 24 hour spike in new infections, with 8,507 reported since 16 march, and 428 deaths. several regions recorded their first cases, including somalia, benin, liberia and the bahamas. 17 march 00:30 gmt   first vaccine clinical trials begin in the united states pharmacist michael witte delivers a shot in an early stage clinical trial for a potential coronavirus vaccine on 16 march.credit: ted s warren/ap/shutterstock the first phase i clinical trial for a potential covid 19 vaccine has begun in seattle, washington. four adults, the first of 45 eventual participants, received their first doses of an experimental vaccine developed through a partnership between the us national institute of allergy and infectious diseases (niaid) and moderna, a biotechnology company based in cambridge, massachusetts. but although it is an important milestone, the phase i trial is just the beginning of a long process to test the drug’s safety and efficacy. the trial is being conducted at kaiser permanente washington health research institute, and will test a range of doses of the vaccine. over the next 6 weeks, participants will receive their first doses, followed by a second 28 days later. follow up visits both in person and over the phone will assess participants’ health over a 14 month period, and blood samples will help researchers evaluate the body’s immune response to the experimental vaccine. the potential vaccine is based on messenger rna, which directs the body to make a protein found on the coronavirus’s outer shell. the hope is that this will elicit an immune response that protects against infection. what china’s coronavirus response can teach the rest of the world what china’s coronavirus response can teach the rest of the world the team at moderna had already been working on a vaccine for middle east respiratory syndrome, which is caused by another coronavirus. the viruses’ similarities helped the researchers pivot to the search for a covid 19 vaccine. as a result, the phase i trial was “launched in record speed”, according to a statement from niaid director anthony fauci on 16 march. it took just 66 days from genetic sequencing of the virus to the first human injection of the vaccine candidate. researchers hope to have initial clinical trial data within three months. but even in the best case scenario, the vaccine would not be widely available to the public for at least another year, according to niaid. 13 march 23:00 gmt   us president declares ‘national emergency’ us president donald trump called the coronavirus outbreak a national emergency on friday afternoon. this gives his administration broad authority in its response to the disease, including access to up to us$50 billion in federal funds to combat the epidemic. trump said that as many as half a million tests would be ready by early next week. how much is coronavirus spreading under the radar? how much is coronavirus spreading under the radar? earlier in the day, the president announced measures to speed up testing in the united states, including providing funding to develop rapid tests and appointing a new federal coordinator to oversee the efforts. more than 1,800 people have tested positive for the virus in the united states and at least 41 have died, according to the new york times. the virus has now been detected in 47 states and the district of columbia. 13 march 22:10 gmt   harvard university orders research labs to shut down research laboratories at harvard university in cambridge, massachusetts, have been ordered to prepare to shut down research operations amid the growing coronavirus outbreak. harvard is one of the first major research universities to announce that it will wind down laboratory research. dozens of universities worldwide have already moved teaching activities online or been closed in a bid to control the spread of the virus. despite harvard’s move, labs there doing direct research on coronavirus will be able to continue their operations, a representative of the university’s medical school told nature. all labs must begin implementing a plan to stop all laboratory research activities by 18 march, said e mails sent from deans to students and staff members in the faculty of arts and sciences and the medical school on 13 march. the suspension is expected to last for at least six to eight weeks, the e mails say. labs that work with live animals will be able to designate staff members for essential animal care, but microbial labs have been ordered to “freeze everything down”, says tanush jagdish, an evolutionary biologist at the university. the race to unravel the united states’ biggest coronavirus outbreak the race to unravel the united states’ biggest coronavirus outbreak exemptions will be made for essential experiments that “if discontinued would generate significant financial and data loss”, according to the e mails. jagdish says that the announcement caught everyone in his lab off guard. “for labs to be shut down in general was something we did not expect.” the labs that he works in had already implemented measures to prevent the spread of the coronavirus disease covid 19. these included alternating shifts and making cleaning protocols stricter, in addition to extra cleaning that was instituted at the department and university levels. until lab work can resume, researchers are devoting their time to writing grant proposals and theses, among other remote work, he says. on 10 march, harvard had mandated that gatherings of more than 25 people be held remotely, but the latest guidelines state that all meetings and courses should do this, regardless of size. in addition to conducting lab meetings by video chat, people have been discussing starting daily or weekly remote social hours, jagdish says. “it helps to know that we’re all in this together.” 13 march 22:00 gmt   europe now centre of pandemic, says who italy on lockdown: rome’s via del corso.credit: giuseppe fama/pacific press/lightrocket/getty europe has now become the epicentre of the covid 19 pandemic, says the world health organization (who). more cases are now being reported there every day than were reported at the height of china’s epidemic, director general tedros adhanom ghebreyesus said in a 13 march press briefing. there are more reported cases and deaths in europe than in the rest of the world combined, apart from china, tedros said. italy, which has the largest outbreak in europe, reported 2,651 new cases in the past day. more than 132,000 cases of covid 19 have now been reported from 123 countries and territories, according to the who. 11 march 16:35 gmt   coronavirus outbreak is a pandemic, says who after weeks of resisting mounting pressure from scientists, politicians and others, the world health organization (who) in geneva, switzerland, has decided to describe the coronavirus outbreak as a pandemic. why does the coronavirus spread so easily between people? why does the coronavirus spread so easily between people? the declaration comes after a 13 fold rise in the number of cases outside china in the past two weeks, and a trebling of countries affected   but does not change who strategy for tackling spread of the virus, director general tedros adhanom ghebreyesus said in an 11 march press briefing. “who has been assessing this outbreak around the clock and we are deeply concerned both by the alarming levels of spread and severity, and by the alarming levels of inaction,” said tedros. “describing the situation as a pandemic does not change who’s assessment of the threat posed by this coronavirus. it doesn’t change what who is doing, and it doesn’t change what countries should do,” he said. “pandemic is not a word to use lightly or carelessly. it is a word that, if misused, can cause unreasonable fear, or unjustified acceptance that the fight is over, leading to unnecessary suffering and death.” many scientists had been calling for the change in language for weeks   after large outbreaks were detected in south korea, iran and italy. at the time, some researchers suggested that countries would soon move from efforts that involve containing as many new cases as possible to social distancing measures, such as school closures, that do not rely on knowing who is infected with the virus and who is not. the virus has now been found in more than 100 countries. it has infected some 120,000 people, killing more than 4,000 of them. several nations have closed schools in a bid to stop the virus, and italy has entered an unprecedented countrywide lockdown. “this is not just a public health crisis, it is a crisis that will touch every sector   so every sector and every individual must be involved in the fight,” said tedros. researchers have been working rapidly since the outbreak came to light in january to characterize the virus, work out why it is so infectious, find out where it came from and help with diagnosing infections. 11 march 12:30 gmt   transgenic animals for coronavirus research in high demand labs are scrambling to get their hands on transgenic animals that can be used to study the coronavirus and test drugs and vaccines. ordinary mice seem to be resistant to infection by this coronavirus, so researchers conduct studies in rodents that produce a human version of the protein ace2, which the virus uses to enter cells. labs rush to study coronavirus in transgenic animals   some are in short supply labs rush to study coronavirus in transgenic animals   some are in short supply but these mice   originally developed for research into severe acute respiratory syndrome, or sars   are in short supply. one us breeding facility, the jackson laboratory in bar harbor, maine, has received requests for 3,000 mice, and is now establishing a colony of these animals. researchers have also already reported initial results from studies in monkeys infected with coronavirus. the animals seemed to experience only a mild illness, similar to that in many humans. scientists are now seeking animal models to mimic the more severe version of the illness. 11 march 07:30 gmt   major chemistry meeting among cancelled scientific conferences the american chemical society (acs), the world’s largest scientific society, cancelled its meeting in philadelphia, pennsylvania, on monday, 13 days before it was due to begin on 22 march. the conference is one of a growing number of scientific meetings and conferences being cancelled because of coronavirus outbreaks. governments and health officials are increasingly calling for the restriction of large gatherings, in an attempt to reduce the virus’s spread. the acs said the decision to cancel was based on several factors, including a rise in covid 19 cases in the greater philadelphia area and input from members who were increasingly concerned about travelling to and attending a large meeting. about 800 participants had already cancelled their registrations before the announcement, an acs press officer told nature. the american physical society’s huge march meeting was also cancelled last week, about a day before it was due to begin. scores of other meetings are being postponed or being held virtually. 10 march 03:30 gmt   call for more funding at least us$8 billion is needed to address the most pressing threats posed by the new coronavirus, says the global preparedness monitoring board (gpmb), an independent group co convened by the world health organization and the world bank group to combat public health emergencies. the money is needed in addition to the tens of billions of dollars already pledged by the international monetary fund, the world bank group and individual governments. the gpmb released a report on 9 march calling on advanced economies, such as the members of the group of seven and group of 20 industrialized nations, and financial institutions, to provide money to address five priority areas. these include strengthening weak health care systems; supporting the world health organization’s efforts to help vulnerable countries; developing diagnostics, therapeutics and vaccines; strengthening regional surveillance; and ensuring that sufficient protective equipment is available for health workers. 9 march 04:00 gmt   global cases pass 100,000 the number of known global cases of covid 19 passed 100,000 over the weekend. on 8 march, the world health organization reported 105,586 confirmed cases across more than 100 countries and territories. although the outbreak has been slowing in china, where it originated, the country still accounts for almost 80% of confirmed cases. 6 march 11:30 gmt   us congress approves us$8.3 billion for coronavirus response the united states congress has passed an emergency spending bill that will allocate us$8.3 billion for the country’s coronavirus response. the house of representatives passed the bill in a near unanimous vote on wednesday afternoon; the senate followed suit on thursday. the bill will provide more than $3 billion to the centers for disease control and prevention, the national institutes of health, and the food and drug administration for research on diagnostics, therapeutics and vaccines. each us state will reportedly receive at least $4 million for state and local government responses. the bill also includes a provision to ensure that an eventual vaccine is affordable. other funding will contribute to the global coronavirus response and provide support for small businesses that are struggling in the wake of the outbreak. the bill will now go to president donald trump to be signed. elsewhere, the us national science foundation in alexandria, virginia, opened up a rapid response research funding mechanism for non medical coronavirus related research. such calls are often used to award funding for work exploring the impacts of natural disasters such as hurricanes and wildfires, and allow for an expedited review of research proposals. 5 march 15:30 gmt   china study suggests children are as likely to be infected as adults children are just as likely to become infected with the new coronavirus as adults, finds one of the most detailed studies yet published on the spread of the virus, known as sars cov 2. the analysis   based on data from shenzhen in china   provides a partial answer to one of the most pressing questions surrounding the outbreak: the role of children. previous studies have suggested that kids are much less likely than other age groups to develop severe symptoms when infected by the coronavirus. but it was not clear whether this was because they weren’t getting infected or because they were fighting off the infection more effectively. “kids are just as likely to get infected and they’re not getting sick,” says justin lessler, an infectious disease epidemiologist at johns hopkins bloomberg school of public health in baltimore, maryland. he co led the study with three other epidemiologists   qifang bi, also at johns hopkins, ting ma at the harbin institute of technology in shenzhen and tiejian feng at the shenzhen center for disease control and prevention. they posted the analysis to the medrxiv preprint server on 4 march. the study is unique in that it looked at not only people who were infected with the virus, but also large numbers of their close contacts, some of whom were infected and many of whom were not. the researchers followed 391 people who were diagnosed on the basis of their symptoms, and 1,286 of their close contacts to see whether these contacts tested positive for the virus even if they didn’t show symptoms. overall, the team found that children under 10 who had potentially been exposed to the virus were just as likely to become infected as other age groups, with between 7% and 8% of contacts of known cases later testing positive. the authors also found that people who lived in the same household as someone infected with the virus were about six times more likely get infected than those who made contact with an infected person in other settings. “this may be the first clear evidence that children are as susceptible as adults to sars cov 2 infection,” says ben cowling, an infectious disease epidemiologist at the university of hong kong. he wonders whether the fact that outbreaks haven’t been observed in schools could be down to the fact that children’s symptoms are mild. lessler says it’s still not clear whether children are important in transmitting the virus, as they are for influenza; children routinely develop flu symptoms and are common hubs in chains of transmission. “that’s one of the current critical remaining questions and we’re trying to figure out how to answer it,” he says. “i have a 7 month old and a 6 year old and i can’t imagine that, if they have any virus at all, they’re not getting it on somebody.” the study could have important implications for slowing the spread of the virus through measures such as school closures. “once we say containment is not an option, we can’t ignore the kids,” says lessler. “this is a key piece of data that may support school closures as an effective intervention,” caitlin rivers, an epidemiologist at johns hopkins bloomberg school of public health, said in a tweet on 5 march. 5 march 12:55 gmt   world bank pledges us$12 billion for coronavirus response on 3 march, the world bank group pledged up to us$12 billion, including $8 billion in new funding, to support countries dealing with the coronavirus outbreak. the funding will be fast tracked and consists of grants and low interest loans, as well as technical support. most of the package is earmarked for strengthening health systems and improving access to treatment. the world bank said it would prioritize funding for countries at high risk and with low capacity to deal with the outbreak. half of the pledged money is from the international finance corporation, and is intended to strengthen global supply chains and support key industries such as pharmaceuticals. 4 march 12:00 gmt   repurposed drugs in coronavirus spotlight more than 80 clinical trials launch to test coronavirus treatments more than 80 clinical trials launch to test coronavirus treatments drugs used to treat hiv and an experimental antiviral drug developed to fight ebola virus are among those that are rapidly being tested against the new coronavirus. there are no approved treatments for diseases caused by coronaviruses. but hundreds of clinical trials of drug candidates are planned or underway, with much of the focus on remdesivir, a candidate drug originally developed to treat the ebola virus. the drug, developed by the pharmaceutical firm gilead sciences of foster city, california, is being tested in partnership with chinese health authorities in randomized, controlled trials; two of these are set to finish in april. the compound works by trying to prevent the replication of the virus. “remdesivir has quite high efficacy across all different coronaviruses and therefore it is one of the prime candidates to start being tested,” says vincent munster, chief of the viral ecology unit at the us national institutes of health. 2 march 21:00 gmt   infections worldwide top 90,000 the number of people worldwide who have been infected with the coronavirus has passed 90,000. more than 3,000 have died since the outbreak began in december. the vast majority of cases   more than 80,000   have occurred in china, but around 60 other countries are now also dealing with outbreaks. many nations are preparing for a global pandemic, as reports of cases caused by spread within communities   rather than being imported from china   rise. south korea, italy and iran are fighting the largest outbreaks outside china. source: johns hopkins university 2 march 20:45 gmt   who raises alert to ‘very high’ at a press briefing on 29 february, the world health organization (who) announced that it had raised the global alert for covid 19 to the highest possible level, short of calling it a pandemic. the virus has now spread to some 60 locations outside china, with new cases detected in ireland, monaco, azerbaijan, qatar and ecuador. the global alert for the spread and impact of the coronavirus outbreak increased from ‘high’ to ‘very high’. the alert remains ‘very high’ in china. the global change was based on an assessment by who epidemiologists, which took into account the continued increase in the number of cases and affected locations, and the difficulties that some regions, including iran and italy, are facing in containing the spread of the coronavirus. tedros adhanom ghebreyesus, director general of the who, said at the briefing that most cases were linked and could still be traced to known contacts or clusters, with no evidence of the virus spreading freely in communities. “as long as that is the case, we still have a chance of containing this virus, if robust action is taken to detect cases early, isolate and care for patients and trace contacts,” said tedros. the organization therefore once again resisted declaring the outbreak a pandemic. mike ryan, director of the who’s emergencies programme, said that such a decision would mean that efforts to contain and slow down the spread of the virus have failed, which has proved to be untrue in china, singapore and other regions. the who is still holding out hope that the virus can be contained, but we have probably crossed that threshold, says adam kamradt scott, a global health security researcher at the university of sydney, australia. some countries have already begun to prepare their pandemic plans, which is an important precautionary measure, says nigel mcmillan, an infectious disease researcher at griffith university in brisbane. australia, for example, initiated its coronavirus emergency response on 27 february. the who is being overly cautious in not declaring a pandemic, says mcmillan. 2 march 20:30 gmt   transmission details emerge from who china analysis china has mounted “perhaps the most ambitious, agile and aggressive disease containment effort in history” against a new infectious disease, the world health organization (who) said in a report released on 28 february, after nine days of meetings and site visits in china from 16 to 24 february. the report analyses data from the outbreak in china, and recommends steps that the country and others should take to curb covid 19. daily reports of new cases are declining in the country, the who confirmed   so much so that authorities are now having problems recruiting participants for the more than 80 clinical trials there that are testing potential treatments for the coronavirus. some experimental treatments should be prioritized over others, the health agency recommended. the report’s analysis of data from china finds 99.9% similarity between the 104 strains of the coronavirus, named sars cov 2, collected from people between december 2019 and mid february 2020. this means that the virus is not mutating significantly. the median age of people infected is 51 years. and most cases of spread from person to person have been in hospitals, prisons or households, which implies that close contact is often required for the virus to spread between people. airborne spread is not believed to be a major driver of transmission, the report says. in one preliminary study from the province of guangdong, people in the same household as someone with covid 19 had a 3 10% chance of being infected. the who credits china’s ability to rein in the epidemic to a variety of measures. one is that 1,800 teams of epidemiologists have rapidly tracked tens of thousands of contacts of people infected with the virus in hubei province, where the outbreak emerged. up to 5% of these contacts ended up having the disease and were diagnosed quickly. and the report says the lockdown on travel out of hubei   an unprecedented measure in a province of this size   curbed wider spread of the disease to china’s 1.4 billion citizens. 2 march 17:45 gmt   coronavirus fears cancel huge physics meeting senior nature reporter davide castelvecchi reports from denver, colorado, where the world’s biggest physics meeting has been cancelled because of coronavirus fears. the meeting was scheduled to host 11,000 attendees. some researchers are finding other ways to share their work, including informal meet ups and virtual talks. several other scientific meetings have also been cancelled, as virus outbreaks emerge and escalate in countries around the world. 28 february 12:45 gmt   coronavirus spreads to sub saharan africa the coronavirus outbreak has spread to 46 countries other than china   and now seems to be spreading faster outside china than inside. this nigerian doctor might just prevent the next deadly pandemic this nigerian doctor might just prevent the next deadly pandemic several nations reported their first infections this week; cases included the first to be confirmed in sub saharan africa, in nigeria. the nigeria centre for disease control reported the case on 27 february and said it was working to trace the infected person’s contacts. health authorities and researchers have feared the virus’s spread to african countries including nigeria, where weak health systems could quickly be overwhelmed by a local outbreak. the world health organization reports that more than 82,000 people worldwide have now been infected   more than 3,600 of those outside china. cases in south korea, which is handling the world’s second largest outbreak, have exploded to more than 2,300. china’s outbreak seems to be slowing, with the daily number of new cases dropping. authorities reported 327 new infections nationwide on 27 february. a week earlier, on 20 february, that figure had been around 900. outside china, about 750 new cases were reported on 27 february. 26 february 18:30 gmt   brazil reports first case in south america a case of covid 19 has been confirmed in brazil   the first in south america. on 26 february, brazil’s minister of health, luiz henrique mandetta, confirmed that a man who travelled to northern italy between 9 and 21 february has the disease. italy’s outbreak has escalated to 324 cases and 12 deaths, according to a virus tracker maintained by johns hopkins university in baltimore, maryland. the brazilian case is in a 61 year old man who sought care for a fever, cough and sore throat yesterday at a hospital in são paulo, where he tested positive for covid 19. officials say he is in stable condition and will be quarantined at home for 14 days. “we should only take those with severe respiratory conditions to the hospital,” said mandetta in a tweet. algeria, greece, afghanistan, bahrain, iraq and oman have all reported their first cases within the past two days. the virus’s appearance in south america now means that it has spread to every continent except antarctica. 25 february 22:30 gmt   trump requests emergency funding for coronavirus response the administration of president donald trump has requested up to us$2.5 billion to fund the us response to covid 19. in a 24 february letter to congress, the office of management and budget requested $1.25 billion in new funding and proposed to make up the rest by repurposing funds allocated to other programmes, including $535 million assigned to the ebola response. time to use the p word? coronavirus enters dangerous new phase time to use the p word? coronavirus enters dangerous new phase democratic legislators immediately criticized the requested sum as overdue and insufficient. the us government has allocated several times that figure for past outbreak responses: congress approved about $5.4 billion for the 2014 ebola outbreak, and in 2009 about $7.7 billion was directed to the h1n1 influenza pandemic response. public health policy analysts expect the government to make some funds available, but it’s unclear how much will be appropriated, and how soon. “my expectation is that something will eventually be passed,” says josh michaud, a public health policy analyst at the kaiser family foundation, a non profit organization in washington dc. “what eventual form that is and whether it conforms to the risk that coronavirus poses is another question.” 25 february 21:00 gmt   researchers anticipate unstoppable spread despite the world health organization’s decision not to describe the escalating coronavirus outbreak as a pandemic, some scientists say that the spread is already moving into a new, dangerous phase. they say measures to limit spread will have to shift from containment to mitigation, as countries including iran, italy and south korea report growing outbreaks with hundreds of infections. 25 february 18:30 gmt   ‘there is lots of anxiety’: a scientist’s view from south korea bartosz grybowski is a crystal chemist in south korea, where cases of the coronavirus have surged. crystal chemist bartosz grzybowski talks to the nature podcast’s nick howe about how the surging outbreak in south korea is affecting daily life as a researcher. grzybowski is at the ulsan national institute of science and technology, about 60 kilometres from the city of daegu, where most of the country’s coronavirus cases have occurred. he says panic and fear reign   but the nation seems well prepared. 24 february 16:30 gmt   who says outbreak isn’t a pandemic at a press briefing on 24 february, the world health organization (who) said that, despite the spread of the disease, the coronavirus outbreak does not yet amount to a pandemic. “using the word pandemic now does not fit the facts, but it may cause fear,” said who director general tedros adhanom ghebreyesus. “for the moment, we are not witnessing the uncontained global spread of this coronavirus, and we are not witnessing large scale severe disease or death,” said tedros. “does this virus have pandemic potential? absolutely. are we there yet? from our assessment, not yet.” mike ryan, director of the who’s emergencies programme, justified the organization’s position by explaining that the virus’s transmission remains poorly understood   and it seems that the rate of new infections is declining in china. he advised countries to focus on treating patients and reducing the chance of people spreading the virus to others. 24 february 14:00 gmt   cases outside china are rising the number of cases of covid 19 outside china jumped over the weekend, with italy, south korea and iran reporting new infections. kuwait, bahrain, afghanistan and iraq also confirmed their first cases on 24 february. coronavirus: hospitals must learn from past pandemics coronavirus: hospitals must learn from past pandemics officials in iran have reported up to 61 cases and 12 deaths. but the figures have been in flux, and case numbers will probably rise in the coming days, given that the number of deaths compared to overall cases is much higher than reported in other countries. south korea had confirmed 833 infections and 8 deaths as of 24 february, according to a virus tracker maintained by researchers at johns hopkins university in baltimore, maryland. the virus is also spreading in italy, where 230 people have been infected and 5 have died, according to the tracker. at a meeting organized by the african union on 22 february, tedros adhanom ghebreyesus, the director general of the world health organization, said he was especially worried about the rise in cases in iran, south korea and italy. “the increasing signs of transmission outside china show that the window of opportunity we have for containing this virus is narrowing,” he said. meanwhile, more than 77,000 people have been infected in china, and the death toll there has passed 2,500. 20 february 13:30 gmt   coronavirus death toll passes 2,000 more than 2,100 people worldwide have now died from covid 19, the disease caused by the new coronavirus. on 20 february, chinese authorities reported that 2,118 people there had died from the illness. infections worldwide have topped 75,000; more than 74,000 are in china. 20 february 13:00 gmt   china’s case counting methods raise concerns scientists have questioned the way in which china is counting cases of the coronavirus. china’s official reports on the number of infections have not been including people who have tested positive for the virus but have no symptoms. researchers fear the practice is masking the epidemic’s true scale   but some public health experts say china is right to prioritize tracking ill people who are spreading the disease. medical staff working in an exhibition centre converted into a hospital in wuhan, chinacredit: afp/getty 18 february 11:00 gmt   has the outbreak in china peaked? a study of nearly 45,000 confirmed covid 19 cases in china suggests that the outbreak might already have reached its climax. the report, from the country’s center for disease control and prevention, says that the peak   the day with the highest number of new infections   occurred around the end of january. the number of new laboratory confirmed cases per day declined from then to 11 february, the end of the study period. however, the number of new suspected cases and cases diagnosed by physicians using chest scans, known as clinically diagnosed cases, stayed at roughly the same levels. keep up to date, with nature briefing keep up to date, with nature briefing the latest data on coronavirus infections in china appear to show a decline in new cases, said tedros adhanom ghebreyesus, director general of the world health organization (who), at a press briefing on 17 february, the same day the chinese report was released. but he said the trend must be interpreted cautiously. “it’s too early to tell if this new reported decline will continue,” he said. “every scenario is still on the table.” raina macintyre, a physician and epidemiologist at the university of new south wales in sydney, australia, agrees that the data need to be considered with caution, but says the general trends are informative. the who’s reports also show a decline in new cases reported per day in china and worldwide, she says. but the extended chinese holiday period that ended on 9 february means there might be another increase in new cases around 21 february, as people return to work. “often with epidemics we see more than one peak,” says macintyre. epidemiologists have been trying to estimate roughly when the outbreak will peak, so public health officials can prepare hospitals and work out when it will be safe to lift travel restrictions in wuhan and several nearby cities. some models suggest that the climax will happen any time now. others say that it is months away and that the virus will infect millions   or, in one estimate, hundreds of millions   of people before then. this model assumes that many more people have been infected than is reflected by official counts, but that these people have no symptoms or are not ill enough to seek medical treatment. the coronavirus sars cov 2, shown in a scanning electron microscope image.credit: niaid rml/de wit/fischer 17 february 00:30 gmt   first case in africa detected the first case of the new coronavirus has been reported in africa   in a person in egypt. the country’s health ministry and the world health organization said on 15 february that the case had been detected as a result of egypt’s programme to trace visitors who had come from affected countries. the person tested positive for the virus but had no symptoms. they are currently being isolated and are in a stable condition. or doi: https://doi.org/10.1038/d41586 020 00154 w correction 31 january 2020: an earlier version of this story misstated the number of countries in which human to human transmission has been confirmed. read, j. m. et al. preprint at medrxiv https://www.medrxiv.org/content/10.1101/2020.01.23.20018549v1 (2020). liu, t. et al. preprint at biorxiv https://www.biorxiv.org/content/10.1101/2020.01.25.919787v1 (2020). fuk woo chan, j. et al. lancet https://doi.org/10.1016/s0140 6736(20)30154 9 (2020). article google scholar download references reprints and permissions coronavirus and covid 19: keep up to date ‘we need to be alert’: scientists fear second coronavirus wave as china’s lockdowns ease how the coronavirus pandemic is affecting the world's biggest physics experiments how blood from coronavirus survivors might save lives covert coronavirus infections could be seeding new outbreaks podcast extra: coronavirus   science in the pandemic how much is coronavirus spreading under the radar? why does the coronavirus spread so easily between people? the race to unravel the united states’ biggest coronavirus outbreak time to use the p word? coronavirus enters dangerous new phase when will the coronavirus outbreak peak? china coronavirus: how many papers have been published? wuhan scientists: what it’s like to be on lockdown why snakes probably aren’t spreading the new china virus china coronavirus: six questions scientists are asking how quickly does the wuhan virus spread? new virus surging in asia rattles scientists these gaza scientists are keeping research alive amid war, destruction and uncertainty news 06 feb 25 how the brain suppresses fear: mouse study offers path to anxiety treatments news 06 feb 25 ‘it is chaos’: us funding freezes are endangering global health news 06 feb 25 how the world health organization can thrive without the united states editorial 04 feb 25 how flight helped bats become invincible to viruses news 29 jan 25 bat genomes illuminate adaptations to viral tolerance and disease resistance article 29 jan 25 discovery of cellular and molecular mechanisms of tissue repair and regeneration. beijing, china the chinese institutes for medical research (cimr), beijing applications are sought for an assistant professor of bioengineering for the circular bio economy within the college of engineering and architecture dublin, leinster (ie) university college dublin applications are sought for an assistant professor of artificial intelligence in food engineering within the college of engineering and architecture. dublin, leinster (ie) university college dublin the moslehi lab is recruiting highly motivated candidates for a three year post doctoral fellowship san francisco, california ucsf   moslehi lab job title: associate or senior editor, nature health location(s): new york or shanghai   hybrid working application deadline: february 14, 2025 a... new york city, new york (us) springer nature ltd coronavirus and covid 19: keep up to date ‘we need to be alert’: scientists fear second coronavirus wave as china’s lockdowns ease how the coronavirus pandemic is affecting the world's biggest physics experiments how blood from coronavirus survivors might save lives covert coronavirus infections could be seeding new outbreaks podcast extra: coronavirus   science in the pandemic how much is coronavirus spreading under the radar? why does the coronavirus spread so easily between people? the race to unravel the united states’ biggest coronavirus outbreak time to use the p word? coronavirus enters dangerous new phase when will the coronavirus outbreak peak? china coronavirus: how many papers have been published? wuhan scientists: what it’s like to be on lockdown why snakes probably aren’t spreading the new china virus china coronavirus: six questions scientists are asking how quickly does the wuhan virus spread? new virus surging in asia rattles scientists an essential round up of science news, opinion and analysis, delivered to your inbox every weekday. sign up for the nature briefing newsletter   what matters in science, free to your inbox daily. nature (nature) issn 1476 4687 (online) issn 0028 0836 (print) © 2025 springer nature limited

an official website of the united states government official websites use .gov a .gov website belongs to an official government organization in the united states. secure .gov websites use https a lock ( lock locked padlock icon ) or https:// means you've safely connected to the .gov website. share sensitive information only on official, secure websites. primary site navigation logged in as: address correspondence to yashpal singh malik, malikyps@gmail.com, or alfonso j. rodriguez morales, arodriguezm@utp.edu.co. citation dhama k, khan s, tiwari r, sircar s, bhat s, malik ys, singh kp, chaicumpa w, bonilla aldana dk, rodriguez morales aj. 2020. coronavirus disease 2019 covid 19. clin microbiol rev 33:e00028 20. https://doi.org/10.1128/cmr.00028 20. corresponding author. collection date 2020 oct. all rights reserved. this article is made available via the pmc open access subset for unrestricted noncommercial re use and secondary analysis in any form or by any means with acknowledgement of the original source. these permissions are granted for the duration of the world health organization (who) declaration of covid 19 as a global pandemic. in recent decades, several new diseases have emerged in different geographical areas, with pathogens including ebola virus, zika virus, nipah virus, and coronaviruses (covs). recently, a new type of viral infection emerged in wuhan city, china, and initial genomic sequencing data of this virus do not match with previously sequenced covs, suggesting a novel cov strain (2019 ncov), which has now been termed severe acute respiratory syndrome cov 2 (sars cov 2). although coronavirus disease 2019 (covid 19) is suspected to originate from an animal host (zoonotic origin) followed by human to human transmission, the possibility of other routes should not be ruled out. keywords: covid 19, emerging coronavirus, sars cov 2, diagnosis, one health, therapy, vaccines in recent decades, several new diseases have emerged in different geographical areas, with pathogens including ebola virus, zika virus, nipah virus, and coronaviruses (covs). recently, a new type of viral infection emerged in wuhan city, china, and initial genomic sequencing data of this virus do not match with previously sequenced covs, suggesting a novel cov strain (2019 ncov), which has now been termed severe acute respiratory syndrome cov 2 (sars cov 2). although coronavirus disease 2019 (covid 19) is suspected to originate from an animal host (zoonotic origin) followed by human to human transmission, the possibility of other routes should not be ruled out. compared to diseases caused by previously known human covs, covid 19 shows less severe pathogenesis but higher transmission competence, as is evident from the continuously increasing number of confirmed cases globally. compared to other emerging viruses, such as ebola virus, avian h7n9, sars cov, and middle east respiratory syndrome coronavirus (mers cov), sars cov 2 has shown relatively low pathogenicity and moderate transmissibility. codon usage studies suggest that this novel virus has been transferred from an animal source, such as bats. early diagnosis by real time pcr and next generation sequencing has facilitated the identification of the pathogen at an early stage. since no antiviral drug or vaccine exists to treat or prevent sars cov 2, potential therapeutic strategies that are currently being evaluated predominantly stem from previous experience with treating sars cov, mers cov, and other emerging viral diseases. in this review, we address epidemiological, diagnostic, clinical, and therapeutic aspects, including perspectives of vaccines and preventive measures that have already been globally recommended to counter this pandemic virus. over the past 2 decades, coronaviruses (covs) have been associated with significant disease outbreaks in east asia and the middle east. the severe acute respiratory syndrome (sars) and the middle east respiratory syndrome (mers) began to emerge in 2002 and 2012, respectively. recently, a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (sars cov 2), causing coronavirus disease 2019 (covid 19), emerged in late 2019, and it has posed a global health threat, causing an ongoing pandemic in many countries and territories (1). health workers worldwide are currently making efforts to control further disease outbreaks caused by the novel cov (originally named 2019 ncov), which was first identified in wuhan city, hubei province, china, on 12 december 2019. on 11 february 2020, the world health organization (who) announced the official designation for the current cov associated disease to be covid 19, caused by sars cov 2. the primary cluster of patients was found to be connected with the huanan south china seafood market in wuhan (2). covs belong to the family coronaviridae (subfamily coronavirinae), the members of which infect a broad range of hosts, producing symptoms and diseases ranging from the common cold to severe and ultimately fatal illnesses, such as sars, mers, and, presently, covid 19. sars cov 2 is considered one of the seven members of the cov family that infect humans (3), and it belongs to the same lineage of covs that causes sars; however, this novel virus is genetically distinct. until 2020, six covs were known to infect humans, including human cov 229e (hcov 229e), hcov nl63, hcov oc43, hcov hku1, sars cov, and mers cov. although sars cov and mers cov have resulted in outbreaks with high mortality, others remain associated with mild upper respiratory tract illnesses (4). newly evolved covs pose a high threat to global public health. the current emergence of covid 19 is the third cov outbreak in humans over the past 2 decades (5). it is no coincidence that fan et al. predicted potential sars  or mers like cov outbreaks in china following pathogen transmission from bats (6). covid 19 emerged in china and spread rapidly throughout the country and, subsequently, to other countries. due to the severity of this outbreak and the potential of spreading on an international scale, the who declared a global health emergency on 31 january 2020; subsequently, on 11 march 2020, they declared it a pandemic situation. at present, we are not in a position to effectively treat covid 19, since neither approved vaccines nor specific antiviral drugs for treating human cov infections are available (7 9). most nations are currently making efforts to prevent the further spreading of this potentially deadly virus by implementing preventive and control strategies. in domestic animals, infections with covs are associated with a broad spectrum of pathological conditions. apart from infectious bronchitis virus, canine respiratory cov, and mouse hepatitis virus, covs are predominantly associated with gastrointestinal diseases (10). the emergence of novel covs may have become possible because of multiple covs being maintained in their natural host, which could have favored the probability of genetic recombination (10). high genetic diversity and the ability to infect multiple host species are a result of high frequency mutations in covs, which occur due to the instability of rna dependent rna polymerases along with higher rates of homologous rna recombination (10, 11). identifying the origin of sars cov 2 and the pathogen’s evolution will be helpful for disease surveillance (12), development of new targeted drugs, and prevention of further epidemics (13). the most common symptoms associated with covid 19 are fever, cough, dyspnea, expectoration, headache, and myalgia or fatigue. in contrast, less common signs at the time of hospital admission include diarrhea, hemoptysis, and shortness of breath (14). recently, individuals with asymptomatic infections were also suspected of transmitting infections, which further adds to the complexity of disease transmission dynamics in covid 19 infections (1). such efficient responses require in depth knowledge regarding the virus, which currently is a novel agent; consequently, further studies are required. comparing the genome of sars cov 2 with that of the closely related sars/sars like cov revealed that the sequence coding for the spike protein, with a total length of 1,273 amino acids, showed 27 amino acid substitutions. six of these substitutions are in the region of the receptor binding domain (rbd), and another six substitutions are in the underpinning subdomain (sd) (16). phylogenetic analyses have revealed that sars cov 2 is closely related (88% similarity) to two sars like covs derived from bat sars like covs (bat sl covzc45 and bat sl covzxc21) (fig. 1). furthermore, sars cov 2 is genetically distinct from sars cov (79% similarity) and mers cov (nearly 50%) (17). covid 19 is associated with afflictions of the lungs in all cases and generated characteristic chest computer tomography findings, such as the presence of multiple lesions in lung lobes that appear as dense, ground glass opaque structures that occasionally coexist with consolidation shadows (18). s gene splitstree analysis. shown is the spike (s) glycoprotein gene based phylogenetic analysis (splitstree 4.0) of sar cov 2 isolates (39 isolates). the sars cov 2 isolates were analyzed with related covs from past human outbreaks and of animal origin, including mers cov, bovine coronavirus, canine coronavirus, bat coronaviruses, bat sl sars cov, and equine cov. the analysis includes all five defined subgenera of betacoronaviruses, namely, sarbecovirus, embecovirus, merbecovirus, nobecovirus, and hibecovirus. the isolates in the gray area are from the current outbreak of sars cov 2 from around the world. the nearest neighbors of sars cov 2 are the bat sl cov, encircled in yellow. some therapeutic options for treating covid 19 showed efficacy in in vitro studies; however, to date, these treatments have not undergone any randomized animal or human clinical trials, which limit their practical applicability in the current pandemic (7, 9, 19 21). the present comprehensive review describes the various features of sars cov 2/covid 19 causing the current disease outbreaks and advances in diagnosis and developing vaccines and therapeutics. it also provides a brief comparison with the earlier sars and mers covs, the veterinary perspective of covs and this emerging novel pathogen, and an evaluation of the zoonotic potential of similar covs to provide feasible one health strategies for the management of this fatal virus (22 367). coronaviruses are positive sense rna viruses having an extensive and promiscuous range of natural hosts and affect multiple systems (23, 24). coronaviruses can cause clinical diseases in humans that may extend from the common cold to more severe respiratory diseases like sars and mers (17, 279). the recently emerging sars cov 2 has wrought havoc in china and caused a pandemic situation in the worldwide population, leading to disease outbreaks that have not been controlled to date, although extensive efforts are being put in place to counter this virus (25). this virus has been proposed to be designated/named severe acute respiratory syndrome coronavirus 2 (sars cov 2) by the international committee on taxonomy of viruses (ictv), which determined the virus belongs to the severe acute respiratory syndrome related coronavirus category and found this virus is related to sars covs (26). sars cov 2 is a member of the order nidovirales, family coronaviridae, subfamily orthocoronavirinae, which is subdivided into four genera, viz., alphacoronavirus, betacoronavirus, gammacoronavirus, and deltacoronavirus (3, 27). the genera alphacoronavirus and betacoronavirus originate from bats, while gammacoronavirus and deltacoronavirus have evolved from bird and swine gene pools (24, 28, 29, 275). coronaviruses possess an unsegmented, single stranded, positive sense rna genome of around 30 kb, enclosed by a 5′ cap and 3′ poly(a) tail (30). the genome of sars cov 2 is 29,891 bp long, with a g+c content of 38% (31). these viruses are encircled with an envelope containing viral nucleocapsid. the nucleocapsids in covs are arranged in helical symmetry, which reflects an atypical attribute in positive sense rna viruses (30). the electron micrographs of sars cov 2 revealed a diverging spherical outline with some degree of pleomorphism, virion diameters varying from 60 to 140 nm, and distinct spikes of 9 to 12 nm, giving the virus the appearance of a solar corona (3). the cov genome is arranged linearly as 5′ leader utr replicase structural genes (s e m n) 3′ utr poly(a) (32). accessory genes, such as 3a/b, 4a/b, and the hemagglutinin esterase gene (he), are also seen intermingled with the structural genes (30). sars cov 2 has also been found to be arranged similarly and encodes several accessory proteins, although it lacks the he, which is characteristic of some betacoronaviruses (31). the positive sense genome of covs serves as the mrna and is translated to polyprotein 1a/1ab (pp1a/1ab) (33). a replication transcription complex (rtc) is formed in double membrane vesicles (dmvs) by nonstructural proteins (nsps), encoded by the polyprotein gene (34). subsequently, the rtc synthesizes a nested set of subgenomic rnas (sgrnas) via discontinuous transcription (35). based on molecular characterization, sars cov 2 is considered a new betacoronavirus belonging to the subgenus sarbecovirus (3). a few other critical zoonotic viruses (mers related cov and sars related cov) belong to the same genus. however, sars cov 2 was identified as a distinct virus based on the percent identity with other betacoronavirus; conserved open reading frame 1a/b (orf1a/b) is below 90% identity (3). an overall 80% nucleotide identity was observed between sars cov 2 and the original sars cov, along with 89% identity with zc45 and zxc21 sars related covs of bats (2, 31, 36). in addition, 82% identity has been observed between sars cov 2 and human sars cov tor2 and human sars cov bj01 2003 (31). a sequence identity of only 51.8% was observed between mers related cov and the recently emerged sars cov 2 (37). phylogenetic analysis of the structural genes also revealed that sars cov 2 is closer to bat sars related cov. therefore, sars cov 2 might have originated from bats, while other amplifier hosts might have played a role in disease transmission to humans (31). of note, the other two zoonotic covs (mers related cov and sars related cov) also originated from bats (38, 39). nevertheless, for sars and mers, civet cat and camels, respectively, act as amplifier hosts (40, 41). coronavirus genomes and subgenomes encode six orfs (31). the majority of the 5′ end is occupied by orf1a/b, which produces 16 nsps. the two polyproteins, pp1a and pp1ab, are initially produced from orf1a/b by a −1 frameshift between orf1a and orf1b (32). the virus encoded proteases cleave polyproteins into individual nsps (main protease [mpro], chymotrypsin like protease [3clpro], and papain like proteases [plps]) (42). sars cov 2 also encodes these nsps, and their functions have been elucidated recently (31). remarkably, a difference between sars cov 2 and other covs is the identification of a novel short putative protein within the orf3 band, a secreted protein with an alpha helix and beta sheet with six strands encoded by orf8 (31). coronaviruses encode four major structural proteins, namely, spike (s), membrane (m), envelope (e), and nucleocapsid (n), which are described in detail below. coronavirus s protein is a large, multifunctional class i viral transmembrane protein. the size of this abundant s protein varies from 1,160 amino acids (ibv, infectious bronchitis virus, in poultry) to 1,400 amino acids (fcov, feline coronavirus) (43). it lies in a trimer on the virion surface, giving the virion a corona or crown like appearance. functionally it is required for the entry of the infectious virion particles into the cell through interaction with various host cellular receptors (44). furthermore, it acts as a critical factor for tissue tropism and the determination of host range (45). notably, s protein is one of the vital immunodominant proteins of covs capable of inducing host immune responses (45). the ectodomains in all covs s proteins have similar domain organizations, divided into two subunits, s1 and s2 (43). the first one, s1, helps in host receptor binding, while the second one, s2, accounts for fusion. the former (s1) is further divided into two subdomains, namely, the n terminal domain (ntd) and c terminal domain (ctd). both of these subdomains act as receptor binding domains, interacting efficiently with various host receptors (45). the s1 ctd contains the receptor binding motif (rbm). in each coronavirus spike protein, the trimeric s1 locates itself on top of the trimeric s2 stalk (45). recently, structural analyses of the s proteins of covid 19 have revealed 27 amino acid substitutions within a 1,273 amino acid stretch (16). six substitutions are located in the rbd (amino acids 357 to 528), while four substitutions are in the rbm at the ctd of the s1 domain (16). of note, no amino acid change is seen in the rbm, which binds directly to the angiotensin converting enzyme 2 (ace2) receptor in sars cov (16, 46). at present, the main emphasis is knowing how many differences would be required to change the host tropism. sequence comparison revealed 17 nonsynonymous changes between the early sequence of sars cov 2 and the later isolates of sars cov. the changes were found scattered over the genome of the virus, with nine substitutions in orf1ab, orf8 (4 substitutions), the spike gene (3 substitutions), and orf7a (single substitution) (4). notably, the same nonsynonymous changes were found in a familial cluster, indicating that the viral evolution happened during person to person transmission (4, 47). such adaptive evolution events are frequent and constitute a constantly ongoing process once the virus spreads among new hosts (47). even though no functional changes occur in the virus associated with this adaptive evolution, close monitoring of the viral mutations that occur during subsequent human to human transmission is warranted. the m protein is the most abundant viral protein present in the virion particle, giving a definite shape to the viral envelope (48). it binds to the nucleocapsid and acts as a central organizer of coronavirus assembly (49). coronavirus m proteins are highly diverse in amino acid contents but maintain overall structural similarity within different genera (50). the m protein has three transmembrane domains, flanked by a short amino terminus outside the virion and a long carboxy terminus inside the virion (50). overall, the viral scaffold is maintained by m m interaction. of note, the m protein of sars cov 2 does not have an amino acid substitution compared to that of sars cov (16). the coronavirus e protein is the most enigmatic and smallest of the major structural proteins (51). it plays a multifunctional role in the pathogenesis, assembly, and release of the virus (52). it is a small integral membrane polypeptide that acts as a viroporin (ion channel) (53). the inactivation or absence of this protein is related to the altered virulence of coronaviruses due to changes in morphology and tropism (54). the e protein consists of three domains, namely, a short hydrophilic amino terminal, a large hydrophobic transmembrane domain, and an efficient c terminal domain (51). the sars cov 2 e protein reveals a similar amino acid constitution without any substitution (16). the n protein of coronavirus is multipurpose. among several functions, it plays a role in complex formation with the viral genome, facilitates m protein interaction needed during virion assembly, and enhances the transcription efficiency of the virus (55, 56). it contains three highly conserved and distinct domains, namely, an ntd, an rna binding domain or a linker region (lkr), and a ctd (57). the ntd binds with the 3′ end of the viral genome, perhaps via electrostatic interactions, and is highly diverged both in length and sequence (58). the charged lkr is serine and arginine rich and is also known as the sr (serine and arginine) domain (59). the lkr is capable of direct interaction with in vitro rna interaction and is responsible for cell signaling (60, 61). it also modulates the antiviral response of the host by working as an antagonist for interferon (ifn) and rna interference (62). compared to that of sars cov, the n protein of sars cov 2 possess five amino acid mutations, where two are in the intrinsically dispersed region (idr; positions 25 and 26), one each in the ntd (position 103), lkr (position 217), and ctd (position 334) (16). besides the important structural proteins, the sars cov 2 genome contains 15 nsps, nsp1 to nsp10 and nsp12 to nsp16, and 8 accessory proteins (3a, 3b, p6, 7a, 7b, 8b, 9b, and orf14) (16). all these proteins play a specific role in viral replication (27). unlike the accessory proteins of sars cov, sars cov 2 does not contain 8a protein and has a longer 8b and shorter 3b protein (16). the nsp7, nsp13, envelope, matrix, and p6 and 8b accessory proteins have not been detected with any amino acid substitutions compared to the sequences of other coronaviruses (16). the virus structure of sars cov 2 is depicted in fig. 2. sars cov 2 virus structure. we assessed the nucleotide percent similarity using the megalign software program, where the similarity between the novel sars cov 2 isolates was in the range of 99.4% to 100%. among the other serbecovirus cov sequences, the novel sars cov 2 sequences revealed the highest similarity to bat sl cov, with nucleotide percent identity ranges between 88.12 and 89.65%. meanwhile, earlier reported sars covs showed 70.6 to 74.9% similarity to sars cov 2 at the nucleotide level. further, the nucleotide percent similarity was 55.4%, 45.5% to 47.9%, 46.2% to 46.6%, and 45.0% to 46.3% to the other four subgenera, namely, hibecovirus, nobecovirus, merbecovirus, and embecovirus, respectively. the percent similarity index of current outbreak isolates indicates a close relationship between sars cov 2 isolates and bat sl cov, indicating a common origin. however, particular pieces of evidence based on further complete genomic analysis of current isolates are necessary to draw any conclusions, although it was ascertained that the current novel sars cov 2 isolates belong to the subgenus sarbecovirus in the diverse range of betacoronaviruses. their possible ancestor was hypothesized to be from bat cov strains, wherein bats might have played a crucial role in harboring this class of viruses. in the unrooted phylogenetic tree of different betacoronaviruses based on the s protein, virus sequences from different subgenera grouped into separate clusters. sars cov 2 sequences from wuhan and other countries exhibited a close relationship and appeared in a single cluster (fig. 1). the covs from the subgenus sarbecovirus appeared jointly in splitstree and divided into three subclusters, namely, sars cov 2, bat sars like cov (bat sl cov), and sars cov (fig. 1). in the case of other subgenera, like merbecovirus, all of the sequences grouped in a single cluster, whereas in embecovirus, different species, comprised of canine respiratory covs, bovine covs, equine covs, and human cov strain (oc43), grouped in a common cluster. isolates in the subgenera nobecovorus and hibecovirus were found to be placed separately away from other reported sars covs but shared a bat origin. this novel virus, sars cov 2, comes under the subgenus sarbecovirus of the orthocoronavirinae subfamily and is entirely different from the viruses responsible for mers cov and sars cov (3). the newly emerged sars cov 2 is a group 2b coronavirus (2). the genome sequences of sars cov 2 obtained from patients share 79.5% sequence similarity to the sequence of sars cov (63). as of 13 may 2020, a total of 4,170,424 confirmed cases of covid 19 (with 287,399 deaths) have been reported in more than 210 affected countries worldwide (who situation report 114 [25]) (fig. 3). world map depicting the current scenario of covid 19. shown are countries, territories, or regions with reported confirmed cases of sars cov 2 as of 13 may 2020. different colors indicate different who designated geographical regions with the number of confirmed cases. the who region wise total number of confirmed cases is depicted in different color strips. the leading information on the confirmed cases and deaths from all six who designated regions are depicted in circled balloons. the numbers of covid 19 cases and fatalities on three major cruise ships are also depicted. (based on data from the who at https://www.who.int/docs/default source/coronaviruse/situation reports/20200513 covid 19 sitrep 114.pdf?sfvrsn=17ebbbe_4; updated numbers of cases, deaths, and patients recovered can be found at https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6.) initially, the epicenter of the sars cov 2 pandemic was china, which reported a significant number of deaths associated with covid 19, with 84,458 laboratory confirmed cases and 4,644 deaths as of 13 may 2020 (fig. 4). as of 13 may 2020, sars cov 2 confirmed cases have been reported in more than 210 countries apart from china (fig. 3 and 4) (who situation report 114) (25, 64). covid 19 has been reported on all continents except antarctica. for many weeks, italy was the focus of concerns regarding the large number of cases, with 221,216 cases and 30,911 deaths, but now, the united states is the country with the largest number of cases, 1,322,054, and 79,634 deaths. now, the united kingdom has even more cases (226,4671) and deaths (32,692) than italy. a john hopkins university web platform has provided daily updates on the basic epidemiology of the covid 19 outbreak (https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6) (238). bar graph and pie chart for cases and deaths. shown are laboratory confirmed cases and deaths in china and the rest of the world due to sars cov 2. (a) sars cov 2 confirmed cases in the top five affected countries from each who designated region, where maximum casualties were reported to who until 13 may 2020. (b) total numbers of deaths and cases in china only. (c) total number of cases worldwide by region. covid 19 has also been confirmed on a cruise ship, named diamond princess, quarantined in japanese waters (port of yokohama), as well as on other cruise ships around the world (239) (fig. 3). the significant events of the sars cov 2/covid 19 virus outbreak occurring since 8 december 2019 are presented as a timeline in fig. 5. timeline depicting the significant events that occurred during the sars cov 2/covid 19 virus outbreak. the timeline describes the significant events during the current sars cov 2 outbreak, from 8 december 2019 to 13 may 2020. at the beginning, china experienced the majority of the burden associated with covid 19 in the form of disease morbidity and mortality (65), but over time the covid 19 menace moved to europe, particularly italy and spain, and now the united states has the highest number of confirmed cases and deaths. the covid 19 outbreak has also been associated with severe economic impacts globally due to the sudden interruption of global trade and supply chains that forced multinational companies to make decisions that led to significant economic losses (66). the recent increase in the number of confirmed critically ill patients with covid 19 has already surpassed the intensive care supplies, limiting intensive care services to only a small portion of critically ill patients (67). this might also have contributed to the increased case fatality rate observed in the covid 19 outbreak. the novel coronavirus was identified within 1 month (28 days) of the outbreak. this is impressively fast compared to the time taken to identify sars cov reported in foshan, guangdong province, china (125 days) (68). immediately after the confirmation of viral etiology, the chinese virologists rapidly released the genomic sequence of sars cov 2, which played a crucial role in controlling the spread of this newly emerged novel coronavirus to other parts of the world (69). the possible origin of sars cov 2 and the first mode of disease transmission are not yet identified (70). analysis of the initial cluster of infections suggests that the infected individuals had a common exposure point, a seafood market in wuhan, hubei province, china (fig. 6). the restaurants of this market are well known for providing different types of wild animals for human consumption (71). the huanan south china seafood market also sells live animals, such as poultry, bats, snakes, and marmots (72). this might be the point where zoonotic (animal to human) transmission occurred (71). although sars cov 2 is alleged to have originated from an animal host (zoonotic origin) with further human to human transmission (fig. 6), the likelihood of foodborne transmission should be ruled out with further investigations, since it is a latent possibility (1). additionally, other potential and expected routes would be associated with transmission, as in other respiratory viruses, by direct contact, such as shaking contaminated hands, or by direct contact with contaminated surfaces (fig. 6). still, whether blood transfusion and organ transplantation (276), as well as transplacental and perinatal routes, are possible routes for sars cov 2 transmission needs to be determined (fig. 6). potential transmission routes for sars cov 2. from experience with several outbreaks associated with known emerging viruses, higher pathogenicity of a virus is often associated with lower transmissibility. compared to emerging viruses like ebola virus, avian h7n9, sars cov, and mers cov, sars cov 2 has relatively lower pathogenicity and moderate transmissibility (15). the risk of death among individuals infected with covid 19 was calculated using the infection fatality risk (ifr). the ifr was found to be in the range of 0.3% to 0.6%, which is comparable to that of a previous asian influenza pandemic (1957 to 1958) (73, 277). notably, the reanalysis of the covid 19 pandemic curve from the initial cluster of cases pointed to considerable human to human transmission. it is opined that the exposure history of sars cov 2 at the wuhan seafood market originated from human to human transmission rather than animal to human transmission (74); however, in light of the zoonotic spillover in covid 19, is too early to fully endorse this idea (1). following the initial infection, human to human transmission has been observed with a preliminary reproduction number (r0) estimate of 1.4 to 2.5 (70, 75), and recently it is estimated to be 2.24 to 3.58 (76). in another study, the average reproductive number of covid 19 was found to be 3.28, which is significantly higher than the initial who estimate of 1.4 to 2.5 (77). it is too early to obtain the exact r0 value, since there is a possibility of bias due to insufficient data. the higher r0 value is indicative of the more significant potential of sars cov 2 transmission in a susceptible population. this is not the first time where the culinary practices of china have been blamed for the origin of novel coronavirus infection in humans. previously, the animals present in the live animal market were identified to be the intermediate hosts of the sars outbreak in china (78). several wildlife species were found to harbor potentially evolving coronavirus strains that can overcome the species barrier (79). one of the main principles of chinese food culture is that live slaughtered animals are considered more nutritious (5). after 4 months of struggle that lasted from december 2019 to march 2020, the covid 19 situation now seems under control in china. the wet animal markets have reopened, and people have started buying bats, dogs, cats, birds, scorpions, badgers, rabbits, pangolins (scaly anteaters), minks, soup from palm civet, ostriches, hamsters, snapping turtles, ducks, fish, siamese crocodiles, and other animal meats without any fear of covid 19. the chinese government is encouraging people to feel they can return to normalcy. however, this could be a risk, as it has been mentioned in advisories that people should avoid contact with live dead animals as much as possible, as sars cov 2 has shown zoonotic spillover. additionally, we cannot rule out the possibility of new mutations in the same virus being closely related to contact with both animals and humans at the market (284). in january 2020, china imposed a temporary ban on the sale of live dead animals in wet markets. however, now hundreds of such wet markets have been reopened without optimizing standard food safety and sanitation practices (286). with china being the most populated country in the world and due to its domestic and international food exportation policies, the whole world is now facing the menace of covid 19, including china itself. wet markets of live dead animals do not maintain strict food hygienic practices. fresh blood splashes are present everywhere, on the floor and tabletops, and such food customs could encourage many pathogens to adapt, mutate, and jump the species barrier. as a result, the whole world is suffering from novel sars cov 2, with more than 4,170,424 cases and 287,399 deaths across the globe. there is an urgent need for a rational international campaign against the unhealthy food practices of china to encourage the sellers to increase hygienic food practices or close the crude live dead animal wet markets. there is a need to modify food policies at national and international levels to avoid further life threats and economic consequences from any emerging or reemerging pandemic due to close animal human interaction (285). even though individuals of all ages and sexes are susceptible to covid 19, older people with an underlying chronic disease are more likely to become severely infected (80). recently, individuals with asymptomatic infection were also found to act as a source of infection to susceptible individuals (81). both the asymptomatic and symptomatic patients secrete similar viral loads, which indicates that the transmission capacity of asymptomatic or minimally symptomatic patients is very high. thus, sars cov 2 transmission can happen early in the course of infection (82). atypical clinical manifestations have also been reported in covid 19 in which the only reporting symptom was fatigue. such patients may lack respiratory signs, such as fever, cough, and sputum (83). hence, the clinicians must be on the look out for the possible occurrence of atypical clinical manifestations to avoid the possibility of missed diagnosis. the early transmission ability of sars cov 2 was found to be similar to or slightly higher than that of sars cov, reflecting that it could be controlled despite moderate to high transmissibility (84). increasing reports of sars cov 2 in sewage and wastewater warrants the need for further investigation due to the possibility of fecal oral transmission. sars cov 2 present in environmental compartments such as soil and water will finally end up in the wastewater and sewage sludge of treatment plants (328). therefore, we have to reevaluate the current wastewater and sewage sludge treatment procedures and introduce advanced techniques that are specific and effective against sars cov 2. since there is active shedding of sars cov 2 in the stool, the prevalence of infections in a large population can be studied using wastewater based epidemiology. recently, reverse transcription quantitative pcr (rt qpcr) was used to enumerate the copies of sars cov 2 rna concentrated from wastewater collected from a wastewater treatment plant (327). the calculated viral rna copy numbers determine the number of infected individuals. the increasing reports of virus shedding via the fecal route warrants the introduction of negative fecal viral nucleic acid test results as one of the additional discharge criteria in laboratory confirmed cases of covid 19 (326). the covid 19 pandemic does not have any novel factors, other than the genetically unique pathogen and a further possible reservoir. the cause and the likely future outcome are just repetitions of our previous interactions with fatal coronaviruses. the only difference is the time of occurrence and the genetic distinctness of the pathogen involved. mutations on the rbd of covs facilitated their capability of infecting newer hosts, thereby expanding their reach to all corners of the world (85). this is a potential threat to the health of both animals and humans. advanced studies using bayesian phylogeographic reconstruction identified the most probable origin of sars cov 2 as the bat sars like coronavirus, circulating in the rhinolophus bat family (86). phylogenetic analysis of 10 whole genome sequences of sars cov 2 showed that they are related to two covs of bat origin, namely, bat sl covzc45 and bat sl covzxc21, which were reported during 2018 in china (17). it was reported that sars cov 2 had been confirmed to use ace2 as an entry receptor while exhibiting an rbd similar to that of sars cov (17, 87, 254, 255). several countries have provided recommendations to their people traveling to china (88, 89). compared to the previous coronavirus outbreaks caused by sars cov and mers cov, the efficiency of sars cov 2 human to human transmission was thought to be less. this assumption was based on the finding that health workers were affected less than they were in previous outbreaks of fatal coronaviruses (2). superspreading events are considered the main culprit for the extensive transmission of sars and mers (90, 91). almost half of the mers cov cases reported in saudi arabia are of secondary origin that occurred through contact with infected asymptomatic or symptomatic individuals through human to human transmission (92). the occurrence of superspreading events in the covid 19 outbreak cannot be ruled out until its possibility is evaluated. like sars and mers, covid 19 can also infect the lower respiratory tract, with milder symptoms (27). the basic reproduction number of covid 19 has been found to be in the range of 2.8 to 3.3 based on real time reports and 3.2 to 3.9 based on predicted infected cases (84). coronavirus infection in humans is commonly associated with mild to severe respiratory diseases, with high fever, severe inflammation, cough, and internal organ dysfunction that can even lead to death (92). most of the identified coronaviruses cause the common cold in humans. however, this changed when sars cov was identified, paving the way for severe forms of the disease in humans (22). our previous experience with the outbreaks of other coronaviruses, like sars and mers, suggests that the mode of transmission in covid 19 as mainly human to human transmission via direct contact, droplets, and fomites (25). recent studies have demonstrated that the virus could remain viable for hours in aerosols and up to days on surfaces; thus, aerosol and fomite contamination could play potent roles in the transmission of sars cov 2 (257). the immune response against coronavirus is vital to control and get rid of the infection. however, maladjusted immune responses may contribute to the immunopathology of the disease, resulting in impairment of pulmonary gas exchange. understanding the interaction between covs and host innate immune systems could enlighten our understanding of the lung inflammation associated with this infection (24). sars is a viral respiratory disease caused by a formerly unrecognized animal cov that originated from the wet markets in southern china after adapting to the human host, thereby enabling transmission between humans (90). the sars outbreak reported in 2002 to 2003 had 8,098 confirmed cases with 774 total deaths (9.6%) (93). the outbreak severely affected the asia pacific region, especially mainland china (94). even though the case fatality rate (cfr) of sars cov 2 (covid 19) is lower than that of sars cov, there exists a severe concern linked to this outbreak due to its epidemiological similarity to influenza viruses (95, 279). this can fail the public health system, resulting in a pandemic (96). mers is another respiratory disease that was first reported in saudi arabia during the year 2012. the disease was found to have a cfr of around 35% (97). the analysis of available data sets suggests that the incubation period of sars cov 2, sars cov, and mers cov is in almost the same range. the longest predicted incubation time of sars cov 2 is 14 days. hence, suspected individuals are isolated for 14 days to avoid the risk of further spread (98). even though a high similarity has been reported between the genome sequence of the new coronavirus (sars cov 2) and sars like covs, the comparative analysis recognized a furin like cleavage site in the sars cov 2 s protein that is missing from other sars like covs (99). the furin like cleavage site is expected to play a role in the life cycle of the virus and disease pathogenicity and might even act as a therapeutic target for furin inhibitors. the highly contagious nature of sars cov 2 compared to that of its predecessors might be the result of a stabilizing mutation that occurred in the endosome associated protein like domain of nsp2 protein. similarly, the destabilizing mutation near the phosphatase domain of nsp3 proteins in sars cov 2 could indicate a potential mechanism that differentiates it from other covs (100). even though the cfr reported for covid 19 is meager compared to those of the previous sars and mers outbreaks, it has caused more deaths than sars and mers combined (101). possibly related to the viral pathogenesis is the recent finding of an 832 nucleotide (nt) deletion in orf8, which appears to reduce the replicative fitness of the virus and leads to attenuated phenotypes of sars cov 2 (256). coronavirus is the most prominent example of a virus that has crossed the species barrier twice from wild animals to humans during sars and mers outbreaks (79, 102). the possibility of crossing the species barrier for the third time has also been suspected in the case of sars cov 2 (covid 19). bats are recognized as a possible natural reservoir host of both sars cov and mers cov infection. in contrast, the possible intermediary host is the palm civet for sars cov and the dromedary camel for mers cov infection (102). bats are considered the ancestral hosts for both sars and mers (103). bats are also considered the reservoir host of human coronaviruses like hcov 229e and hcov nl63 (104). in the case of covid 19, there are two possibilities for primary transmission: it can be transmitted either through intermediate hosts, similar to that of sars and mers, or directly from bats (103). the emergence paradigm put forward in the sars outbreak suggests that sars cov originated from bats (reservoir host) and later jumped to civets (intermediate host) and incorporated changes within the receptor binding domain (rbd) to improve binding to civet ace2. this civet adapted virus, during their subsequent exposure to humans at live markets, promoted further adaptations that resulted in the epidemic strain (104). transmission can also occur directly from the reservoir host to humans without rbd adaptations. the bat coronavirus that is currently in circulation maintains specific “poised” spike proteins that facilitate human infection without the requirement of any mutations or adaptations (105). altogether, different species of bats carry a massive number of coronaviruses around the world (106). the high plasticity in receptor usage, along with the feasibility of adaptive mutation and recombination, may result in frequent interspecies transmission of coronavirus from bats to animals and humans (106). the pathogenesis of most bat coronaviruses is unknown, as most of these viruses are not isolated and studied (4). hedgehog coronavirus hku31, a betacoronavirus, has been identified from amur hedgehogs in china. studies show that hedgehogs are the reservoir of betacoronavirus, and there is evidence of recombination (107). the current scientific evidence available on mers infection suggests that the significant reservoir host, as well as the animal source of mers infection in humans, is the dromedary camels (97). the infected dromedary camels may not show any visible signs of infection, making it challenging to identify animals actively excreting mers cov that has the potential to infect humans. however, they may shed mers cov through milk, urine, feces, and nasal and eye discharge and can also be found in the raw organs (108). in a study conducted to evaluate the susceptibility of animal species to mers cov infection, llamas and pigs were found to be susceptible, indicating the possibility of mers cov circulation in animal species other than dromedary camels (109). following the outbreak of sars in china, sars cov like viruses were isolated from himalayan palm civets (paguma larvata) and raccoon dogs (nyctereutes procyonoides) found in a live animal market in guangdong, china. the animal isolates obtained from the live animal market retained a 29 nucleotide sequence that was not present in most of the human isolates (78). these findings were critical in identifying the possibility of interspecies transmission in sars cov. the higher diversity and prevalence of bat coronaviruses in this region compared to those in previous reports indicate a host/pathogen coevolution. sars like coronaviruses also have been found circulating in the chinese horseshoe bat (rhinolophus sinicus) populations. the in vitro and in vivo studies carried out on the isolated virus confirmed that there is a potential risk for the reemergence of sars cov infection from the viruses that are currently circulating in the bat population (105). the disease caused by sars cov 2 is also named severe specific contagious pneumonia (sscp), wuhan pneumonia, and, recently, covid 19 (110). compared to sars cov, sars cov 2 has less severe pathogenesis but has superior transmission capability, as evidenced by the rapidly increasing number of covid 19 cases (111). the incubation period of sars cov 2 in familial clusters was found to be 3 to 6 days (112). the mean incubation period of covid 19 was found to be 6.4 days, ranging from 2.1 to 11.1 days (113). among an early affected group of 425 patients, 59 years was the median age, of which more males were affected (114). similar to sars and mers, the severity of this ncov is high in age groups above 50 years (2, 115). symptoms of covid 19 include fever, cough, myalgia or fatigue, and, less commonly, headache, hemoptysis, and diarrhea (116, 282). compared to the sars cov 2 infected patients in wuhan during the initial stages of the outbreak, only mild symptoms were noticed in those patients that are infected by human to human transmission (14). the initial trends suggested that the mortality associated with covid 19 was less than that of previous outbreaks of sars (101). the updates obtained from countries like china, japan, thailand, and south korea indicated that the covid 19 patients had relatively mild manifestations compared to those with sars and mers (4). regardless of the coronavirus type, immune cells, like mast cells, that are present in the submucosa of the respiratory tract and nasal cavity are considered the primary barrier against this virus (92). advanced in depth analysis of the genome has identified 380 amino acid substitutions between the amino acid sequences of sars cov 2 and the sars/sars like coronaviruses. these differences in the amino acid sequences might have contributed to the difference in the pathogenic divergence of sars cov 2 (16). further research is required to evaluate the possible differences in tropism, pathogenesis, and transmission of this novel agent associated with this change in the amino acid sequence. with the current outbreak of covid 19, there is an expectancy of a significant increase in the number of published studies about this emerging coronavirus, as occurred with sars and mers (117). sars cov 2 invades the lung parenchyma, resulting in severe interstitial inflammation of the lungs. this is evident on computed tomography (ct) images as ground glass opacity in the lungs. this lesion initially involves a single lobe but later expands to multiple lung lobes (118). the histological assessment of lung biopsy samples obtained from covid 19 infected patients revealed diffuse alveolar damage, cellular fibromyxoid exudates, hyaline membrane formation, and desquamation of pneumocytes, indicative of acute respiratory distress syndrome (119). it was also found that the sars cov 2 infected patients often have lymphocytopenia with or without leukocyte abnormalities. the degree of lymphocytopenia gives an idea about disease prognosis, as it is found to be positively correlated with disease severity (118). pregnant women are considered to have a higher risk of getting infected by covid 19. the coronaviruses can cause adverse outcomes for the fetus, such as intrauterine growth restriction, spontaneous abortion, preterm delivery, and perinatal death. nevertheless, the possibility of intrauterine maternal fetal transmission (vertical transmission) of covs is low and was not seen during either the sars  or mers cov outbreak (120). however, there has been concern regarding the impact of sars cov 2/covid 19 on pregnancy. researchers have mentioned the probability of in utero transmission of novel sars cov 2 from covid 19 infected mothers to their neonates in china based upon the rise in igm and igg antibody levels and cytokine values in the blood obtained from newborn infants immediately postbirth; however, rt pcr failed to confirm the presence of sars cov 2 genetic material in the infants (283). recent studies show that at least in some cases, preterm delivery and its consequences are associated with the virus. nonetheless, some cases have raised doubts for the likelihood of vertical transmission (240 243). covid 19 infection was associated with pneumonia, and some developed acute respiratory distress syndrome (ards). the blood biochemistry indexes, such as albumin, lactate dehydrogenase, c reactive protein, lymphocytes (percent), and neutrophils (percent) give an idea about the disease severity in covid 19 infection (121). during covid 19, patients may present leukocytosis, leukopenia with lymphopenia (244), hypoalbuminemia, and an increase of lactate dehydrogenase, aspartate transaminase, alanine aminotransferase, bilirubin, and, especially, d dimer (244). middle aged and elderly patients with primary chronic diseases, especially high blood pressure and diabetes, were found to be more susceptible to respiratory failure and, therefore, had poorer prognoses. providing respiratory support at early stages improved the disease prognosis and facilitated recovery (18). the ards in covid 19 is due to the occurrence of cytokine storms that results in exaggerated immune response, immune regulatory network imbalance, and, finally, multiple organ failure (122). in addition to the exaggerated inflammatory response seen in patients with covid 19 pneumonia, the bile duct epithelial cell derived hepatocytes upregulate ace2 expression in liver tissue by compensatory proliferation that might result in hepatic tissue injury (123). coronavirus can cause disease in several species of domestic and wild animals, as well as humans (23). the different animal species that are infected with cov include horses, camels, cattle, swine, dogs, cats, rodents, birds, ferrets, minks, bats, rabbits, snakes, and various other wild animals (20, 30, 79, 93, 124, 125, 287). coronavirus infection is linked to different kinds of clinical manifestations, varying from enteritis in cows and pigs, upper respiratory disease in chickens, and fatal respiratory infections in humans (30). among the cov genera, alphacoronavirus and betacoronavirus infect mammals, while gammacoronavirus and deltacoronavirus mainly infect birds, fishes, and, sometimes, mammals (27, 29, 106). several novel coronaviruses that come under the genus deltacoronavirus have been discovered in the past from birds, like wigeon coronavirus hku20, bulbul coronavirus hku11, munia coronavirus hku13, white eye coronavirus hku16, night heron coronavirus hku19, and common moorhen coronavirus hku21, as well as from pigs (porcine coronavirus hku15) (6, 29). transmissible gastroenteritis virus (tgev), porcine epidemic diarrhea virus (pedv), and porcine hemagglutinating encephalomyelitis virus (phev) are some of the coronaviruses of swine. among them, tgev and pedv are responsible for causing severe gastroenteritis in young piglets with noteworthy morbidity and mortality. infection with phev also causes enteric infection but can cause encephalitis due to its ability to infect the nervous system (30). bovine coronaviruses (bocovs) are known to infect several domestic and wild ruminants (126). bocov inflicts neonatal calf diarrhea in adult cattle, leading to bloody diarrhea (winter dysentery) and respiratory disease complex (shipping fever) in cattle of all age groups (126). bocov like viruses have been noted in humans, suggesting its zoonotic potential as well (127). feline enteric and feline infectious peritonitis (fip) viruses are the two major feline covs (128), where feline covs can affect the gastrointestinal tract, abdominal cavity (peritonitis), respiratory tract, and central nervous system (128). canines are also affected by covs that fall under different genera, namely, canine enteric coronavirus in alphacoronavirus and canine respiratory coronavirus in betacoronavirus, affecting the enteric and respiratory tract, respectively (129, 130). ibv, under gammacoronavirus, causes diseases of respiratory, urinary, and reproductive systems, with substantial economic losses in chickens (131, 132). in small laboratory animals, mouse hepatitis virus, rat sialodacryoadenitis coronavirus, and guinea pig and rabbit coronaviruses are the major covs associated with disease manifestations like enteritis, hepatitis, and respiratory infections (10, 133). swine acute diarrhea syndrome coronavirus (sads cov) was first identified in suckling piglets having severe enteritis and belongs to the genus alphacoronavirus (106). the outbreak was associated with considerable scale mortality of piglets (24,693 deaths) across four farms in china (134). the virus isolated from the piglets was almost identical to and had 95% genomic similarity with horseshoe bat (rhinolophus species) coronavirus hku2, suggesting a bat origin of the pig virus (106, 134, 135). it is also imperative to note that the sads cov outbreak started in guangdong province, near the location of the sars pandemic origin (134). before this outbreak, pigs were not known to be infected with bat origin coronaviruses. this indicates that the bat origin coronavirus jumped to pig by breaking the species barrier. the next step of this jump might not end well, since pigs are considered the mixing vessel for influenza a viruses due to their ability to be infected by both human and avian influenza a viruses (136). similarly, they may act as the mixing vessel for coronaviruses, since they are in frequent contact with both humans and multiple wildlife species. additionally, pigs are also found to be susceptible to infection with human sars cov and mers cov, making this scenario a nightmare (109, 137). it is only a matter of time before another zoonotic coronavirus results in an epidemic by jumping the so called species barrier (287). the host spectrum of coronavirus increased when a novel coronavirus, namely, sw1, was recognized in the liver tissue of a captive beluga whale (delphinapterus leucas) (138). in recent decades, several novel coronaviruses were identified from different animal species. bats can harbor these viruses without manifesting any clinical disease but are persistently infected (30). they are the only mammals with the capacity for self powered flight, which enables them to migrate long distances, unlike land mammals. bats are distributed worldwide and also account for about a fifth of all mammalian species (6). this makes them the ideal reservoir host for many viral agents and also the source of novel coronaviruses that have yet to be identified. it has become a necessity to study the diversity of coronavirus in the bat population to prevent future outbreaks that could jeopardize livestock and public health. the repeated outbreaks caused by bat origin coronaviruses calls for the development of efficient molecular surveillance strategies for studying betacoronavirus among animals (12), especially in the rhinolophus bat family (86). chinese bats have high commercial value, since they are used in traditional chinese medicine (tcm). therefore, the handling of bats for trading purposes poses a considerable risk of transmitting zoonotic cov epidemics (139). due to the possible role played by farm and wild animals in sars cov 2 infection, the who, in their novel coronavirus (covid 19) situation report, recommended the avoidance of unprotected contact with both farm and wild animals (25). the live animal markets, like the one in guangdong, china, provides a setting for animal coronaviruses to amplify and to be transmitted to new hosts, like humans (78). such markets can be considered a critical place for the origin of novel zoonotic diseases and have enormous public health significance in the event of an outbreak. bats are the reservoirs for several viruses; hence, the role of bats in the present outbreak cannot be ruled out (140). in a qualitative study conducted for evaluating the zoonotic risk factors among rural communities of southern china, the frequent human animal interactions along with the low levels of environmental biosecurity were identified as significant risks for the emergence of zoonotic disease in local communities (141, 142). the comprehensive sequence analysis of the sars cov 2 rna genome identified that the cov from wuhan is a recombinant virus of the bat coronavirus and another coronavirus of unknown origin. the recombination was found to have happened within the viral spike glycoprotein, which recognizes the cell surface receptor. further analysis of the genome based on codon usage identified the snake as the most probable animal reservoir of sars cov 2 (143). contrary to these findings, another genome analysis proposed that the genome of sars cov 2 is 96% identical to bat coronavirus, reflecting its origin from bats (63). the involvement of bat derived materials in causing the current outbreak cannot be ruled out. high risk is involved in the production of bat derived materials for tcm practices involving the handling of wild bats. the use of bats for tcm practices will remain a severe risk for the occurrence of zoonotic coronavirus epidemics in the future (139). furthermore, the pangolins are an endangered species of animals that harbor a wide variety of viruses, including coronaviruses (144). the coronavirus isolated from malayan pangolins (manis javanica) showed a very high amino acid identity with covid 19 at e (100%), m (98.2%), n (96.7%), and s genes (90.4%). the rbd of s protein in cov isolated from pangolin was almost identical (one amino acid difference) to that of sars cov 2. a comparison of the genomes suggests recombination between pangolin cov like viruses with the bat cov ratg13 like virus. all this suggests the potential of pangolins to act as the intermediate host of sars cov 2 (145). human wildlife interactions, which are increasing in the context of climate change (142), are further considered high risk and responsible for the emergence of sars cov. covid 19 is also suspected of having a similar mode of origin. hence, to prevent the occurrence of another zoonotic spillover (1), exhaustive coordinated efforts are needed to identify the high risk pathogens harbored by wild animal populations, conducting surveillance among the people who are susceptible to zoonotic spillover events (12), and to improve the biosecurity measures associated with the wildlife trade (146). the serological surveillance studies conducted in people living in proximity to bat caves had earlier identified the serological confirmation of sars related covs in humans. people living at the wildlife human interface, mainly in rural china, are regularly exposed to sars related covs (147). these findings will not have any significance until a significant outbreak occurs due to a virus like sars cov 2. there is a steady increase in the reports of covid 19 in companion and wild animals around the world. further studies are required to evaluate the potential of animals (especially companion animals) to serve as an efficient reservoir host that can further alter the dynamics of human to human transmission (330). to date, two pet dogs (hong kong) and four pet cats (one each from belgium and hong kong, two from the united states) have tested positive for sars cov 2 (335). the world organization for animal health (oie) has confirmed the diagnosis of covid 19 in both dogs and cats due to human to animal transmission (331). the similarity observed in the gene sequence of sars cov 2 from an infected pet owner and his dog further confirms the occurrence of human to animal transmission (333). even though asymptomatic, feline species should be considered a potential transmission route from animals to humans (326). however, currently, there are no reports of sars cov 2 transmission from felines to human beings. based on the current evidence, we can conclude that cats are susceptible to sars cov 2 and can get infected by human beings. however, evidence of cat to human transmission is lacking and requires further studies (332). rather than waiting for firmer evidence on animal to human transmission, necessary preventive measures are advised, as well as following social distancing practices among companion animals of different households (331). one of the leading veterinary diagnostic companies, idexx, has conducted large scale testing for covid 19 in specimens collected from dogs and cats. however, none of the tests turned out to be positive (334). in a study conducted to investigate the potential of different animal species to act as the intermediate host of sars cov 2, it was found that both ferrets and cats can be infected via experimental inoculation of the virus. in addition, infected cats efficiently transmitted the disease to naive cats (329). sars cov 2 infection and subsequent transmission in ferrets were found to recapitulate the clinical aspects of covid 19 in humans. the infected ferrets also shed virus via multiple routes, such as saliva, nasal washes, feces, and urine, postinfection, making them an ideal animal model for studying disease transmission (337). experimental inoculation was also done in other animal species and found that the dogs have low susceptibility, while the chickens, ducks, and pigs are not at all susceptible to sars cov 2 (329). similarly, the national veterinary services laboratories of the usda have reported covid 19 in tigers and lions that exhibited respiratory signs like dry cough and wheezing. the zoo animals are suspected to have been infected by an asymptomatic zookeeper (335). the total number of covid 19 positive cases in human beings is increasing at a high rate, thereby creating ideal conditions for viral spillover to other species, such as pigs. the evidence obtained from sars cov suggests that pigs can get infected with sars cov 2 (336). however, experimental inoculation with sars cov 2 failed to infect pigs (329). further studies are required to identify the possible animal reservoirs of sars cov 2 and the seasonal variation in the circulation of these viruses in the animal population. research collaboration between human and animal health sectors is becoming a necessity to evaluate and identify the possible risk factors of transmission between animals and humans. such cooperation will help to devise efficient strategies for the management of emerging zoonotic diseases (12). rna tests can confirm the diagnosis of sars cov 2 (covid 19) cases with real time rt pcr or next generation sequencing (148, 149, 245, 246). at present, nucleic acid detection techniques, like rt pcr, are considered an effective method for confirming the diagnosis in clinical cases of covid 19 (148). several companies across the world are currently focusing on developing and marketing sars cov 2 specific nucleic acid detection kits. multiple laboratories are also developing their own in house rt pcr. one of them is the sars cov 2 nucleic acid detection kit produced by shuoshi biotechnology (double fluorescence pcr method) (150). up to 30 march 2020, the u.s. food and drug administration (fda) had granted 22 in vitro diagnostics emergency use authorizations (euas), including for the rt pcr diagnostic panel for the universal detection of sars like betacoronaviruses and specific detection of sars cov 2, developed by the u.s. cdc (table 1) (258, 259). fda approved in vitro emergency use authorization diagnostics available for sars cov 2 as of 30 march 2020a data are from references 258 and 259. recently, 95 full length genomic sequences of saras cov 2 strains available in the national center for biotechnology information and gisaid databases were subjected to multiple sequence alignment and phylogenetic analyses for studying variations in the viral genome (260). all the viral strains revealed high homology of 99.99% (99.91% to 100%) at the nucleotide level and 99.99% (99.79% to 100%) at the amino acid level. overall variation was found to be low in orf regions, with 13 variation sites recognized in 1a, 1b, s, 3a, m, 8, and n regions. mutation rates of 30.53% (29/95) and 29.47% (28/95) were observed at nt 28144 (orf8) and nt 8782 (orf1a) positions, respectively. owing to such selective mutations, a few specific regions of sars cov 2 should not be considered for designing primers and probes. the sars cov 2 reference sequence could pave the way to study molecular biology and pathobiology, along with developing diagnostics and appropriate prevention and control strategies for countering sars cov 2 (260). nucleic acids of sars cov 2 can be detected from samples (64) such as bronchoalveolar lavage fluid, sputum, nasal swabs, fiber bronchoscope brush biopsy specimen, pharyngeal swabs, feces, blood, and urine, with different levels of diagnostic performance (table 2) (80, 245, 246). the viral loads of sars cov 2 were measured using n gene specific quantitative rt pcr in throat swab and sputum samples collected from covid 19 infected individuals. the results indicated that the viral load peaked at around 5 to 6 days following the onset of symptoms, and it ranged from 104 to 107 copies/ml during this time (151). in another study, the viral load was found to be higher in the nasal swabs than the throat swabs obtained from covid 19 symptomatic patients (82). although initially it was thought that viral load would be associated with poor outcomes, some case reports have shown asymptomatic individuals with high viral loads (247). recently, the viral load in nasal and throat swabs of 17 symptomatic patients was determined, and higher viral loads were recorded soon after the onset of symptoms, particularly in the nose compared to the throat. the pattern of viral nucleic acid shedding of sars cov 2 infected patients was similar to that of influenza patients but seemed to be different from that of sars cov patients. the viral load detected in asymptomatic patients resembled that of symptomatic patients as studied in china, which reflects the transmission perspective of asymptomatic or symptomatic patients having minimum signs and symptoms (82). another study, conducted in south korea, related to sars cov 2 viral load, opined that sars cov 2 kinetics were significantly different from those of earlier reported cov infections, including sars cov (253). sars cov 2 transmission can occur early in the viral infection phase; thus, diagnosing cases and isolation attempts for this virus warrant different strategies than those needed to counter sars cov. studies are required to establish any correlation between sars cov 2 viral load and cultivable virus. recognizing patients with fewer or no symptoms, along with having modest detectable viral rna in the oropharynx for 5 days, indicates the requirement of data for assessing sars cov 2 transmission dynamics and updating the screening procedures in the clinics (82). clinical specimens for detection of sars cov 2 recommendations are based on references 245 and 246. +++, strong; ++, moderate; +, weak. the results of the studies related to sars cov 2 viral loads reflect active replication of this virus in the upper respiratory tract and prolonged viral shedding after symptoms disappear, including via stool. thus, the current case definition needs to be updated along with a reassessment of the strategies to be adopted for restraining the sars cov 2 outbreak spread (248). in some cases, the viral load studies of sars cov 2 have also been useful to recommend precautionary measures when handling specific samples, e.g., feces. in a recent survey from 17 confirmed cases of sars cov 2 infection with available data (representing days 0 to 13 after onset), stool samples from nine cases (53%; days 0 to 11 after onset) were positive on rt pcr analysis. although the viral loads were lower than those of respiratory samples (range, 550 copies per ml to 1.21 × 105 copies per ml), this has essential biosafety implications (151). the samples from 18 sars cov 2 positive patients in singapore who had traveled from wuhan to singapore showed the presence of viral rna in stool and whole blood but not in urine by real time rt pcr (288). further, novel sars cov 2 infections have been detected in a variety of clinical specimens, like bronchoalveolar lavage fluid, sputum, nasal swabs, fibrobronchoscope brush biopsy specimens, pharyngeal swabs, feces, and blood (246). the presence of sars cov 2 in fecal samples has posed grave public health concerns. in addition to the direct transmission mainly occurring via droplets of sneezing and coughing, other routes, such as fecal excretion and environmental and fomite contamination, are contributing to sars cov 2 transmission and spread (249 252). fecal excretion has also been documented for sars cov and mers cov, along with the potential to stay viable in situations aiding fecal oral transmission. thus, sars cov 2 has every possibility to be transmitted through this mode. fecal oral transmission of sars cov 2, particularly in regions having low standards of hygiene and poor sanitation, may have grave consequences with regard to the high spread of this virus. ethanol and disinfectants containing chlorine or bleach are effective against coronaviruses (249 252). appropriate precautions need to be followed strictly while handling the stools of patients infected with sars cov 2. biowaste materials and sewage from hospitals must be adequately disinfected, treated, and disposed of properly. the significance of frequent and good hand hygiene and sanitation practices needs to be given due emphasis (249 252). future explorative research needs to be conducted with regard to the fecal oral transmission of sars cov 2, along with focusing on environmental investigations to find out if this virus could stay viable in situations and atmospheres facilitating such potent routes of transmission. the correlation of fecal concentrations of viral rna with disease severity needs to be determined, along with assessing the gastrointestinal symptoms and the possibility of fecal sars cov 2 rna detection during the covid 19 incubation period or convalescence phases of the disease (249 252). the lower respiratory tract sampling techniques, like bronchoalveolar lavage fluid aspirate, are considered the ideal clinical materials, rather than the throat swab, due to their higher positive rate on the nucleic acid test (148). the diagnosis of covid 19 can be made by using upper respiratory tract specimens collected using nasopharyngeal and oropharyngeal swabs. however, these techniques are associated with unnecessary risks to health care workers due to close contact with patients (152). similarly, a single patient with a high viral load was reported to contaminate an entire endoscopy room by shedding the virus, which may remain viable for at least 3 days and is considered a great risk for uninfected patients and health care workers (289). recently, it was found that the anal swabs gave more positive results than oral swabs in the later stages of infection (153). hence, clinicians have to be cautious while discharging any covid 19 infected patient based on negative oral swab test results due to the possibility of fecal oral transmission. even though the viral loads in stool samples were found to be less than those of respiratory samples, strict precautionary measures have to be followed while handling stool samples of covid 19 suspected or infected patients (151). children infected with sars cov 2 experience only a mild form of illness and recover immediately after treatment. it was recently found that stool samples of sars cov 2 infected children that gave negative throat swab results were positive within ten days of negative results. this could result in the fecal oral transmission of sars cov 2 infections, especially in children (290). hence, to prevent the fecal oral transmission of sars cov 2, infected covid 19 patients should only be considered negative when they test negative for sars cov 2 in the stool sample. a suspected case of covid 19 infection is said to be confirmed if the respiratory tract aspirate or blood samples test positive for sars cov 2 nucleic acid using rt pcr or by the identification of sars cov 2 genetic sequence in respiratory tract aspirate or blood samples (80). the patient will be confirmed as cured when two subsequent oral swab results are negative (153). recently, the live virus was detected in the self collected saliva of patients infected with covid 19. these findings were confirmative of using saliva as a noninvasive specimen for the diagnosis of covid 19 infection in suspected individuals (152). it has also been observed that the initial screening of covid 19 patients infected with rt pcr may give negative results even if they have chest ct findings that are suggestive of infection. hence, for the accurate diagnosis of covid 19, a combination of repeated swab tests using rt pcr and ct scanning is required to prevent the possibility of false negative results during disease screening (154). rt pcr is the most widely used test for diagnosing covid 19. however, it has some significant limitations from the clinical perspective, since it will not give any clarity regarding disease progression. droplet digital pcr (ddpcr) can be used for the quantification of viral load in the samples obtained from lower respiratory tracts. hence, based on the viral load, we can quickly evaluate the progression of infection (291). in addition to all of the above findings, sequencing and phylogenetics are critical in the correct identification and confirmation of the causative viral agent and useful to establish relationships with previous isolates and sequences, as well as to know, especially during an epidemic, the nucleotide and amino acid mutations and the molecular divergence. the rapid development and implementation of diagnostic tests against emerging novel diseases like covid 19 pose significant challenges due to the lack of resources and logistical limitations associated with an outbreak (155). sars cov 2 infection can also be confirmed by isolation and culturing. the human airway epithelial cell culture was found to be useful in isolating sars cov 2 (3). the efficient control of an outbreak depends on the rapid diagnosis of the disease. recently, in response to the covid 19 outbreak, 1 step quantitative real time reverse transcription pcr assays were developed that detect the orf1b and n regions of the sars cov 2 genome (156). that assay was found to achieve the rapid detection of sars cov 2. nucleic acid based assays offer high accuracy in the diagnosis of sars cov 2, but the current rate of spread limits its use due to the lack of diagnostic assay kits. this will further result in the extensive transmission of covid 19, since only a portion of suspected cases can be diagnosed. in such situations, conventional serological assays, like enzyme linked immunosorbent assay (elisa), that are specific to covid 19 igm and igg antibodies can be used as a high throughput alternative (149). at present, there is no diagnostic kit available for detecting the sars cov 2 antibody (150). the specific antibody profiles of covid 19 patients were analyzed, and it was found that the igm level lasted more than 1 month, indicating a prolonged stage of virus replication in sars cov 2 infected patients. the igg levels were found to increase only in the later stages of the disease. these findings indicate that the specific antibody profiles of sars cov 2 and sars cov were similar (325). these findings can be utilized for the development of specific diagnostic tests against covid 19 and can be used for rapid screening. even though diagnostic test kits are already available that can detect the genetic sequences of sars cov 2 (95), their availability is a concern, as the number of covid 19 cases is skyrocketing (155, 157). a major problem associated with this diagnostic kit is that it works only when the test subject has an active infection, limiting its use to the earlier stages of infection. several laboratories around the world are currently developing antibody based diagnostic tests against sars cov 2 (157). chest ct is an ideal diagnostic tool for identifying viral pneumonia. the sensitivity of chest ct is far superior to that of x ray screening. the chest ct findings associated with covid 19 infected patients include characteristic patchy infiltration that later progresses to ground glass opacities (158). early manifestations of covid 19 pneumonia might not be evident in x ray chest radiography. in such situations, a chest ct examination can be performed, as it is considered highly specific for covid 19 pneumonia (118). those patients having covid 19 pneumonia will exhibit the typical ground glass opacity in their chest ct images (154). the patients infected with covid 19 had elevated plasma angiotensin 2 levels. the level of angiotensin 2 was found to be linearly associated with viral load and lung injury, indicating its potential as a diagnostic biomarker (121). the chest ct imaging abnormalities associated with covid 19 pneumonia have also been observed even in asymptomatic patients. these abnormalities progress from the initial focal unilateral to diffuse bilateral ground glass opacities and will further progress to or coexist with lung consolidation changes within 1 to 3 weeks (159). the role played by radiologists in the current scenario is very important. radiologists can help in the early diagnosis of lung abnormalities associated with covid 19 pneumonia. they can also help in the evaluation of disease severity, identifying its progression to acute respiratory distress syndrome and the presence of secondary bacterial infections (160). even though chest ct is considered an essential diagnostic tool for covid 19, the extensive use of ct for screening purposes in the suspected individuals might be associated with a disproportionate risk benefit ratio due to increased radiation exposure as well as increased risk of cross infection. hence, the use of ct for early diagnosis of sars cov 2 infection in high risk groups should be done with great caution (292). more recently, other advanced diagnostics have been designed and developed for the detection of sars cov 2 (345, 347, 350 352). a reverse transcriptional loop mediated isothermal amplification (rt lamp), namely, ilaco, has been developed for rapid and colorimetric detection of this virus (354). rt lamp serves as a simple, rapid, and sensitive diagnostic method that does not require sophisticated equipment or skilled personnel (349). an interactive web based dashboard for tracking sars cov 2 in a real time mode has been designed (238). a smartphone integrated home based point of care testing (poct) tool, a paper based poct combined with lamp, is a useful point of care diagnostic (353). an abbott id now covid 19 molecular poct based test, using isothermal nucleic acid amplification technology, has been designed as a point of care test for very rapid detection of sars cov 2 in just 5 min (344). a crispr based sherlock (specific high sensitivity enzymatic reporter unlocking) diagnostic for rapid detection of sars cov 2 without the requirement of specialized instrumentation has been reported to be very useful in the clinical diagnosis of covid 19 (360). a crispr cas12 based lateral flow assay also has been developed for rapid detection of sars cov 2 (346). artificial intelligence, by means of a three dimensional deep learning model, has been developed for sensitive and specific diagnosis of covid 19 via ct images (332). tracking and mapping of the rising incidence rates, disease outbreaks, community spread, clustered transmission events, hot spots, and superspreader potential of sars cov 2/covid warrant full exploitation of real time disease mapping by employing geographical information systems (gis), such as the gis software kosmo 3.1, web based real time tools and dashboards, apps, and advances in information technology (356 359). researchers have also developed a few prediction tools/models, such as the prediction model risk of bias assessment tool (probast) and critical appraisal and data extraction for systematic reviews of prediction modeling studies (charms), which could aid in assessing the possibility of getting infection and estimating the prognosis in patients; however, such models may suffer from bias issues and, hence, cannot be considered completely trustworthy, which necessitates the development of new and reliable predictors (360). recently emerged viruses, such as zika, ebola, and nipah viruses, and their grave threats to humans have begun a race in exploring the designing and developing of advanced vaccines, prophylactics, therapeutics, and drug regimens to counter emerging viruses (161 163, 280). several attempts are being made to design and develop vaccines for cov infection, mostly by targeting the spike glycoprotein. nevertheless, owing to extensive diversity in antigenic variants, cross protection rendered by the vaccines is significantly limited, even within the strains of a phylogenetic subcluster (104). due to the lack of effective antiviral therapy and vaccines in the present scenario, we need to depend solely on implementing effective infection control measures to lessen the risk of possible nosocomial transmission (68). recently, the receptor for sars cov 2 was established as the human angiotensin converting enzyme 2 (hace2), and the virus was found to enter the host cell mainly through endocytosis. it was also found that the major components that have a critical role in viral entry include pikfyve, tpc2, and cathepsin l. these findings are critical, since the components described above might act as candidates for vaccines or therapeutic drugs against sars cov 2 (293). the majority of the treatment options and strategies that are being evaluated for sars cov 2 (covid 19) have been taken from our previous experiences in treating sars cov, mers cov, and other emerging viral diseases. several therapeutic and preventive strategies, including vaccines, immunotherapeutics, and antiviral drugs, have been exploited against the previous cov outbreaks (sars cov and mers cov) (8, 104, 164 167). these valuable options have already been evaluated for their potency, efficacy, and safety, along with several other types of current research that will fuel our search for ideal therapeutic agents against covid 19 (7, 9, 19, 21, 36). the primary cause of the unavailability of approved and commercial vaccines, drugs, and therapeutics to counter the earlier sars cov and mers cov seems to owe to the lesser attention of the biomedicine and pharmaceutical companies, as these two covs did not cause much havoc, global threat, and panic like those posed by the sars cov 2 pandemic (19). moreover, for such outbreak situations, the requirement for vaccines and therapeutics/drugs exists only for a limited period, until the outbreak is controlled. the proportion of the human population infected with sars cov and mers cov was also much lower across the globe, failing to attract drug and vaccine manufacturers and producers. therefore, by the time an effective drug or vaccine is designed against such disease outbreaks, the virus would have been controlled by adopting appropriate and strict prevention and control measures, and patients for clinical trials will not be available. the newly developed drugs cannot be marketed due to the lack of end users. the s protein plays a significant role in the induction of protective immunity against sars cov by mediating t cell responses and neutralizing antibody production (168). in the past few decades, we have seen several attempts to develop a vaccine against human coronaviruses by using s protein as the target (168, 169). however, the developed vaccines have minimal application, even among closely related strains of the virus, due to a lack of cross protection. that is mainly because of the extensive diversity existing among the different antigenic variants of the virus (104). the contributions of the structural proteins, like spike (s), matrix (m), small envelope (e), and nucleocapsid (n) proteins, of sars cov to induce protective immunity has been evaluated by expressing them in a recombinant parainfluenza virus type 3 vector (bhpiv3). of note, the result was conclusive that the expression of m, e, or n proteins without the presence of s protein would not confer any noticeable protection, with the absence of detectable serum sars cov neutralizing antibodies (170). antigenic determinant sites present over s and n structural proteins of sars cov 2 can be explored as suitable vaccine candidates (294). in the asian population, s, e, m, and n proteins of sars cov 2 are being targeted for developing subunit vaccines against covid 19 (295). the identification of the immunodominant region among the subunits and domains of s protein is critical for developing an effective vaccine against the coronavirus. the c terminal domain of the s1 subunit is considered the immunodominant region of the porcine deltacoronavirus s protein (171). similarly, further investigations are needed to determine the immunodominant regions of sars cov 2 for facilitating vaccine development. however, our previous attempts to develop a universal vaccine that is effective for both sars cov and mers cov based on t cell epitope similarity pointed out the possibility of cross reactivity among coronaviruses (172). that can be made possible by selected potential vaccine targets that are common to both viruses. sars cov 2 has been reported to be closely related to sars cov (173, 174). hence, knowledge and understanding of s protein based vaccine development in sars cov will help to identify potential s protein vaccine candidates in sars cov 2. therefore, vaccine strategies based on the whole s protein, s protein subunits, or specific potential epitopes of s protein appear to be the most promising vaccine candidates against coronaviruses. the rbd of the s1 subunit of s protein has a superior capacity to induce neutralizing antibodies. this property of the rbd can be utilized for designing potential sars cov vaccines either by using rbd containing recombinant proteins or recombinant vectors that encode rbd (175). hence, the superior genetic similarity existing between sars cov 2 and sars cov can be utilized to repurpose vaccines that have proven in vitro efficacy against sars cov to be utilized for sars cov 2. the possibility of cross protection in covid 19 was evaluated by comparing the s protein sequences of sars cov 2 with that of sars cov. the comparative analysis confirmed that the variable residues were found concentrated on the s1 subunit of s protein, an important vaccine target of the virus (150). hence, the possibility of sars cov specific neutralizing antibodies providing cross protection to covid 19 might be lower. further genetic analysis is required between sars cov 2 and different strains of sars cov and sars like (sl) covs to evaluate the possibility of repurposed vaccines against covid 19. this strategy will be helpful in the scenario of an outbreak, since much time can be saved, because preliminary evaluation, including in vitro studies, already would be completed for such vaccine candidates. multiepitope subunit vaccines can be considered a promising preventive strategy against the ongoing covid 19 pandemic. in silico and advanced immunoinformatic tools can be used to develop multiepitope subunit vaccines. the vaccines that are engineered by this technique can be further evaluated using docking studies and, if found effective, then can be further evaluated in animal models (365). identifying epitopes that have the potential to become a vaccine candidate is critical to developing an effective vaccine against covid 19. the immunoinformatics approach has been used for recognizing essential epitopes of cytotoxic t lymphocytes and b cells from the surface glycoprotein of sars cov 2. recently, a few epitopes have been recognized from the sars cov 2 surface glycoprotein. the selected epitopes explored targeting molecular dynamic simulations, evaluating their interaction with corresponding major histocompatibility complex class i molecules. they potentially induce immune responses (176). the recombinant vaccine can be designed by using rabies virus (rv) as a viral vector. rv can be made to express mers cov s1 protein on its surface so that an immune response is induced against mers cov. the rv vector based vaccines against mers cov can induce faster antibody response as well as higher degrees of cellular immunity than the gram positive enhancer matrix (gem) particle vector based vaccine. however, the latter can induce a very high antibody response at lower doses (167). hence, the degree of humoral and cellular immune responses produced by such vaccines depends upon the vector used. dual vaccines have been getting more popular recently. among them, the rabies virus based vectored vaccine platform is used to develop vaccines against emerging infectious diseases. the dual vaccine developed from inactivated rabies virus particles that express the mers cov s1 domain of s protein was found to induce immune responses for both mers cov and rabies virus. the vaccinated mice were found to be completely protected from challenge with mers cov (169). the intranasal administration of the recombinant adenovirus based vaccine in balb/c mice was found to induce long lasting neutralizing immunity against mers spike pseudotyped virus, characterized by the induction of systemic igg, secretory iga, and lung resident memory t cell responses (177). immunoinformatics methods have been employed for the genome wide screening of potential vaccine targets among the different immunogens of mers cov (178). the n protein and the potential b cell epitopes of mers cov e protein have been suggested as immunoprotective targets inducing both t cell and neutralizing antibody responses (178, 179). the collaborative effort of the researchers of rocky mountain laboratories and oxford university is designing a chimpanzee adenovirus vectored vaccine to counter covid 19 (180). the coalition for epidemic preparedness innovations (cepi) has initiated three programs to design sars cov 2 vaccines (181). cepi has a collaborative project with inovio for designing a mers cov dna vaccine that could potentiate effective immunity. cepi and the university of queensland are designing a molecular clamp vaccine platform for mers cov and other pathogens, which could assist in the easier identification of antigens by the immune system (181). cepi has also funded moderna to develop a vaccine for covid 19 in partnership with the vaccine research center (vrc) of the national institute of allergy and infectious diseases (niaid), part of the national institutes of health (nih) (182). by employing mrna vaccine platform technology, a vaccine candidate expressing sars cov 2 spike protein is likely to go through clinical testing in the coming months (180). on 16 march 2020, jennifer haller became the first person outside china to receive an experimental vaccine, developed by moderna, against this pandemic virus. moderna, along with china’s cansino biologics, became the first research group to launch small clinical trials of vaccines against covid 19. their study is evaluating the vaccine’s safety and ability to trigger immune responses (296). scientists from all over the world are trying hard to develop working vaccines with robust protective immunity against covid 19. vaccine candidates, like mrna 1273 sars cov 2 vaccine, ino 4800 dna coronavirus vaccine, and adenovirus type 5 vector vaccine candidate (ad5 ncov), are a few examples under phase i clinical trials, while self amplifying rna vaccine, oral recombinant covid 19 vaccine, bnt162, plant based covid 19 vaccine, and ii key peptide covid 19 vaccine are under preclinical trials (297). similarly, the who, on its official website, has mentioned a detailed list of covid 19 vaccine agents that are under consideration. different phases of trials are ongoing for live attenuated virus vaccines, formaldehyde alum inactivated vaccine, adenovirus type 5 vector vaccine, lnp encapsulated mrna vaccine, dna plasmid vaccine, and s protein, s trimer, and ii key peptide as a subunit protein vaccine, among others (298). the process of vaccine development usually takes approximately ten years, in the case of inactivated or live attenuated vaccines, since it involves the generation of long term efficacy data. however, this was brought down to 5 years during the ebola emergency for viral vector vaccines. in the urgency associated with the covid 19 outbreaks, we expect a vaccine by the end of this year (343). the development of an effective vaccine against covid 19 with high speed and precision is the combined result of advancements in computational biology, gene synthesis, protein engineering, and the invention of advanced manufacturing platforms (342). the recurring nature of the coronavirus outbreaks calls for the development of a pan coronavirus vaccine that can produce cross reactive antibodies. however, the success of such a vaccine relies greatly on its ability to provide protection not only against present versions of the virus but also the ones that are likely to emerge in the future. this can be achieved by identifying antibodies that can recognize relatively conserved epitopes that are maintained as such even after the occurrence of considerable variations (362). even though several vaccine clinical trials are being conducted around the world, pregnant women have been completely excluded from these studies. pregnant women are highly vulnerable to emerging diseases such as covid 19 due to alterations in the immune system and other physiological systems that are associated with pregnancy. therefore, in the event of successful vaccine development, pregnant women will not get access to the vaccines (361). hence, it is recommended that pregnant women be included in the ongoing vaccine trials, since successful vaccination in pregnancy will protect the mother, fetus, and newborn. the heterologous immune effects induced by bacillus calmette guérin (bcg) vaccination is a promising strategy for controlling the covid 19 pandemic and requires further investigations. bcg is a widely used vaccine against tuberculosis in high risk regions. it is derived from a live attenuated strain of mycobacterium bovis. at present, three new clinical trials have been registered to evaluate the protective role of bcg vaccination against sars cov 2 (363). recently, a cohort study was conducted to evaluate the impact of childhood bcg vaccination in covid 19 pcr positivity rates. however, childhood bcg vaccination was found to be associated with a rate of covid 19 positive test results similar to that of the nonvaccinated group (364). further studies are required to analyze whether bcg vaccination in childhood can induce protective effects against covid 19 in adulthood. population genetic studies conducted on 103 genomes identified that the sars cov 2 virus has evolved into two major types, l and s. among the two types, l type is expected to be the most prevalent (∼70%), followed by the s type (∼30%) (366). this finding has a significant impact on our race to develop an ideal vaccine, since the vaccine candidate has to target both strains to be considered effective. at present, the genetic differences between the l and s types are very small and may not affect the immune response. however, we can expect further genetic variations in the coming days that could lead to the emergence of new strains (367). there is no currently licensed specific antiviral treatment for mers  and sars cov infections, and the main focus in clinical settings remains on lessening clinical signs and providing supportive care (183 186). effective drugs to manage covid 19 patients include remdesivir, lopinavir/ritonavir alone or in a blend with interferon beta, convalescent plasma, and monoclonal antibodies (mabs); however, efficacy and safety issues of these drugs require additional clinical trials (187, 281). a controlled trial of ritonavir boosted lopinavir and interferon alpha 2b treatment was performed on covid 19 hospitalized patients (chictr2000029308) (188). in addition, the use of hydroxychloroquine and tocilizumab for their potential role in modulating inflammatory responses in the lungs and antiviral effect has been proposed and discussed in many research articles. still, no fool proof clinical trials have been published (194, 196, 197, 261 272). recently, a clinical trial conducted on adult patients suffering from severe covid 19 revealed no benefit of lopinavir ritonavir treatment over standard care (273). the efforts to control sars cov 2 infection utilize defined strategies as followed against mers and sars, along with adopting and strengthening a few precautionary measures owing to the unknown nature of this novel virus (36, 189). presently, the main course of treatment for severely affected sars cov 2 patients admitted to hospitals includes mechanical ventilation, intensive care unit (icu) admittance, and symptomatic and supportive therapies. additionally, rna synthesis inhibitors (lamivudine and tenofovir disoproxil fumarate), remdesivir, neuraminidase inhibitors, peptide (ek1), anti inflammatory drugs, abidol, and chinese traditional medicine (lianhuaqingwen and shufengjiedu capsules) could aid in covid 19 treatment. however, further clinical trials are being carried out concerning their safety and efficacy (7). it might require months to a year(s) to design and develop effective drugs, therapeutics, and vaccines against covid 19, with adequate evaluation and approval from regulatory bodies and moving to the bulk production of many millions of doses at commercial levels to meet the timely demand of mass populations across the globe (9). continuous efforts are also warranted to identify and assess viable drugs and immunotherapeutic regimens that revealed proven potency in combating other viral agents similar to sars cov 2. covid 19 patients showing severe signs are treated symptomatically along with oxygen therapy. in such cases where the patients progress toward respiratory failure and become refractory to oxygen therapy, mechanical ventilation is necessitated. the covid 19 induced septic shock can be managed by providing adequate hemodynamic support (299). several classes of drugs are currently being evaluated for their potential therapeutic action against sars cov 2. therapeutic agents that have anti sars cov 2 activity can be broadly classified into three categories: drugs that block virus entry into the host cell, drugs that block viral replication as well as its survival within the host cell, and drugs that attenuate the exaggerated host immune response (300). an inflammatory cytokine storm is commonly seen in critically ill covid 19 patients. hence, they may benefit from the use of timely anti inflammation treatment. anti inflammatory therapy using drugs like glucocorticoids, cytokine inhibitors, jak inhibitors, and chloroquine/hydroxychloroquine should be done only after analyzing the risk/benefit ratio in covid 19 patients (301). there have not been any studies concerning the application of nonsteroidal anti inflammatory drugs (nsaid) to covid 19 infected patients. however, reasonable pieces of evidence are available that link nsaid uses with the occurrence of respiratory and cardiovascular adverse effects. hence, as a cautionary approach, it is better to recommend the use of nsaids as the first line option for managing covid 19 symptoms (302). the use of corticosteroids in covid 19 patients is still a matter of controversy and requires further systematic clinical studies. the guidelines that were put forward to manage critically ill adults suggest the use of systemic corticosteroids in mechanically ventilated adults with ards (303). the generalized use of corticosteroids is not indicated in covid 19, since there are some concerns associated with the use of corticosteroids in viral pneumonia. stem cell therapy using mesenchymal stem cells (mscs) is another hopeful strategy that can be used in clinical cases of covid 19 owing to its potential immunomodulatory capacity. it may have a beneficial role in attenuating the cytokine storm that is observed in severe cases of sars cov 2 infection, thereby reducing mortality. among the different types of mscs, expanded umbilical cord mscs can be considered a potential therapeutic agent that requires further validation for managing critically ill covid 19 patients (304). repurposed broad spectrum antiviral drugs having proven uses against other viral pathogens can be employed for sars cov 2 infected patients. these possess benefits of easy accessibility and recognized pharmacokinetic and pharmacodynamic activities, stability, doses, and side effects (9). repurposed drugs have been studied for treating cov infections, like lopinavir/ritonavir, and interferon 1β revealed in vitro anti mers cov action. the in vivo experiment carried out in the nonhuman primate model of common marmosets treated with lopinavir/ritonavir and interferon beta showed superior protective results in treated animals than in the untreated ones (190). a combination of these drugs is being evaluated to treat mers in humans (miracle trial) (191). these two protease inhibitors (lopinavir and ritonavir), in combination with ribavirin, gave encouraging clinical outcomes in sars patients, suggesting their therapeutic values (165). however, in the current scenario, due to the lack of specific therapeutic agents against sars cov 2, hospitalized patients confirmed for the disease are given supportive care, like oxygen and fluid therapy, along with antibiotic therapy for managing secondary bacterial infections (192). patients with novel coronavirus or covid 19 pneumonia who are mechanically ventilated often require sedatives, analgesics, and even muscle relaxation drugs to prevent ventilator related lung injury associated with human machine incoordination (122). the result obtained from a clinical study of four patients infected with covid 19 claimed that combination therapy using lopinavir/ritonavir, arbidol, and shufeng jiedu capsules (traditional chinese medicine) was found to be effective in managing covid 19 pneumonia (193). it is difficult to evaluate the therapeutic potential of a drug or a combination of drugs for managing a disease based on such a limited sample size. before choosing the ideal therapeutic agent for the management of covid 19, randomized clinical control studies should be performed with a sufficient study population. several classes of routinely used antiviral drugs, like oseltamivir (neuraminidase inhibitor), acyclovir, ganciclovir, and ribavirin, do not have any effect on covid 19 and, hence, are not recommended (187). oseltamivir, a neuraminidase inhibitor, has been explored in chinese hospitals for treating suspected covid 19 cases, although proven efficacy against sars cov 2 is still lacking for this drug (7). the in vitro antiviral potential of fad approved drugs, viz., ribavirin, penciclovir, nitazoxanide, nafamostat, and chloroquine, tested in comparison to remdesivir and favipiravir (broad spectrum antiviral drugs) revealed remdesivir and chloroquine to be highly effective against sars cov 2 infection in vitro (194). ribavirin, penciclovir, and favipiravir might not possess noteworthy in vivo antiviral actions for sars cov 2, since higher concentrations of these nucleoside analogs are needed in vitro to lessen the viral infection. both remdesivir and chloroquine are being used in humans to treat other diseases, and such safer drugs can be explored for assessing their effectiveness in covid 19 patients. several therapeutic agents, such as lopinavir/ritonavir, chloroquine, and hydroxychloroquine, have been proposed for the clinical management of covid 19 (299). a molecular docking study, conducted in the rna dependent rna polymerase (rdrp) of sars cov 2 using different commercially available antipolymerase drugs, identified that drugs such as ribavirin, remdesivir, galidesivir, tenofovir, and sofosbuvir bind rdrp tightly, indicating their vast potential to be used against covid 19 (305). a broad spectrum antiviral drug that was developed in the united states, tilorone dihydrochloride (tilorone), was previously found to possess potent antiviral activity against mers, marburg, ebola, and chikungunya viruses (306). even though it had broad spectrum activity, it was neglected for an extended period. tilorone is another antiviral drug that might have activity against sars cov 2. remdesivir, a novel nucleotide analog prodrug, was developed for treating ebola virus disease (evd), and it was also found to inhibit the replication of sars cov and mers cov in primary human airway epithelial cell culture systems (195). recently, in vitro study has proven that remdesivir has better antiviral activity than lopinavir and ritonavir. further, in vivo studies conducted in mice also identified that treatment with remdesivir improved pulmonary function and reduced viral loads and lung pathology both in prophylactic and therapeutic regimens compared to lopinavir/ritonavir ifn γ treatment in mers cov infection (8). remdesivir also inhibits a diverse range of coronaviruses, including circulating human cov, zoonotic bat cov, and prepandemic zoonotic cov (195). remdesivir is also considered the only therapeutic drug that significantly reduces pulmonary pathology (8). all these findings indicate that remdesivir has to be further evaluated for its efficacy in the treatment of covid 19 infection in humans. the broad spectrum activity exhibited by remdesivir will help control the spread of disease in the event of a new coronavirus outbreak. chloroquine is an antimalarial drug known to possess antiviral activity due to its ability to block virus cell fusion by raising the endosomal ph necessary for fusion. it also interferes with virus receptor binding by interfering with the terminal glycosylation of sars cov cellular receptors, such as ace2 (196). in a recent multicenter clinical trial that was conducted in china, chloroquine phosphate was found to exhibit both efficacy and safety in the therapeutic management of sars cov 2 associated pneumonia (197). this drug is already included in the treatment guidelines issued by the national health commission of the people’s republic of china. the preliminary clinical trials using hydroxychloroquine, another aminoquinoline drug, gave promising results. the covid 19 patients received 600 mg of hydroxychloroquine daily along with azithromycin as a single arm protocol. this protocol was found to be associated with a noteworthy reduction in viral load. finally, it resulted in a complete cure (271); however, the study comprised a small population and, hence, the possibility of misinterpretation could arise. however, in another case study, the authors raised concerns over the efficacy of hydroxychloroquine azithromycin in the treatment of covid 19 patients, since no observable effect was seen when they were used. in some cases, the treatment was discontinued due to the prolongation of the qt interval (307). hence, further randomized clinical trials are required before concluding this matter. recently, another fda approved drug, ivermectin, was reported to inhibit the in vitro replication of sars cov 2. the findings from this study indicate that a single treatment of this drug was able to induce an ∼5,000 fold reduction in the viral rna at 48 h in cell culture. (308). one of the main disadvantages that limit the clinical utility of ivermectin is its potential to cause cytotoxicity. however, altering the vehicles used in the formulations, the pharmacokinetic properties can be modified, thereby having significant control over the systemic concentration of ivermectin (338). based on the pharmacokinetic simulation, it was also found that ivermectin may have limited therapeutic utility in managing covid 19, since the inhibitory concentration that has to be achieved for effective anti sars cov 2 activity is far higher than the maximum plasma concentration achieved by administering the approved dose (340). however, ivermectin, being a host directed agent, exhibits antiviral activity by targeting a critical cellular process of the mammalian cell. therefore, the administration of ivermectin, even at lower doses, will reduce the viral load at a minor level. this slight decrease will provide a great advantage to the immune system for mounting a large scale antiviral response against sars cov 2 (341). further, a combination of ivermectin and hydroxychloroquine might have a synergistic effect, since ivermectin reduces viral replication, while hydroxychloroquine inhibits the entry of the virus in the host cell (339). further, in vivo studies and randomized clinical control trials are required to understand the mechanism as well as the clinical utility of this promising drug. nafamostat is a potent inhibitor of mers cov that acts by preventing membrane fusion. nevertheless, it does not have any sort of inhibitory action against sars cov 2 infection (194). recently, several newly synthesized halogenated triazole compounds were evaluated, using fluorescence resonance energy transfer (fret) based helicase assays, for their ability to inhibit helicase activity. among the evaluated compounds, 4 (cyclopent 1 en 3 ylamino) 5 [2 (4 iodophenyl)hydrazinyl] 4h 1,2,4 triazole 3 thiol and 4 (cyclopent 1 en 3 ylamino) 5 [2 (4 chlorophenyl)hydrazinyl] 4h 1,2,4 triazole 3 thiol were found to be the most potent. these compounds were used for in silico studies, and molecular docking was accomplished into the active binding site of mers cov helicase nsp13 (21). further studies are required for evaluating the therapeutic potential of these newly identified compounds in the management of covid 19 infection. monoclonal antibodies (mabs) may be helpful in the intervention of disease in cov exposed individuals. patients recovering from sars showed robust neutralizing antibodies against this cov infection (164). a set of mabs aimed at the mers cov s protein specific domains, comprising six specific epitope groups interacting with receptor binding, membrane fusion, and sialic acid binding sites, make up crucial entry tasks of s protein (198, 199). passive immunization employing weaker and strongly neutralizing antibodies provided considerable protection in mice against a mers cov lethal challenge. such antibodies may play a crucial role in enhancing protective humoral responses against the emerging covs by aiming appropriate epitopes and functions of the s protein. the cross neutralization ability of sars cov rbd specific neutralizing mabs considerably relies on the resemblance between their rbds; therefore, sars cov rbd specific antibodies could cross neutralized sl covs, i.e., bat sl cov strain wiv1 (rbd with eight amino acid differences from sars cov) but not bat sl cov strain shc014 (24 amino acid differences) (200). appropriate rbd specific mabs can be recognized by a relative analysis of rbd of sars cov 2 to that of sars cov, and cross neutralizing sars cov rbd specific mabs could be explored for their effectiveness against covid 19 and further need to be assessed clinically. the u.s. biotechnology company regeneron is attempting to recognize potent and specific mabs to combat covid 19. an ideal therapeutic option suggested for sars cov 2 (covid 19) is the combination therapy comprised of mabs and the drug remdesivir (covid 19) (201). the sars cov specific human mab cr3022 is found to bind with sars cov 2 rbd, indicating its potential as a therapeutic agent in the management of covid 19. it can be used alone or in combination with other effective neutralizing antibodies for the treatment and prevention of covid 19 (202). furthermore, sars cov specific neutralizing antibodies, like m396 and cr3014, failed to bind the s protein of sars cov 2, indicating that a particular level of similarity is mandatory between the rbds of sars cov and sars cov 2 for the cross reactivity to occur. further assessment is necessary before confirming the effectiveness of such combination therapy. in addition, to prevent further community and nosocomial spread of covid 19, the postprocedure risk management program should not be neglected (309). development of broad spectrum inhibitors against the human coronaviral pathogens will help to facilitate clinical trials on the effectiveness of such inhibitors against endemic and emerging coronaviruses (203). a promising animal study revealed the protective effect of passive immunotherapy with immune serum from mers immune camels on mice infected with mers cov (204). passive immunotherapy using convalescent plasma is another strategy that can be used for treating covid 19 infected, critically ill patients (205). the exploration of fully human antibodies (human single chain antibodies; huscfvs) or humanized nanobodies (single domain antibodies; sdab, vh/vhh) could aid in blocking virus replication, as these agents can traverse the virus infected cell membranes (transbodies) and can interfere with the biological characteristics of the replicating virus proteins. such examples include transbodies to the influenza virus, hepatitis c virus, ebola virus, and dengue virus (206). producing similar transbodies against intracellular proteins of coronaviruses, such as papain like proteases (plpro), cysteine like protease (3clpro), or other nsps, which are essential for replication and transcription of the virus, might formulate a practical move forward for a safer and potent passive immunization approach for virus exposed persons and rendering therapy to infected patients. in a case study on five grimly sick patients having symptoms of severe pneumonia due to covid 19, convalescent plasma administration was found to be helpful in patients recovering successfully. the convalescent plasma containing a sars cov 2 specific elisa (serum) antibody titer higher than 1:1,000 and neutralizing antibody titer more significant than 40 was collected from the recovered patients and used for plasma transfusion twice in a volume of 200 to 250 ml on the day of collection (310). at present, treatment for sepsis and ards mainly involves antimicrobial therapy, source control, and supportive care. hence, the use of therapeutic plasma exchange can be considered an option in managing such severe conditions. further randomized trials can be designed to investigate its efficacy (311). potent therapeutics to combat sars cov 2 infection include virus binding molecules, molecules or inhibitors targeting particular enzymes implicated in replication and transcription process of the virus, helicase inhibitors, vital viral proteases and proteins, protease inhibitors of host cells, endocytosis inhibitors, short interfering rna (sirna), neutralizing antibodies, mabs against the host receptor, mabs interfering with the s1 rbd, antiviral peptide aimed at s2, and natural drugs/medicines (7, 166, 186). the s protein acts as the critical target for developing cov antivirals, like inhibitors of s protein and s cleavage, neutralizing antibodies, rbd ace2 blockers, sirnas, blockers of the fusion core, and proteases (168). all of these therapeutic approaches have revealed both in vitro and in vivo anti cov potential. although in vitro research carried out with these therapeutics showed efficacy, most need appropriate support from randomized animal or human trials. therefore, they might be of limited applicability and require trials against sars cov 2 to gain practical usefulness. the binding of sars cov 2 with ace2 leads to the exacerbation of pneumonia as a consequence of the imbalance in the renin angiotensin system (ras). the virus induced pulmonary inflammatory responses may be reduced by the administration of ace inhibitors (acei) and angiotensin type 1 receptor (at1r) (207). several investigations have suggested the use of small molecule inhibitors for the potential control of sars cov infections. drugs of the fda approved compound library were screened to identify four small molecule inhibitors of mers cov (chlorpromazine, chloroquine, loperamide, and lopinavir) that inhibited viral replication. these compounds also hinder sars cov and human covs (208). therapeutic strategies involving the use of specific antibodies or compounds that neutralize cytokines and their receptors will help to restrain the host inflammatory responses. such drugs acting specifically in the respiratory tract will help to reduce virus triggered immune pathologies in covid 19 (209). the later stages of coronavirus induced inflammatory cascades are characterized by the release of proinflammatory interleukin 1 (il 1) family members, such as il 1 and il 33. hence, there exists a possibility that the inflammation associated with coronavirus can be inhibited by utilizing anti inflammatory cytokines that belong to the il 1 family (92). it has also been suggested that the actin protein is the host factor that is involved in cell entry and pathogenesis of sars cov 2. hence, those drugs that modulate the biological activity of this protein, like ibuprofen, might have some therapeutic application in managing the disease (174). the plasma angiotensin 2 level was found to be markedly elevated in covid 19 infection and was correlated with viral load and lung injury. hence, drugs that block angiotensin receptors may have potential for treating covid 19 infection (121). a scientist from germany, named rolf hilgenfeld, has been working on the identification of drugs for the treatment of coronaviral infection since the time of the first sars outbreak (19). the sars cov s2 subunit has a significant function in mediating virus fusion that provides entry into the host cell. heptad repeat 1 (hr1) and heptad repeat 2 (hr2) can interact and form a six helix bundle that brings the viral and cellular membranes in close proximity, facilitating its fusion. the sequence alignment study conducted between covid 19 and sars cov identified that the s2 subunits are highly conserved in these covs. the hr1 and hr2 domains showed 92.6% and 100% overall identity, respectively (210). from these findings, we can confirm the significance of covid 19 hr1 and hr2 and their vital role in host cell entry. hence, fusion inhibitors target the hr1 domain of s protein, thereby preventing viral fusion and entry into the host cell. this is another potential therapeutic strategy that can be used in the management of covid 19. other than the specific therapy directed against covid 19, general treatments play a vital role in the enhancement of host immune responses against the viral agent. inadequate nutrition is linked to the weakening of the host immune response, making the individual more susceptible. the role played by nutrition in disease susceptibility should be measured by evaluating the nutritional status of patients with covid 19 (205). for evaluating the potential of vaccines and therapeutics against covs, including sars cov, mers covs, and the presently emerging sars cov 2, suitable animal models that can mimic the clinical disease are needed (211, 212). various animal models were assessed for sars  and mers covs, such as mice, guinea pigs, golden syrian hamsters, ferrets, rabbits, nonhuman primates like rhesus macaques and marmosets, and cats (185, 213 218). the specificity of the virus to hace2 (receptor of sars cov) was found to be a significant barrier in developing animal models. consequently, a sars cov transgenic mouse model has been developed by inserting the hace2 gene into the mouse genome (219). the inability of mers cov to replicate in the respiratory tracts of animals (mice, hamsters, and ferrets) is another limiting factor. however, with genetic engineering, a 288 330+/+ mers cov genetically modified mouse model was developed and now is in use for the assessment of novel drugs and vaccines against mers cov (220). in the past, small animals (mice or hamsters) have been targeted for being closer to a humanized structure, such as mouse dpp4 altered with human dpp4 (hdpp4), hdpp4 transduced mice, and hdpp4 tg mice (transgenic for expressing hdpp4) for mers cov infection (221). the crispr cas9 gene editing tool has been used for inserting genomic alterations in mice, making them susceptible to mers cov infection (222). efforts are under way to recognize suitable animal models for sars cov2/covid 19, identify the receptor affinity of this virus, study pathology in experimental animal models, and explore virus specific immune responses and protection studies, which together would increase the pace of efforts being made for developing potent vaccines and drugs to counter this emerging virus. cell lines, such as monkey epithelial cell lines (llc mk2 and vero b4), goat lung cells, alpaca kidney cells, dromedary umbilical cord cells, and advanced ex vivo three dimensional tracheobronchial tissue, have been explored to study human covs (mers cov) (223, 224). vero and huh 7 cells (human liver cancer cells) have been used for isolating sars cov 2 (194). recently, an experimental study with rhesus monkeys as animal models revealed the absence of any viral loads in nasopharyngeal and anal swabs, and no viral replication was recorded in the primary tissues at a time interval of 5 days post reinfection in reexposed monkeys (274). the subsequent virological, radiological, and pathological observations indicated that the monkeys with reexposure had no recurrence of covid 19, like the sars cov 2 infected monkeys without rechallenge. these findings suggest that primary infection with sars cov 2 could protect from later exposures to the virus, which could help in defining disease prognosis and crucial inferences for designing and developing potent vaccines against covid 19 (274). in contrast to their response to the 2002 sars outbreak, china has shown immense political openness in reporting the covid 19 outbreak promptly. they have also performed rapid sequencing of covid 19 at multiple levels and shared the findings globally within days of identifying the novel virus (225). the move made by china opened a new chapter in global health security and diplomacy. even though complete lockdown was declared following the covid 19 outbreak in wuhan, the large scale movement of people has resulted in a radiating spread of infections in the surrounding provinces as well as to several other countries. large scale screening programs might help us to control the spread of this virus. however, this is both challenging as well as time consuming due to the present extent of infection (226). the current scenario demands effective implementation of vigorous prevention and control strategies owing to the prospect of covid 19 for nosocomial infections (68). follow ups of infected patients by telephone on day 7 and day 14 are advised to avoid any further unintentional spread or nosocomial transmission (312). the availability of public data sets provided by independent analytical teams will act as robust evidence that would guide us in designing interventions against the covid 19 outbreak. newspaper reports and social media can be used to analyze and reconstruct the progression of an outbreak. they can help us to obtain detailed patient level data in the early stages of an outbreak (227). immediate travel restrictions imposed by several countries might have contributed significantly to preventing the spread of sars cov 2 globally (89, 228). following the outbreak, a temporary ban was imposed on the wildlife trade, keeping in mind the possible role played by wild animal species in the origin of sars cov 2/covid 19 (147). making a permanent and bold decision on the trade of wild animal species is necessary to prevent the possibility of virus spread and initiation of an outbreak due to zoonotic spillover (1). personal protective equipment (ppe), like face masks, will help to prevent the spread of respiratory infections like covid 19. face masks not only protect from infectious aerosols but also prevent the transmission of disease to other susceptible individuals while traveling through public transport systems (313). another critical practice that can reduce the transmission of respiratory diseases is the maintenance of hand hygiene. however, the efficacy of this practice in reducing the transmission of respiratory viruses like sars cov 2 is much dependent upon the size of droplets produced. hand hygiene will reduce disease transmission only if the virus is transmitted through the formation of large droplets (314). hence, it is better not to overemphasize that hand hygiene will prevent the transmission of sars cov 2, since it may produce a false sense of safety among the general public that further contributes to the spread of covid 19. even though airborne spread has not been reported in sars cov 2 infection, transmission can occur through droplets and fomites, especially when there is close, unprotected contact between infected and susceptible individuals. hence, hand hygiene is equally as important as the use of appropriate ppe, like face masks, to break the transmission cycle of the virus; both hand hygiene and face masks help to lessen the risk of covid 19 transmission (315). medical staff are in the group of individuals most at risk of getting covid 19 infection. this is because they are exposed directly to infected patients. hence, proper training must be given to all hospital staff on methods of prevention and protection so that they become competent enough to protect themselves and others from this deadly disease (316). as a preventive measure, health care workers caring for infected patients should take extreme precautions against both contact and airborne transmission. they should use ppe such as face masks (n95 or ffp3), eye protection (goggles), gowns, and gloves to nullify the risk of infection (299). the human to human transmission reported in sars cov 2 infection occurs mainly through droplet or direct contact. due to this finding, frontline health care workers should follow stringent infection control and preventive measures, such as the use of ppe, to prevent infection (110). the mental health of the medical/health workers who are involved in the covid 19 outbreak is of great importance, because the strain on their mental well being will affect their attention, concentration, and decision making capacity. hence, for control of the covid 19 outbreak, rapid steps should be taken to protect the mental health of medical workers (229). since the living mammals sold in the wet market are suspected to be the intermediate host of sars cov 2, there is a need for strengthening the regulatory mechanism for wild animal trade (13). the total number of covid 19 confirmed cases is on a continuous rise and the cure rate is relatively low, making disease control very difficult to achieve. the chinese government is making continuous efforts to contain the disease by taking emergency control and prevention measures. they have already built a hospital for patients affected by this virus and are currently building several more for accommodating the continuously increasing infected population (230). the effective control of sars cov 2/covid 19 requires high level interventions like intensive contact tracing, as well as the quarantine of people with suspected infection and the isolation of infected individuals. the implementation of rigorous control and preventive measures together might control the r0 number and reduce the transmission risk (228). considering the zoonotic links associated with sars cov 2, the one health approach may play a vital role in the prevention and control measures being followed to restrain this pandemic virus (317 319). the substantial importation of covid 19 presymptomatic cases from wuhan has resulted in independent, self sustaining outbreaks across major cities both within the country and across the globe. the majority of chinese cities are now facing localized outbreaks of covid 19 (231). hence, deploying efficient public health interventions might help to cut the spread of this virus globally. the occurrence of covid 19 infection on several cruise ships gave us a preliminary idea regarding the transmission pattern of the disease. cruise ships act as a closed environment and provide an ideal setting for the occurrence of respiratory disease outbreaks. such a situation poses a significant threat to travelers, since people from different countries are on board, which favors the introduction of the pathogen (320). although nearly 30 cruise ships from different countries have been found harboring covid 19 infection, the major cruise ships that were involved in the covid 19 outbreaks are the diamond princess, grand princess, celebrity apex, and ruby princess. the number of confirmed covid 19 cases around the world is on the rise. the success of preventive measures put forward by every country is mainly dependent upon their ability to anticipate the approaching waves of patients. this will help to properly prepare the health care workers and increase the intensive care unit (icu) capacity (321). instead of entirely relying on lockdown protocols, countries should focus mainly on alternative intervention strategies, such as large scale testing, contract tracing, and localized quarantine of suspected cases for limiting the spread of this pandemic virus. such intervention strategies will be useful either at the beginning of the pandemic or after lockdown relaxation (322). lockdown should be imposed only to slow down disease progression among the population so that the health care system is not overloaded. the reproduction number (r0) of covid 19 infection was earlier estimated to be in the range of 1.4 to 2.5 (70); recently, it was estimated to be 2.24 to 3.58 (76). compared to its coronavirus predecessors, covid 19 has an r0 value that is greater than that of mers (r0 < 1) (108) but less than that of sars (r0 value of 2 to 5) (93). still, to prevent further spread of disease at mass gatherings, functions remain canceled in the affected cities, and persons are asked to work from home (232). hence, it is a relief that the current outbreak of covid 19 infection can be brought under control with the adoption of strategic preventive and control measures along with the early isolation of subsequent cases in the coming days. studies also report that since air traffic between china and african countries increased many times over in the decade after the sars outbreak, african countries need to be vigilant to prevent the spread of novel coronavirus in africa (225). due to fear of virus spread, wuhan city was completely shut down (233). the immediate control of the ongoing covid 19 outbreaks appears a mammoth task, especially for developing countries, due to their inability to allocate quarantine stations that could screen infected individuals’ movements (234). such underdeveloped countries should divert their resources and energy to enforcing the primary level of preventive measures, like controlling the entry of individuals from china or countries where the disease has flared up, isolating the infected individuals, and quarantining individuals with suspected infection. most of the sub saharan african countries have a fragile health system that can be crippled in the event of an outbreak. effective management of covid 19 would be difficult for low income countries due to their inability to respond rapidly due to the lack of an efficient health care system (65). controlling the imported cases is critical in preventing the spread of covid 19 to other countries that have not reported the disease until now. the possibility of an imported case of covid 19 leading to sustained human to human transmission was estimated to be 0.41. this can be reduced to a value of 0.012 by decreasing the mean time from the onset of symptoms to hospitalization and can only be made possible by using intense disease surveillance systems (235). the silent importations of infected individuals (before the manifestation of clinical signs) also contributed significantly to the spread of disease across the major cities of the world. even though the travel ban was implemented in wuhan (89), infected persons who traveled out of the city just before the imposition of the ban might have remained undetected and resulted in local outbreaks (236). emerging novel diseases like covid 19 are difficult to contain within the country of origin, since globalization has led to a world without borders. hence, international collaboration plays a vital role in preventing the further spread of this virus across the globe (237). we also predict the possibility of another outbreak, as predicted by fan et al. (6). indeed, the present outbreak caused by sars cov 2 (covid 19) was expected. similar to previous outbreaks, the current outbreak also will be contained shortly. however, the real issue is how we are planning to counter the next zoonotic cov epidemic that is likely to occur within the next 5 to 10 years or even sooner (fig. 7). coronavirus origins. coronavirus is the most prominent example of an emerging virus that has crossed the species barrier from wild animals to humans, like sars and mers. the origin of sars cov 2 is also suspected to be from an intermediate animal host. the possibility of crossing the species barrier again for the fourth time cannot be ruled out. several years after the global sars epidemic, the current sars cov 2/covid 19 pandemic has served as a reminder of how novel pathogens can rapidly emerge and spread through the human population and eventually cause severe public health crises. further research should be conducted to establish animal models for sars cov 2 to investigate replication, transmission dynamics, and pathogenesis in humans. this may help develop and evaluate potential therapeutic strategies against zoonotic cov epidemics. present trends suggest the occurrence of future outbreaks of covs due to changes in the climate, and ecological conditions may be associated with human animal contact. live animal markets, such as the huanan south china seafood market, represent ideal conditions for interspecies contact of wildlife with domestic birds, pigs, and mammals, which substantially increases the probability of interspecies transmission of cov infections and could result in high risks to humans due to adaptive genetic recombination in these viruses (323 325). the covid 19 associated symptoms are fever, cough, expectoration, headache, and myalgia or fatigue. individuals with asymptomatic and atypical clinical manifestations were also identified recently, further adding to the complexity of disease transmission dynamics. atypical clinical manifestations may only express symptoms such as fatigue instead of respiratory signs such as fever, cough, and sputum. in such cases, the clinician must be vigilant for the possible occurrence of asymptomatic and atypical clinical manifestations to avoid the possibility of missed diagnoses. the present outbreak caused by sars cov 2 was, indeed, expected. similar to previous outbreaks, the current pandemic also will be contained shortly. however, the real question is, how are we planning to counter the next zoonotic cov epidemic that is likely to occur within the next 5 to 10 years or perhaps sooner? our knowledge of most of the bat covs is scarce, as these viruses have not been isolated and studied, and extensive studies on such viruses are typically only conducted when they are associated with specific disease outbreaks. the next step following the control of the covid 19 outbreak in china should be focused on screening, identification, isolation, and characterization of covs present in wildlife species of china, particularly in bats. both in vitro and in vivo studies (using suitable animal models) should be conducted to evaluate the risk of future epidemics. presently, licensed antiviral drugs or vaccines against sars cov, mers cov, and sars cov 2 are lacking. however, advances in designing antiviral drugs and vaccines against several other emerging diseases will help develop suitable therapeutic agents against covid 19 in a short time. until then, we must rely exclusively on various control and prevention measures to prevent this new disease from becoming a pandemic. all authors substantially contributed to the conception, design, analysis, and interpretation of data and checking and approving the final version of the manuscript, and we agree to be accountable for its contents. this compilation is a review article written, analyzed, and designed by its authors and required no substantial funding to be developed. all authors declare that there are no existing commercial or financial relationships that could, in any way, lead to a potential conflict of interest. kuldeep dhama, m.v.sc., ph.d. (gold medalist), is working as principal scientist in the division of pathology, icar indian veterinary research institute, izatnagar, uttar pradesh, india. with 25 years of research and teaching experience in the areas of microbiology, immunology, virology, public health, medicine, and biomedicine as an eminent researcher, he has developed several diagnostics, vaccines, immunomodulatory modules, and hypotheses to counter infectious diseases of animals, poultry, and public health concerns. he has to his credit 600 publications, 6 books, and 65 book chapters. dr. dhama has been recognized as an extremely productive researcher in the journal nature. he has been honored with 50 best paper awards and other recognitions. he is an naas (national academy of agricultural science, india) associate and has worked as nodal officer, wto, and member, wildlife health specialist group (iucn). he is actively serving as editor in chief, co eic, editor, and member, editorial board, of nearly 20 scientific journals. his google scholar h index is 47 and scopus h index is 31. sharun khan, m.v.sc., is currently working as a researcher in the stem cell laboratory, division of surgery, icar indian veterinary research institute, izatnagar, india. his area of interest is regenerative medicine with a focus on understanding cell biology and molecular pathways involved in the maintenance and differentiation of stem cells originating from different tissues. he has particular interest and knowledge in the fields of veterinary medicine, pharmacology, infectious diseases of animals, wildlife diseases, diagnosis and therapy of animal diseases, nutrition, and biomedicine. with excellent academic records, he has received awards and recognitions (fellowships and scholarships) and participated in national and international workshops, training programs, and courses. he has a keen interest in learning excellent scientific writing skills and has published 30 papers, including in international journals of repute. he is highly enthusiastic about gaining knowledge of advancements in educational and scientific research areas. ruchi tiwari is currently working as assistant professor in the department of veterinary microbiology, college of veterinary sciences, duvasu, mathura, india. she is currently pursuing her ph.d. (hons) degree from duvasu. with an excellent academic record and 10 years of research and teaching experience, she has expertise in the field of diagnosis, prevention, and control of important livestock/poultry diseases/pathogens having public health significance, along with particular reference to veterinary microbiology, immunology, ethnoveterinary medicine, alternative and complementary therapies, and bacteriophage therapy. dr. tiwari has published 150 research/review articles and 5 book chapters. she has been honored with the young scientist award, best paper awards (10), and outstanding women faculty award (2019). she is serving as editor and member, editorial board, and reviewer of 15 international journals. her google scholar h index is 40 and scopus h index is 26. shubhankar sircar, a ph.d. scholar, received his master’s degree from integral university lucknow, india, in 2012 and is presently serving as a senior research fellow in an icar national fellow scheme in the division of biological standardization at the icar indian veterinary research institute (ivri), izatnagar, india. his area of interest is molecular epidemiology and genotype distribution of major enteric viruses, with a focus on developing different molecular as well as serological diagnostic testing assays. apart from his expertise in viral diagnosis, he has particular interest and knowledge in the fields of infectious diseases of farms, animals, and wildlife. with good academic records, he has received a few awards and recognitions (best poster and young scientist) and participated in several national and international workshops, training programs, and conferences. he has published 30 papers in journals of repute. he is highly enthusiastic about gaining knowledge of advancements in educational and scientific research areas. sudipta bhat, a ph.d. scholar, received his bachelor's (b.v.sc.) from west bengal university of animal and fishery sciences, kolkata, india, and masters (m.v.sc.) from icar indian veterinary research institute (ivri), bareilly, india. he has been pursuing a ph.d. in veterinary virology, icar ivri, since 2016. he has worked on the highly pathogenic h5n1 avian influenza virus and now is working on emerging enteric viruses of zoonotic importance from different animal species. he has published his research findings in international journals. his area of interest is infectious diseases with a focus on understanding the antigenic and genetic diversity of viruses causing disease of several livestock species. with brilliant academic records, he has also been awarded several fellowships and scholarships and participated in several national and international workshops, training programs, and courses. yashpal singh malik, m.v.sc., ph.d., serving as an icar national fellow and professor, is an expert on enteric viral infections, zoonosis, and emerging viral diseases of animals and humans. he has contributed immensely to viral disease epidemiology, virus host interactions, microbial biodiversity, characterization, and diagnosis of pathogens. he performed his postdoctoral work at the university of minnesota. he acquired advanced training in molecular virology from the division of virology, university of ottawa, canada, and wuhan institute of virology, china. he has represented india in the scientific arena in more than 12 countries. he is the secretary general of the indian virological society and secretary for the world society for virology (usa). he is a study group member of the ictv on birnaviridae and picobirnaviridae. he has authored five books from reputed publishers, including elsevier and springer nature, and has published 225 scientific research articles and reviews in journals of high impact factor. his h index is 29, and his rg score is 39. karam pal singh, ph.d., obtained his b.v.sc. and a.h. degrees from csa university of agriculture & technology, kanpur, india, and m.v.sc. (1987) and ph.d. (1990) degrees in veterinary pathology from the icar indian veterinary research institute (ivri), izatnagar, india. he worked as scientist, senior scientist, and principal scientist before taking charge as the acting head, division of pathology, on 1 january 2019. he worked at the institute of animal health, pirbright, united kingdom, as a visiting fellow from april to december 1996. he worked at the institute of animal health, pirbright, united kingdom, as a postdoctoral fellow on a wellcome trust fellowship from september 2002 to august 2004. further, he worked at the veterinary research centre, muscat, sultanate of oman, as an expert pathologist from june 2008 to may 2009. dr. singh is a veterinary pathologist. his area of interest is infectious diseases with a focus on understanding the pathogenesis and molecular diagnosis of viral diseases, with particular reference to rabies and bluetongue viruses. wanpen chaicumpa, d.v.m. (hons.), ph.d. (microbiology), is emeritus professor, research consultant, and head of the center of research excellence on therapeutic proteins and antibody engineering at the department of parasitology, faculty of medicine siriraj hospital, mahidol university, bangkok, and consultant of the faculty of allied health sciences, thammasat university, thailand. her research interests are intestinal immunity against enteric infections, vaccine development, immuno  and molecular diagnoses of tropical infections, allergy, immunotherapy, and antibody engineering. she is an executive member of the thailand academy of sciences. she has served as editor in chief of the asian pacific journal of allergy and immunology. she served as a consultant to the who southeast asian regional office, india. she has published over 250 publications, owns more than 30 patents/patent applications, and has published three textbooks (animal viruses, immunology for diagnosis of diseases, and practical immunology for students of diploma of tropical medicines). d. katterine bonilla aldana, d.v.m., m.sc., graduated from universidad de la amazonia, school of veterinary medicine and zootechnics, in florencia, colombia, in 2015. she completed a master of sciences in microbiology, universidad metropolitana, barranquilla, colombia, in 2019. she served as a young researcher, public health and infection research group, faculty of health sciences, universidad tecnológica de pereira (utp), in pereira, risaralda, colombia. she is a member of the colombian infectious diseases association (acin) and the international society for infectious diseases. she is a member of the committee on tropical medicine, zoonoses, and travel medicine of the acin. she has been recognized as junior researcher, ministry of science in colombia, minciencias. she is a professor of veterinary medicine and zootechnics, fundación universitaria autónoma de las americas (fuam), in pereira, risaralda, colombia. she is a lead professor of the zoonoses research incubator (sizoo), fuam. her main research interest is the study of zoonotic tick borne and vector borne diseases. alfonso j. rodriguez morales, m.d., m.sc., d.t.m. and h., f.r.s.t.m.h. (lon), f.f.t.m.r.c.p.s. (glasg), f.a.c.e., ph.d.(c), hon.d.sc., is an expert in tropical and emerging diseases, particularly in zoonotic and vector borne diseases. he is president of the travel medicine committee, pan american infectious diseases association (api), as well as the vice president, colombian infectious diseases association (acin). he is a member of the committee on tropical medicine, zoonoses, and travel medicine, acin. he is part of the executive board of the latin american society for travel medicine (slamvi) and of the council of the international society for infectious diseases. since 2014, he has been recognized as senior researcher, ministry of science (minciencias), colombia. he is professor, faculty of health sciences, universidad tecnológica de pereira, and of the fundacion universitaria autonoma de las americas, in pereira, risaralda, colombia. he is codirector of the public health and infection research group, utp, classified a1 by colciencias. his scopus h index is 30 (google scholar h index, 46). articles from clinical microbiology reviews are provided here courtesy of american society for microbiology (asm) connect with nlm national library of medicine 8600 rockville pike bethesda, md 20894

official websites use .gov a .gov website belongs to an official government organization in the united states. secure .gov websites use https a lock ( ) or https:// means you've safely connected to the .gov website. share sensitive information only on official, secure websites. weekly / january 22, 2021 / 70(3);95 99 on january 15, 2021, this report was posted online as an mmwr early release. please note:. this report has been corrected. summer e. galloway, phd1; prabasaj paul, phd1; duncan r. maccannell, phd2; michael a. johansson, phd1; john t. brooks, md1; adam macneil, phd1; rachel b. slayton, phd1; suxiang tong, phd1; benjamin j. silk, phd1; gregory l. armstrong, md2; matthew biggerstaff, scd1; vivien g. dugan, phd1 (view author affiliations) what is already known about this topic? a more highly transmissible variant of sars cov 2, b.1.1.7, has been detected in start highlight12end highlight u.s. states. what is added by this report? modeling data indicate that b.1.1.7 has the potential to increase the u.s. pandemic trajectory in the coming months. cdc’s system for genomic surveillance and the effort to expand sequencing will increase the availability of timely u.s. genomic surveillance data. what are the implications for public health practice? the increased transmissibility of the b.1.1.7 variant warrants universal and increased compliance with mitigation strategies, including distancing and masking. higher vaccination coverage might need to be achieved to protect the public. genomic sequence analysis through the national sars cov 2 strain surveillance program will enable a targeted approach to identifying variants of concern in the united states. views equals page views plus pdf downloads figure 1 figure 2 on december 14, 2020, the united kingdom reported a sars cov 2 variant of concern (voc), lineage b.1.1.7, also referred to as voc 202012/01 or 20i/501y.v1.* the b.1.1.7 variant is estimated to have emerged in september 2020 and has quickly become the dominant circulating sars cov 2 variant in england (1). b.1.1.7 has been detected in over 30 countries, including the united states. as of january 13, 2021, approximately 76 cases of b.1.1.7 have been detected in start highlight12end highlight u.s. states.† multiple lines of evidence indicate that b.1.1.7 is more efficiently transmitted than are other sars cov 2 variants (1 3). the modeled trajectory of this variant in the u.s. exhibits rapid growth in early 2021, becoming the predominant variant in march. increased sars cov 2 transmission might threaten strained health care resources, require extended and more rigorous implementation of public health strategies (4), and increase the percentage of population immunity required for pandemic control. taking measures to reduce transmission now can lessen the potential impact of b.1.1.7 and allow critical time to increase vaccination coverage. collectively, enhanced genomic surveillance combined with continued compliance with effective public health measures, including vaccination, physical distancing, use of masks, hand hygiene, and isolation and quarantine, will be essential to limiting the spread of sars cov 2, the virus that causes coronavirus disease 2019 (covid 19). strategic testing of persons without symptoms but at higher risk of infection, such as those exposed to sars cov 2 or who have frequent unavoidable contact with the public, provides another opportunity to limit ongoing spread. global genomic surveillance and rapid open source sharing of viral genome sequences have facilitated near real time detection, comparison, and tracking of evolving sars cov 2 variants that can inform public health efforts to control the pandemic. whereas some mutations in the viral genome emerge and then recede, others might confer a selective advantage to the variant, including enhanced transmissibility, so that such a variant can rapidly dominate other circulating variants. early in the pandemic, variants of sars cov 2 containing the d614g mutation in the spike (s) protein that increases receptor binding avidity rapidly became dominant in many geographic regions (5,6). in late fall 2020, multiple countries reported detecting sars cov 2 variants that spread more efficiently. in addition to the b.1.1.7 variant, notable variants include the b.1.351 lineage first detected in south africa and the recently identified b.1.1.28 subclade (renamed “p.1”) detected in four travelers from brazil during routine screening at the haneda (tokyo) airport.§ these variants carry a constellation of genetic mutations, including in the s protein receptor binding domain, which is essential for binding to the host cell angiotensin converting enzyme 2 (ace 2) receptor to facilitate virus entry. evidence suggests that other mutations found in these variants might confer not only increased transmissibility but might also affect the performance of some diagnostic real time reverse transcription polymerase chain reaction (rt pcr) assays¶ and reduce susceptibility to neutralizing antibodies (2,3,5 10). a recent case report documented the first case of sars cov 2 reinfection in brazil with a sars cov 2 variant that contained the e484k mutation,** which has been shown to reduce neutralization by convalescent sera and monoclonal antibodies (9,10). this report focuses on the emergence of the b.1.1.7 variant in the united states. as of january 12, 2021, neither the b.1.351 nor the p.1 variants have been detected in the united states. for information about emerging sars cov 2 variants of concern, cdc maintains a webpage dedicated to providing information on emerging sars cov 2 variants.†† top the b.1.1.7 variant carries a mutation in the s protein (n501y) that affects the conformation of receptor binding domain. this variant has 13 other b.1.1.7 lineage defining mutations (table), several of which are in the s protein, including a deletion at positions 69 and 70 (del69 70) that evolved spontaneously in other sars cov 2 variants and is hypothesized to increase transmissibility (2,7). the deletion at positions 69 and 70 causes s gene target failure (sgtf) in at least one rt pcr based diagnostic assay (i.e., with the thermofisher taqpath covid 19 assay, the b.1.1.7 variant and other variants with the del69 70 produce a negative result for s gene target and a positive result for the other two targets); sgtf has served as a proxy in the united kingdom for identifying b.1.1.7 cases (1). multiple lines of evidence indicate that b.1.1.7 is more efficiently transmitted compared with other sars cov 2 variants circulating in the united kingdom. u.k. regions with a higher proportion of b.1.1.7 sequences had faster epidemic growth than did other areas, diagnoses with sgtf increased faster than did non sgtf diagnoses in the same areas, and a higher proportion of contacts were infected by index patients with b.1.1.7 infections than by index patients infected with other variants (1,3). variant b.1.1.7 has the potential to increase the u.s. pandemic trajectory in the coming months. to illustrate this effect, a simple, two variant compartmental model was developed. the current u.s. prevalence of b.1.1.7 among all circulating viruses is unknown but is thought to be <0.5% based on the limited number of cases detected and sgtf data (8). for the model, initial assumptions included a b.1.1.7 prevalence of 0.5% among all infections, sars cov 2 immunity from previous infection of 10% 30%, a time varying reproductive number (rt) of 1.1 (mitigated but increasing transmission) or 0.9 (decreasing transmission) for current variants, and a reported incidence of 60 cases per 100,000 persons per day on january 1, 2021. these assumptions do not precisely represent any single u.s. location, but rather, indicate a generalization of conditions common across the country. the change in rt over time resulting from acquired immunity and increasing prevalence of b.1.1.7, was modeled, with the b.1.1.7 rt assumed to be a constant 1.5 times the rt of current variants, based on initial estimates from the united kingdom (1,3). next, the potential impact of vaccination was modeled assuming that 1 million vaccine doses were administered per day beginning january 1, 2021, and that 95% immunity was achieved 14 days after receipt of 2 doses. specifically, immunity against infection with either current variants or the b.1.1.7 variant was assumed, although the effectiveness and duration of protection against infection remains uncertain, because these were not the primary endpoint of clinical trials for initial vaccines. in this model, b.1.1.7 prevalence is initially low, yet because it is more transmissible than are current variants, it exhibits rapid growth in early 2021, becoming the predominant variant in march (figure 1). whether transmission of current variants is increasing (initial rt = 1.1) or slowly decreasing (initial rt = 0.9) in january, b.1.1.7 drives a substantial change in the transmission trajectory and a new phase of exponential growth. with vaccination that protects against infection, the early epidemic trajectories do not change and b.1.1.7 spread still occurs (figure 2). however, after b.1.1.7 becomes the dominant variant, its transmission was substantially reduced. the effect of vaccination on reducing transmission in the near term was greatest in the scenario in which transmission was already decreasing (initial rt = 0.9) (figure 2). early efforts that can limit the spread of the b.1.1.7 variant, such as universal and increased compliance with public health mitigation strategies, will allow more time for ongoing vaccination to achieve higher population level immunity. top currently, there is no known difference in clinical outcomes associated with the described sars cov 2 variants; however, a higher rate of transmission will lead to more cases, increasing the number of persons overall who need clinical care, exacerbating the burden on an already strained health care system, and resulting in more deaths. continued genomic surveillance to identify b.1.1.7 cases, as well as the emergence of other variants of concern in the united states, is important for the covid 19 public health response. whereas the sgtf results can help identify potential b.1.1.7 cases that can be confirmed by sequencing, identifying priority variants that do not exhibit sgtf relies exclusively on sequence based surveillance. the experience in the united kingdom and the b.1.1.7 models presented in this report illustrate the impact a more contagious variant can have on the number of cases in a population. the increased transmissibility of this variant requires an even more rigorous combined implementation of vaccination and mitigation measures (e.g., distancing, masking, and hand hygiene) to control the spread of sars cov 2. these measures will be more effective if they are instituted sooner rather than later to slow the initial spread of the b.1.1.7 variant. efforts to prepare the health care system for further surges in cases are warranted. increased transmissibility also means that higher than anticipated vaccination coverage must be attained to achieve the same level of disease control to protect the public compared with less transmissible variants. in collaboration with academic, industry, state, territorial, tribal, and local partners, cdc and other federal agencies are coordinating and enhancing genomic surveillance and virus characterization efforts across the united states. cdc coordinates u.s. sequencing efforts through the sars cov 2 sequencing for public health emergency response, epidemiology, and surveillance (spheres)§§ consortium, which includes approximately 170 participating institutions and promotes open data sharing to facilitate the use of sars cov 2 sequence data. to track sars cov 2 viral evolution, cdc is implementing multifaceted genomic surveillance to understand the epidemiologic, immunologic, and evolutionary processes that shape viral phylogenies (phylodynamics); guide outbreak investigations; and facilitate the detection and characterization of possible reinfections, vaccine breakthrough cases, and emerging viral variants. in november 2020, cdc established the national sars cov 2 strain surveillance (ns3) program to improve the representativeness of domestic sars cov 2 sequences. the program collaborates with 64 u.s. public health laboratories to support a genomic surveillance system; ns3 is also building a collection of sars cov 2 specimens and sequences to support public health response and scientific research to evaluate the impact of concerning mutations on existing recommended medical countermeasures. cdc has also contracted with several large commercial clinical laboratories to rapidly sequence tens of thousands of sars cov 2 positive specimens each month and has funded seven academic institutions to conduct genomic surveillance in partnership with public health agencies, thereby adding substantially to the availability of timely genomic surveillance data from across the united states. in addition to these national initiatives, many state and local public health agencies are sequencing sars cov 2 to better understand local epidemiology and support public health response to the pandemic. the findings in this report are subject to at least three limitations. first, the magnitude of the increase in transmissibility in the united states compared with that observed in the united kingdom remains unclear. second, the prevalence of b.1.1.7 in the united states is also unknown at this time, but detection of variants and estimation of prevalence will improve with enhanced u.s. surveillance efforts. finally, local mitigation measures are also highly variable, leading to variation in rt. the specific outcomes presented here are based on simulations and assumed no change in mitigations beyond january 1. the increased transmissibility of the b.1.1.7 variant warrants rigorous implementation of public health strategies to reduce transmission and lessen the potential impact of b.1.1.7, buying critical time to increase vaccination coverage. cdc’s modeling data show that universal use of and increased compliance with mitigation measures and vaccination are crucial to reduce the number of new cases and deaths substantially in the coming months. further, strategic testing of persons without symptoms of covid 19, but who are at increased risk for infection with sars cov 2, provides another opportunity to limit ongoing spread. collectively, enhanced genomic surveillance combined with increased compliance with public health mitigation strategies, including vaccination, physical distancing, use of masks, hand hygiene, and isolation and quarantine, will be essential to limiting the spread of sars cov 2 and protecting public health. top members of the sequencing for public health emergency response, epidemiology and surveillance consortium; state and local public health laboratories; association of public health laboratories; cdc covid 19 response team; respiratory viruses branch, division of viral diseases, cdc. top corresponding author: summer e. galloway, nmd3@cdc.gov. top 1cdc covid 19 response team; 2office of advanced molecular detection, national center for emerging and zoonotic infectious diseases, cdc. top all authors have completed and submitted the international committee of medical journal editors form for disclosure of potential conflicts of interest. no potential conflicts of interest were disclosed. top * https://www.gov.uk/government/news/phe investigating a novel variant of covid 19. † https://www.cdc.gov/coronavirus/2019 ncov/transmission/variant cases.html. § https://www.japantimes.co.jp/news/2021/01/11/national/science health/new coronavirus variant japan/. ¶ https://www.fda.gov/news events/press announcements/fda issues alert regarding sars cov 2 viral mutation health care providers and clinical laboratory?utm_medium. ** https://virological.org/t/spike e484k mutation in the first sars cov 2 reinfection case confirmed in brazil 2020/584. †† https://www.cdc.gov/coronavirus/2019 ncov/more/science and research/scientific brief emerging variants.html. §§ https://www.cdc.gov/coronavirus/2019 ncov/covid data/spheres.html. top top abbreviations: del = deletion; e = envelope protein; n = nucleocapsid protein; orf = open reading frame; s = spike protein. top abbreviation: rt = time varying reproductive number. * for all simulations, it was assumed that the reporting rate was 25% and that persons who were seropositive or infected within the simulation became immune. the simulation was initialized with 60 reported cases of sars cov 2 infection per 100,000 persons (approximately 200,000 cases per day in the u.s. population) on january 1, 2021. bands represent simulations with 10% 30% population level immunity as of january 1, 2021. † initial b.1.1.7 prevalence is assumed to be 0.5% among all infections and b.1.1.7 is assumed to be 50% more transmissible than current variants. top abbreviation: rt = time varying reproductive number. * for all simulations, it was assumed that the reporting rate was 25% and that persons who were seropositive or infected within the simulation became immune. the simulation was initialized with 60 reported cases of sars cov 2 infection per 100,000 persons (approximately 200,000 cases per day in the u.s. population) on january 1, 2021. bands represent simulations with 10% 30% population level immunity as of january 1, 2021. † initial b.1.1.7 prevalence is assumed to be 0.5% among all infections and b.1.1.7 is assumed to be 50% more transmissible than current variants. § for vaccination, it was assumed that 300 doses were administered per 100,000 persons per day (approximately 1 million doses per day in the u.s. population) beginning january 1, 2021, that 2 doses achieved 95% immunity against infection, and that there was a 14 day delay between vaccination and protection. top suggested citation for this article: galloway se, paul p, maccannell dr, et al. emergence of sars cov 2 b.1.1.7 lineage   united states, december 29, 2020 january 12, 2021. mmwr morb mortal wkly rep 2021;70:95 99. doi: http://dx.doi.org/10.15585/mmwr.mm7003e2. mmwr and morbidity and mortality weekly report are service marks of the u.s. department of health and human services. use of trade names and commercial sources is for identification only and does not imply endorsement by the u.s. department of health and human services. references to non cdc sites on the internet are provided as a service to mmwr readers and do not constitute or imply endorsement of these organizations or their programs by cdc or the u.s. department of health and human services. cdc is not responsible for the content of pages found at these sites. url addresses listed in mmwr were current as of the date of publication. all html versions of mmwr articles are generated from final proofs through an automated process. this conversion might result in character translation or format errors in the html version. users are referred to the electronic pdf version (https://www.cdc.gov/mmwr) and/or the original mmwr paper copy for printable versions of official text, figures, and tables. questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
covid 19 guidance supported by the panel endorsed targeting a variant of the coronavirus that is now receding, though some officials suggested aiming at newer versions of the virus that have emerged in recent weeks. by noah weiland and christina jewett a committee of advisers to the food and drug administration voted on wednesday to update the formula for the covid vaccine ahead of an anticipated fall immunization campaign, now an annual step to try to offer better protection against versions of the virus in circulation. the unanimous vote by the 16 advisers recommends a formula aimed at combating the variant jn.1, which dominated infections in the united states in february, or a version of it. in recent weeks, jn.1 has been overtaken by descendants known as kp.2 and kp.3. in the coming weeks, the f.d.a. is expected to formally recommend a variant target for vaccine makers for the next round of shots in the late summer or early fall. any decision involves some educated guesswork, given that any new vaccine formula won’t be available until months after a variant becomes dominant. “it’s becoming clear that the ideal timing for a vaccine composition decision remains elusive,” said jerry weir, an official with the f.d.a.’s vaccine division. dr. peter marks, who oversees that division, urged the committee to consider encouraging the mrna vaccine makers to focus on the latest versions of the virus in broader circulation. “we always say we shouldn’t be chasing strains, but we’re paying an incredibly high premium for mrna vaccines to be able to have the freshest vaccines,” he said, referring to the technology used by moderna and pfizer. he compared the choice of a vaccine to selecting fresher milk at the grocery store.

 supported by the updated shots are now available in the u.s. here’s who should get them and what to expect. by knvul sheikh a new formulation is coming, and there are two main reasons to wait for it. by dana g. smith while mandates and lockdowns are long gone, the virus isn’t and, for some americans, neither are masks. by campbell robertson early in the pandemic, scientists began testing an old tb vaccine against the coronavirus. but the trial enrolled fewer participants than expected as new covid vaccines were introduced, and no discernible effect was found. by roni caryn rabin u.s. authorizes a new round of covid boosters older americans and those with weakened immune systems, groups still particularly vulnerable to the virus, may receive additional shots of the reformulated vaccine, federal officials said. by apoorva mandavilli f.d.a. plans to allow a second updated covid booster for vulnerable americans federal regulators plan to authorize an additional dose for seniors and immunocompromised people in the coming weeks, ahead of the introduction of a newly formulated booster later in the year. by noah weiland and sharon lafraniere should you get another covid booster? britain and canada have authorized another round of booster shots for older and immunocompromised citizens. so far, u.s. officials haven’t followed suit.